Genome-Wide Host Gene Expression Analysis Before and After the Initiation of Highly Active Antiretroviral Therapy And Natural Control of HIV in Therapy Naïve HIV+ Non-Progressors by Conceicao, Viviane
GENOME-WIDE HOST GENE EXPRESSION 
ANALYSIS BEFORE AND AFTER THE INITIATION 
OF HIGHLY ACTIVE ANTIRETROVIRAL 
THERAPY AND NATURAL CONTROL OF HIV IN 
THERAPY NAÏVE HIV+ NON-PROGRESSORS 
 
 
 
 
 
 
 
 
  
The University of Sydney 
 
Viviane Nascimento da Conceição 
 
A thesis submitted for fulfilment of the requirements 
for the degree of Doctor of Philosophy, 2013. Faculty 
of Medicine, The University of Sydney, Sydney, 
NSW, Australia. 
 
 
 
 
 
i 
The University of Sydney 
Preface  
 
 
The work described in this thesis was performed by the author under the supervision of Dr Nitin K 
Saksena and Dr Bin Wang at the Centre for Virus Research, Westmead Millennium Institute, 
Westmead, NSW, Australia. These studies were completed between March 2009 and March 2013 to 
fulfil the requirements for the degree of Doctor of Philosophy in the Faculty of Medicine, The 
University of Sydney, NSW, Australia. This study was approved by the Sydney West Area Health 
Services Research Ethics Committee. None of this work has been submitted previously for the 
purpose of obtaining another degree, and the author is entirely responsible for the work in this thesis 
unless otherwise stated.  
 
 
Signed: _________________________ 
 
Viviane Nascimento da Conceição,  
 
30
th 
August, 2013      
 
 
 
 
 
 
ii 
The University of Sydney 
Acknowledgements 
I wish to thank first and foremost my supervisor, Dr Nitin Saksena, who without even knowing who 
I was, believed in me and brought me to Sydney, Australia. He made this dissertation possible with 
his guidance, support and help throughout my long PhD journey. Your strength is an inspiration to 
me and I really admire you for the successful professional that you are. I also would like to 
acknowledge my co-supervisor Dr Bin Wang, for his assistance with all my technical work; he was 
a great advisor during the course of my work, helping me with some laboratory techniques and 
making them look much easier. I cannot find words to express my gratitude to Dr Kaushal Gandhi 
with his incredible patience in teaching me statistical analysis; without him I would not have come 
so far. I also owe an enormous gratitude to Dr Monica Miranda-Saksena for all the time and effort 
she has spent with me. I became the “trouble” student she never had, and she devoted so much of 
her precious time to me, in order to get the perfect pictures in confocal and DeltaVision microscopy. 
Thanks so much Mon!! Without your help, a lot of this work would not make it to these final stages. 
I cannot forget to thank all my special “team” of co-workers and fellow students, especially the 
ones who stayed with me until the end and those who eventually moved on. I could never forget Dr 
Katherine Lau, Dr Jingqin Wu, Maly Soedjono and Tara Sasse. Thank you guys for giving me a 
great welcome in the laboratory and in the city, and also for helping me in the beginning with the 
training I much needed!! You guys made my life so much easier!! Thank you, Dr Julie Zhou, for the 
help anytime I needed. And I have to say it was not only one time I asked for help, but you were 
always ready to advise me. Thanks for the talks as well, I really appreciate that!!  
My very special thanks go to the following people, for their advice, timely help and suggestions 
reading my work and providing technical help throughout my PhD studies: Dr Maggie Wang for 
flow cytometer, Dr Hong Yu in using the confocal laser scanning microscope and also the 
Deltavision microscope, Dr Laurence Cantrill in using the confocal microscope in the Children‟s 
Hospital, Dr Andrew Harman for the use of his Interferon primers in some of my PCR experiments, 
Dr Russel Diefenbach and Dr Barbara Kelly in using their equipment for Western Blot. A special 
thanks to my fellow PC3 friends: Kabo Matlho, thank you for the long hours late at night, you 
always helped me whenever you could, especially processing patient samples; Priyanka Gupta, 
thanks for being so friendly and helpful and for the time it took you to help me with PCR when I 
was away, and also for reading my work; Amber Campbell, Manu Pokharna and Josh Givorshner 
for the help with Western Blot even though it didn‟t work  - you guys were the best in trying with 
me, even being very busy with your work. Thank you so much!! Raany Rahme, thank you for your 
friendship, always having a nice thing to say to me and listening to my problems; Suneth 
iii 
The University of Sydney 
“Sunnybear” Perera, you stayed with me until the end and it was so much easier to “suffer” the 
writing process with you. Thanks for the snacks during the long nights in the end!! With you guys, I 
had the best time I could ever have asked for. Thank you all for the long PC3 hours with the jokes 
and talks and the after hour help whenever I needed.  
I would also like to acknowledge our collaborators: Dr. Wayne Dyer (Australian Red Cross) for the 
frozen PBMCs for this work, to Professor Dominic Dwyer and Dr Choo Beng Chew, for all the 
samples from HIV patients. A very special acknowledgement goes to all the study participants who 
agreed to give blood for these studies.  
If I have forgotten anybody, I just wish to say that you are not forgotten. A big thank you to all who 
participated in helping me and enabled me to pursue my PhD studies.  
Without the mention of Endeavour International Postgraduate Research Scholarship (EIPRS) from 
the University of Sydney, Top-up Grant from the Millennium Foundation, this work would not have 
finished. I owe my gratitude to them. I also want to thank my dear friends in Brazil, who always 
supported me even though is hard to be so far away - you guys never made me guilty for coming to 
Australia. Thank you for all your love and faith in me! My heartfelt thanks go to my „aussie‟ 
family: Erika, Shirlley, Indinna, Ranni - you guys made my life so much better. Without your 
support I would not have made it this far. To my flatmate and great friend Jeana, who put up with 
my mood changes and the fact that I was never around, thank you for always being there for me. 
You guys were rock solid in supporting me throughout!!  
Finally, my utmost acknowledgement goes to my own beloved family, without whom all this would 
not have taken place. Your support and love were the pillars of my strength and inspiration I needed 
to finish this long journey. My very loving Mum and Dad, who always supported me in everything I 
did and taught me to believe that I could do anything. Thank you for all the talks and 
encouragement over the phone. To my loving brother and sister, I owe you a special “thank you” 
for not stopping to believe in me, even when I doubted myself. A special consideration to my big 
sis, Fabs, for her assistance in reviewing my thesis, you did a great job, thank you so much for your 
time. The end to this great journey could not have been achieved without your undoubting love, 
faith and encouragement. 
 
 
iv 
The University of Sydney 
Abstract 
Since its discovery 25 years ago, the HIV virus has infected more than 34 million people in the 
world; the infection caused by this virus has led the world to its most terrible pandemic, and the 
greatest global health crises of our times.  
The host-virus interaction and natural history of the disease are influenced by the distinctive 
interface the virus has with each infected individual. The infection with HIV-1 is characterized by 
the destruction of CD4
+
 T-cells during the typical course of the infection, but HIV has the arsenal to 
infect practically all the major blood leukocytes. Taken from these observations, it is apparent that 
HIV has the innate ability to subvert and manipulate the host gene machinery at the transcriptomic 
level. 
The highly active anti-retroviral therapy (HAART) consists of a combination of powerful drugs, 
which serve as potent defence mechanism against the ways in which the HIV virus attacks the 
human body. Although these drugs are not able to rid the body of HIV virus, they can significantly 
delay the onset of AIDS and reduce the incidence of opportunistic infections, morbidity and 
mortality related to HIV infection. After the introduction of HAART treatment, it is observed that 
most patients with good adherence respond to HAART, which is defined by a decrease of plasma 
viral load to undetectable levels and an immune reconstitution with a significant increase of CD4
+
 T 
cell levels. Around 30% of the patients fail to achieve this response and continue to express high 
plasma viral load and low CD4
+
 T cell numbers. In contrast, some rare HIV
+
 patients maintain 
below detectable levels of plasma viremia without the treatment. These are termed long-term non-
progressors (LTNPs), less commonly called elite controllers. These rare individuals are infected 
with HIV, but have the natural ability to control the infection with the strength of their immune 
system. Many of these patients have been HIV positive for 30 years or more and off therapy for the 
entire duration of their infection, showing high CD4
+
T cells counts and no progression to the 
disease. In this context, it is important to mention that the genomic basis of this natural effective 
immunological control of viremia in LTNPs, as opposed to drug-mediated control of HIV, remains 
unknown. The development of high throughput microarray platforms and bioinformatic platforms to 
visualize and analyse the complex dataset has enabled considerable progress in the field of viral 
genomics, and also the visualization of host-virus interactions at the molecular level.  
In chapter III, we carried out a comparative genome-wide (encompassing all 25,000 human genes) 
pharmacogenomic study using whole primary peripheral blood mononuclear cells (PBMC) derived 
from 14 HIV
+
 patients at two time points: pre-HAART (TP-1 with detectable viremia) and post-
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HAART (TP2: below detectable level (BDL) of plasma HIV <40 copies of HIV RNA/mL plasma), 
to ascertain how genomically distinct viremic phase is from the phase in which virus is fully 
controlled with HAART. Another goal was to define the underlying pharmacogenomic basis of HIV 
control during HAART. In the second study shown in Chapter IV, we compared the two time points 
against the 9 LTNPs to unravel the genomic basis of natural control of viremia in therapy naïve 
LTNPs showing below detectable levels of viremia (<20 copies of HIV RNA/mL plasma) and high 
and stable CD4
+
T cell counts. Genomic RNA extracted from the PBMCs was used in genome-wide 
microarray analysis, using HT-12v3 Illumina chips. Quantile normalization was performed to 
normalize the data and inter-patient variability. Illumina®BeadStudio Data Analysis Software was 
used to obtain differentially expressed (DE) genes. Only the significant genes with p value <0.01 
and FDR of <5% (for the comparison between TP1 and TP2) and FDR <1% (for the comparison 
between LTNP versus TP1 and LTNP versus TP2) were considered appropriate for analysis. 
Pathway analysis was performed in MetaCore
TM
 from GeneGo, Inc to derive functional annotations. 
Functionally significant genes were validated by quantitative real time PCR. Between TP1 and TP2, 
234 genes were differentially expressed. Within these genes, 212 were down-regulated and 22 up-
regulated. Between the comparison between LTNP vs TP1, 965 genes were differently expressed 
(706 genes were up-regulated and 259 genes were down-regulated), and when LTNP was compared 
to the TP2 group, we found 1181 DE genes (with 727 genes up-regulated and 454 genes down-
regulated). In the first part of this study, comparing the TP1 and TP2 only, we found that of the top 
10 pathways, 8 belonged to the immune response system. This was the most significant pathway 
up-regulated in TP1 when compared to TP2. This comprised of genes that were involved in antiviral 
action of interferon (IFN) and their signalling function, antiviral response, dendritic cell maturation 
and migration, and cell metabolism. Map folder and enrichment analysis corroborated with our 
findings, thereby confirming an intrinsic role of the immune, inflammatory and interferon response 
family-related genes during HIV viremia in the absence of treatment. But a closer examination of 
this contrast also showed a mirror down-regulation of genes involved in innate and adaptive 
immunity, inflammation, apoptosis and antiviral functions. This directly implies a functional 
relevance of these pathways, through their modulation in TP1 and TP2 stages. Although these data 
are intuitive and expected, such analysis has never been performed before.  
The second part of this study, on comparisons between LTNP and TP1 and LTNP against TP2, we 
show the first evidence demonstrating that the natural control of HIV in LTNP is guided by the 
genes enriched in the immune response, cytoskeleton remodelling, apoptosis and T cell signalling 
pathways. Another striking observation was that, even though the LTNP and TP2 groups 
maintained BDL of plasma viremia (<40 copies), the LTNP group was genomically distinct from 
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the TP2, which controlled viremia with HAART. This highlights the qualitative distinction and 
critical role of enriched pathways in natural control of viremia in the LTNPs. Seventeen genes 
encompassing all these pathways were validated by q-PCR, which showed consistent trends 
between microarray and q-RT PCR. One gene in particular, the thrombospondin (THBS1) (R
2
= 
0.942) was identified as a biomarker in our study, discriminating between viremic patients and 
LTNPs at the genomic (R
2
= 0.942, p<2.654e.08) and proteomic levels (p<0.003761). The levels of 
expression of THBS1 showed excellent correlation with plasma viremia (R
2
=0.81557; 
p<.0.0003761), the first description of such an important protein. This is the most unique finding of 
this work, which has significance in HIV disease prognostics and diagnostics, in addition to 
predicting the strength of the host immune system, as evident from its down-regulation and low 
expression in the natural controllers.  
Overall, through these analyses, we have shown that, although there are common set of key genes 
associated with HIV at all stages, each stage also showed unique molecular signatures. This was 
demonstrated with the identification of molecular signatures for the control of virus with HAART 
therapy, as well as for the natural control of HIV in LTNPs. Especially for the LTNPs, the down-
regulation of the apoptosis was the most significant feature, which may have important implications 
in therapy, especially in the context of using apoptosis as a target for future therapies.  
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1.1  Background 
 The Human Immunodeficiency Virus (HIV), is classified as a retrovirus that slowly and 
gradually destroys the immune system and is the causative agent of the Acquired 
Immunodeficiency Syndrome (AIDS) (Castelli 2002), which has resulted in global AIDS 
pandemic. In 1981, North American physicians in the cities of New York and San 
Francisco focused their attention on the young homosexual men dying from a rare 
infection, which caused immunodeficiency. Within a year, the United States Centers for 
Disease Control and Prevention (CDC) determined the term ‘acquired immunodeficiency 
syndrome’ (AIDS). 
In the beginning it was thought that various behavioural and environmental mechanisms 
could be involved. Nevertheless, in 1983-85 (Clavel, Klatzmann et al. 1985; Clavel, 
Guetard et al. 1986) two retroviruses were isolated from the blood of patients with AIDS, 
confirming the suspicion that AIDS had an infectious cause, known to us today as the 
human immunodeficiency virus type 1 (HIV-1) (Castelli, Deeks et al. 2002) and type 2 
(HIV-2). HIV-1 has resulted in global pandemic and HIV-2 has remained localized to 
Western Africa and is known to be much less infectious, with poor transmission properties, 
which has hampered its global dissemination. The levels of HIV-1 are significantly higher 
in the peripheral blood and genital fluids of individuals, with the greatest chance of 
transmitting the virus. HIV-1 is now well documented as the aetiologic agent of AIDS and 
its related disorders (Barre-Sinoussi, Chermann et al. 1983; Clavel, Guetard et al. 1986; 
Clavel 1987; Rowland-Jones 2003; Potter, Chew et al. 2004).  HIV can be transmitted in 
various different ways: blood and blood products, sexual activity and from mother to child 
during birth, in utero or through breastfeeding (Blattner 1991; Aaron and Cohan 2013). 
HIV-1 remains a global health problem of unprecedented dimensions. Since its discovery 
in 1983, 60 million people have become infected with HIV, 25 million of whom have since 
died. Although the percentage of people living with HIV globally has stabilized since 
2000, the overall number of people infected with HIV has steadily increased to an 
estimated 33.3 million in 2009 (Hemelaar 2012).  
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1.2 Molecular Biology of HIV 
1.2.1 The HIV Structure  
HIV is a member of the genus Lentivirus, part of the family of Retroviridae. Retroviruses 
are best known for indefinitely persisting in their hosts and replicating continuously at 
variable rates during the course of the lifelong infection. Persistent replication of the 
viruses depends on their ability to circumvent host defences. HIV has evolved a repertoire 
of strategies that surpass those of any other known pathogen. Examples of these strategies 
are promoting viral gene expression; synthetising multiple spliced mRNA to overcome the 
genetic information restrained on a small genome; and developing chronic infection with 
slow progression in the host and also latency (Clavel, Guetard et al. 1986; Narayan, Zink et 
al. 1988; Narayan and Clements 1989). 
There are two subgroups inside the Lentivirus: HIV-1 and HIV-2. They share up to 50% 
overall nucleotide homology and are similar in structure and cellular tropism. Although 
both viruses can cause AIDS, they show different courses of infection, with HIV-2 being 
less pathogenic and transmissible and HIV-1 being a highly infectious and transmissible 
virus, which has disseminated globally to cause AIDS pandemic.  Geographically, these 
two viruses occur in different regions of the world: HIV-2 is localized in West Africa, with 
limited expansion to other parts of the world; HIV-1 is present globally (Guyader, 
Emerman et al. 1987; Evans, Moreau et al. 1988; George, Ou et al. 1992; Castelli 2002).  
The genomes of HIV-1 and HIV-2 consist of two identical single RNA strands enclosed 
within a cone-shaped core, surrounded by a glycosylated outer virion surface, that are the 
glycoprotein spikes, consisting of a trans-membrane viral protein gp41 and a surface viral 
protein gp120. The first step in virus infection involves binding the virion to the surface of 
a target cell. This is mediated by binding the envelope gp120 to the CD4 surface protein 
found on most helper T cells (Clavel, Guyader et al. 1986; Guyader, Emerman et al. 1987). 
After binding to the cell surface, the virus becomes internalized into the host cell, where it 
becomes uncoated. The viral RNA is then reverse transcribed into linear double-stranded 
viral DNA in the cytoplasm of infected cells by the viral DNA polymerase, and then 
transported to the nucleus, where it is first ‘circularized’ and integrated into the host cell. 
The 9.8-kb RNA genome contains a 5’ cap (Gppp), a 3’ poly (A) tail, and several open 
reading frames (ORFs). This genome codes for 15 major molecular products. The core and 
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matrix of viral proteins are surrounded by a lipid envelop (as shown in Figure 1.1), which 
is derived from the host cell (Peterlin and Luciw 1988; Subbarao and Schochetman 1996; 
Cowley 2001).  
The viral genome contains three major structural genes, including gag (for group-specific 
antigen), pol (for polymerase), and env (for envelope glycoprotein). Gag and pol are in the 
core of viral particles, whereas env glycoproteins are imbedded into the lipid bilayer coat 
of the mature virion, gag proteins are non-covalently associated with two single-stranded 
copies of viral RNA.  
There are six regulatory genes, namely vif (viral infectivity factor), vpr (viral protein R), 
tat (trans-activator of transcription), rev (regulator of virion expression), vpu (viral protein 
unique), and nef (negative regulatory factor). At each end of the genome there are long-
terminal repeat (LTR) sequences that contain promoters, enhancers, and other gene 
sequences required for binding of different cellular (or viral) transcription factors, such as 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), NFAT (nuclear 
factor of activated T-cells), and activator protein (AP)-1, involved in viral replication 
(Figure 1.2) (Peterlin and Luciw 1988; Potter, Chew et al. 2004). 
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Figure 1.1. Structure of the HIV virion. The HIV RNA genome is encapsulated in a capsid (CA) composed of p24 and is stabilized by a matrix composed of MA. 
The cellular lipid bilayer containing envelope glycoproteins completes the outer structure. Several proteins located inside the capsid are required for maturation and 
infectivity of HIV. The figure (available for free distribution) was accessed at: http://www.armageddononline.org/viruses.html.  
Chapter 1 
 
5 
The University of Sydney 
 
 
 
 
 
 
 
 
Figure 1.2. Genetic organization of HIV-1. LTR (long term repeat); gag (group-specific antigen): encodes for the precursor gag polyprotein, which is processed by 
viral protease during maturation to MA (matrix protein, p17); CA (capsid protein, p24); NC (nucleocapsid protein, p7) and p6; pol (polymerase, encodes for HIV) 
protease (PR) and viral enzyme reverse transcriptase (RT) and integrase (IN) . HIV protease is required to cleave the precursor gag polyprotein to produce structural 
proteins, RT is required to transcribe DNA from RNA template, as well as IN, to integrate the ds viral DNA into the host genome; env (envelope, encodes for 
gp160), which is cleaved by cellular protease rather than virus to produce the surface (SU) lipoprotein gp120(SU), which attaches to the CD4 receptors present on 
lymphocytes and gp41(transmembrane, TM), proteins embedded in the viral envelope that enable the virus to attach and fuse with target cell;  essential regulatory 
elements: Tat (HIV trans-activator (Tat) plays an important role in regulating the reverse transcription of viral genome RNA, ensuring efficient synthesis of viral 
mRNAs as well as regulating the release of the virions from the infected cells) and Rev (important for the synthesis of major viral proteins, hence essential for viral 
replication). The figure was accessed at: http://images.sciencedaily.com/2011/12/111221140349-large.jpg. 
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One of the major characteristics of HIV is the extremely high genetic variability. This extensive 
heterogeneity is the result of high mutation rate of reverse transcriptase and its infidelity, viral 
genomic recombination, high viral turnover rate, immune and therapeutic selection. The envelope 
gp160 is the most variable region of HIV, which also assists in immune escape. Based on genetic 
variability, HIV-1 has been classified into three genetic groups: M (major), O (outlier) and N (non-
M, non-O). Most HIV-1 infections globally are caused by the M viruses, with group O and N only 
causing a small minority of infections in Central Africa pressures (Figure 1.3). This group is further 
divided based on the sequence variability of its env and gag genes into ten subtypes or clades, 
named A through K, and circulating recombinant forms (CRFs) (Cohen, Hellmann et al. 2008; 
Yaotse, Nicole et al. 2009; Lopez de Victoria, Kieslich et al. 2012).  
To date, 19 CRFs have been identified: some CRFs, e.g. CRF01_AE and CRF02_AG, which have 
played a significant role in regional epidemics. Although this classification was initially based on 
env sequences, it currently applies to all regions of the genome. Genetic variation within a subtype 
can be of the order of 15–20%, whereas variation between subtypes is approximately 25–35%, 
depending on the subtypes and genome regions examined. Analyses of multiple genome regions, 
and in particular full-length genome sequencing, have revealed inter-subtype recombinants, which 
are thought to originate from individuals with multiple infections, i.e. infected with viruses of two 
or more subtypes simultaneously (Peeters and Sharp 2000; Peeters, Toure-Kane et al. 2003).  
The different subtypes have distinct global distribution patterns. Differences in co-receptor usage, 
geographical distribution and global prevalence have been demonstrated for several of the identified 
subtypes. Therefore, the issue of recombination has become an important consideration in tracking 
the global spread of HIV-1 (Hemelaar, Gouws et al. 2006; McCutchan 2006). 
Various studies demonstrate that the geographic distribution of the different HIV-1M variants is 
very heterogeneous. Also, specific distributions of the various subtypes are seen among the 
different continents, even from country to country or within countries. Even though studies have 
demonstrated that the subtype B is predominant in the western world, the subtype C is the most 
widely spread across continents. Subtypes A, D and G are more prevalent in Africa than elsewhere, 
and CRF01_AE predominates in Southeast Asia (Peeters and Sharp 2000; Vidal, Peeters et al. 
2000). In Africa, all groups, subtypes, and many CRFs have been documented. CRF02_AG 
predominates in West and West-Central Africa, with CRF06_cpx being the second most important 
variant. In East Africa, subtypes A and D predominate, but subtype C is also present and is the 
predominant and almost unique subtype in the Eastern tip and Southern Africa. The highest genetic 
diversity is observed in Central Africa and the initial diversification of group M may have occurred 
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within or near the Democratic Republic of Congo, where also the earliest cases of HIV-1 infection, 
dating from 1959 and 1960, have been documented (Worobey, Gemmel et al. 2008; Yaotse, Nicole 
et al. 2009). More work is needed to define the exact origins of HIV-1 virus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Sequence clustering analysis of the HIV-1 subtypes, from the 2009 consensus sequences, based 
on sequence similarity. The horizontal axis of the dendrogram represents sequence similarity distance. 
Global prevalence, co-receptor selectivity and geographic distribution of each subtype are indicated in the 
figure. Modified from López de Victoria (2012).  
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1.3 Global Epidemiology of HIV 
In 2011 the progress report from World Health Organization (WHO), together with United Nations 
Children's Fund (UNICEF) and United Nations Programme on HIV/AIDS (UNAIDS) showed that, 
at the end of 2010, an estimated 34 million people were living with HIV globally, including 3.4 
million children with less than 15 years of age. Globally, the annual number of people newly 
infected with HIV continues to decline, although there is a stark regional. In sub-Saharan Africa, 
where most of the people newly infected with HIV live, an estimated 1.9 million people became 
infected in 2010. This was 16% fewer than the estimated 2.2 million people newly infected with 
HIV in 2001 and 27% fewer than the annual number of people newly infected between 1996 and 
1998, when the incidence of HIV in sub-Saharan Africa peaked overall (WHO 2011). Two-thirds of 
all people around the world who are infected with the HIV virus live in sub-Saharan Africa, 
although this region contains little more than 12% of the world’s population. HIV and AIDS have 
caused immense human suffering especially in this continent. The most obvious effect of this crisis 
has been illness and death, but the impact of the epidemic has certainly not been confined to the 
health sector; households, schools, workplaces and economies have also been badly affected. 
AIDS-related mortality began to decline in 2005–2006 in sub-Saharan Africa, South and South-East 
Asia and the Caribbean, and has continued to decline subsequently. Two signal developments have 
caused this decline: first, the increased availability of antiretroviral therapy, as well as care and 
support, to people living with HIV; and second, fewer people newly infected with HIV since the 
late 1990s. The effects of antiretroviral therapy are especially evident in sub-Saharan Africa, where 
an estimated of 30% fewer people died from AIDS related causes in 2010 than in 2004, when 
access to antiretroviral therapy began to be dramatically expanded (WHO 2011). 
The HIV epidemic in Oceania remains small and appears to be stable, although the number of 
people living with HIV in this region nearly doubled between 2001 and 2009, from 28000 to 57000. 
However, the number of people newly infected with HIV has begun to decline from 4700 in 2001 to 
4500 in 2009. The annual number of people newly infected with HIV increased slowly until the 
early 2000s and then declined to 3300 in 2010 (down from about 4000 in 2001). The number of 
people living with HIV in this region reached an estimated 54000 at the end of 2010, about 34% 
more than the estimate of 40000 for 2001. The number of people dying from AIDS-related causes 
has decreased considerably, falling to 1600 in 2010 (compared with the annual figure of about 2400 
in 2005–2007) (WHO 2011). 
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The number of children acquiring HIV infection also declined significantly in the Caribbean (32%) 
and Oceania (36%), with a more modest decline in Asia (12%). Declines have also been modest in 
Latin America (24%), Eastern Europe and Central Asia (13%). However, these three regions had 
already significantly reduced the numbers of children newly acquiring HIV infection (UNAIDS 
2012). 
 In Australia, the annual number of people newly diagnosed with HIV infection has stayed 
relatively stable at about 1000 since 2005 (following an earlier increase up to the late 1990s). Even 
though Australia has limited progress in slowing the spread of HIV among people who inject drugs, 
it has implemented evidence-informed HIV prevention strategies that sharply reduced the number 
of people who inject drugs acquiring HIV infection, with some approaching the elimination of drug-
related transmission (WHO 2011; UNAIDS 2012). Nevertheless, in 2009, injecting drug use in 
Australia was the probable cause of transmission for about 20% of the Aboriginal and Torres Strait 
Islander people newly infected with HIV (WHO 2011; UNAIDS 2012).  
As in many other high-income countries with older HIV epidemics, new HIV diagnoses have 
increased among men who have sex with men in Australia and New Zealand in the past decade. 
This trend may point to increased higher-risk sexual behaviour in this population group (UNAIDS 
2012). The global view of HIV infection recorded in 2010 is shown in Figure 1.4.  
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Figure 1.4. Global view of the HIV infection. Source: WHO 2011 report - Epidemic update and health sector progress towards Universal Access. 
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1.4 HIV Transmission and Risk Factors  
According to the Centers for Disease Control (CDC), the HIV virus can be detected in several fluids 
and tissue of an infected person. However, the existence of the virus in body fluids does not 
necessarily transmit the disease. Only blood, semen, vaginal secretions, and breast milk can 
transmit HIV. These specific fluids must come in contact with a mucous membrane or damaged 
tissue or be directly injected into the blood-stream (from a needle or syringe) for the possibility of 
transmission to occur (Cohen, Hellmann et al. 2008; Cohen and Gay 2010). 
The probability of a transmission event, whether from blood, sexual intercourse, or vertical 
transmission, broadly correlates with the concentration of HIV-1 in the host secretion (Mitsuya and 
Broder 1987; Vernazza, Troiani et al. 2000; Cohen and Gay 2010). Sexual transmission of HIV 
almost certainly relates to the concentration of HIV in semen, as documented for transmission by all 
other routes (Vernazza, Eron et al. 1999). It is now clear that human saliva inhibits oral 
transmission of HIV, thereby ruling out possibility of HIV transmission through kissing, 
aerosolization, etc. The saliva is known to harbour active factors that can inhibit HIV-1 infection 
(Stephenson 2000; Boily, Masse et al. 2011; Ganor and Bomsel 2011). Thus, the risk of oral 
salivary transmission of HIV-1 through contact with an infected individual is exceedingly small or 
none. In this context, it is important to mention that the anti-HIV-1 activity appears to be specific to 
saliva, as other body fluids, such as cerebrospinal fluid and urine, are devoid of anti-HIV-1 activity 
(Arakeri 2010).  
With the increasing prevalence of HIV-1 infection among women worldwide, many millions of 
children are presently at risk of this infection. Studies have shown that breastfeeding is still 
recognized as the most significant mode of transmission, and it has been estimated to account for 
40% of mother-child transmission. That fact suggests that the specific humoral mucosal immune 
response to the virus in the milk does not appear as a predominant factor for protection of viral 
transmission (Embree, Njenga et al. 2000). These findings lead to the dilemma, in resource-poor 
settings, of the replacement feeding: although it would protect the infant against HIV-1 infection, it 
could also place the infant at risk of mortality from other infections. The newborns could also be 
infected by their mothers still in utero or during labour or delivery (Becquart, Hocini et al. 2000; 
Gottlieb 2000; Read 2003; Humphrey, Marinda et al. 2010). The burden of HIV-1 infection has the 
largest impact in the low-income countries of Africa and Asia, where HIV-1 prevalence among 
pregnant women may exceed 25%, and where medical resources are limited (Embree, Njenga et al. 
2000; Read 2003). Although the risk of perinatal mother-to-child transmission of HIV is 
significantly decreased with the use of antiretroviral chemoprophylaxis, this type of transmission 
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occurs in 13% to 40% of children born to HIV-1-infected women. Understanding why some HIV-
infected women transmit HIV to their children, while most do not, is critically important to fully 
comprehend the power of anti-HIV factors in the maternal immune system, in controlling HIV 
transmission and exploring new ways of eradicating this disease (St Louis, Kamenga et al. 1993; 
Connor, Sperling et al. 1994; Becquart, Hocini et al. 2000). 
Geographically speaking, the transmission varies tremendously. Even though most new infections 
are transmitted heterosexually (especially in Africa), other cases like men who have sex with men, 
injecting drug users, and sex workers are at significant risk. In Europe and America sexual 
transmission has occurred primarily among homosexual populations, and the prevalence of the 
HIV-1 infection in the heterosexual populations remains low (Cameron, Simonsen et al. 1989). The 
frequency of sexual exposure is far higher than the frequency of unsafe injections, and so 
heterosexual sex is the main mode of transmission, with unsafe injections playing a minor role 
(Imperato 1986; Ndinya-achola, Plummer et al. 1986; Baggaley, Boily et al. 2006). Table 1.1 
shows all the major risks that lead to HIV transmission.  
Table 1.1. Risk factors of HIV type 1 transmission associated with various sexual activities.  
Risk Level Sexual Activity 
No risk 
Dry kissing 
Body-to-body rubbing 
Massage 
Nipple stimulation 
Using unshared inserted sexual devices 
Being masturbated by partner without semen or 
vaginal fluids 
Erotic bathing and showering 
Contact with feces or urine on intact skin 
Theoretical risk 
Wet kissing 
Cunnilingus with barrier 
Anilingus 
Digital-anal and digital-vaginal intercourse, with or 
without glove 
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Source: Practice Guideline for the Treatment of Patients with HIV/AID (2000). 
 
1.5 HIV Disease Progression  
It is well known that the HIV-1 virus has a complex life cycle. Throughout its life span, it interacts 
with multiple host cellular components and eventually compromises immune functions by targeting 
immune cells for virus replication, utilizing host transcription factors and enzymes for virus 
production, leading to infection (den Uyl, van der Horst-Bruinsma et al. 2004; Mehla and Ayyavoo 
2012). The natural history of the HIV-1 infection has been well characterized by the progressive 
immune system damage that ultimately induces oportunistic infections, being clinically-defined as 
AIDS (Barre-Sinoussi, Chermann et al. 1983; Sheppard, Lang et al. 1993). The course of HIV virus 
ensues three mainly distinct phases shown in Figure 1.5. 
- Phase 1 (Primarily HIV infection) 
 The acute phase of the HIV-1 infection from sexual transmission starts with the breaching of 
the mucosal barrier by infectious virions, resulting in the establishment of a localized focus of 
infection in the mucosa. Initially (within 1 to 3 weeks) the patient shows clinical symptoms that 
are very similar to the influenza or mononucleosis infection with nonspecific “flu-like” 
syndrome, such as extreme tiredness, swollen lymph nodes, sore throat, rash, nausea, etc. 
Using shared but disinfected inserted sexual devices 
Low risk 
Sharing non-disinfected personal hygiene items 
(razors, toothbrushes) 
Cunnilingus without barrier during or outside 
menstruation 
Fellatio and ejaculation, with or without ingestion of 
semen 
Fellatio, with or without condom 
High risk 
Penile-vaginal intercourse without condom Penile-anal 
intercourse without condom 
Coitus interruptus (intercourse with withdrawal before 
ejaculation) 
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(Hewson, Lone et al. 1999; Boutwell, Rolland et al. 2010). HIV antibody tests are usually 
negative during this phase. Because the virus is widely disseminated during this early stage, it 
is believed that the subsequent course of HIV infection may be influenced by the seeding of 
virus, particularly in the lymphoid organs. (Chen, Jha et al. 2007). 
- Phase 2 (Asymptomatic stage) 
After primary infection, studies have shown that viral dissemination appears to diminish in 
most patients, as the host’s immune system begins to recognize the pathogen and mounts a 
response to control the infection. This period is called “clinical latency” and it seems to last for 
years in some cases (J. Stephen McDaniel, Larry Brown et al. 2000; Betts, Nason et al. 2006; 
Streeck, Jolin et al. 2009).  During the course of this phase, the viral load stabilizes throughout 
much of the chronic phase of infection (Streeck, Jolin et al. 2009; Boutwell, Rolland et al. 
2010). Although the immune system may appear to control the initial infection, chronic viral 
replication persists. Studies have shown that resting CD4
+
 T cells can become infected rapidly 
after transmission, and once the virus hides within them, antiretroviral therapy is unlikely to 
affect this so called sanctuary for HIV (2000). Throughout the clinically latent period 
associated with HIV infection, the virus continues to slowly replicate, usually resulting in 
asymptomatic illness (Langford, Ananworanich et al. 2007). This is likely to last 2-3 decades or 
more in some HIV-infected individuals with below detectable plasma viremia and high CD4
+
 T 
cell counts in the absence of HAART. Only a small subset of patients originally classified as 
long term non progressors (LTNPs) maintained HIV-1 RNA levels below the limits of 
detection (Saksena, Rodes et al. 2007).  
- Phase 3 (AIDS progression) 
The immune system eventually deteriorates to the point that the human body is unable to fight off 
other infections, and as a consequence, cancers and opportunistic infections can overcome the 
immune system. The median time from infection to AIDS is estimated to be approximately 10 
years, but it can occur in around to 2-4 months.Some infected individuals have remained healthy for 
more than 13 years (Sheppard, Lang et al. 1993; Betts, Nason et al. 2006; Migueles and Connors 
2010). The rate of progression to AIDS is influenced by viral and host genetic factors, as well as 
host immune responses (Haynes, Pantaleo et al. 1996). The virus destroys the white blood cells 
(symptoms began to be noticed at blood levels with less than 500 cells/L), which are crucial to 
sustain function of the human immune system.  
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Figure 1.5. The Course of Untreated Adult HIV Infection. Source and courtesy: Southeast AIDS Training and Education Center, Emory University, 
Atlanta.  
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1.6 HIV entry into the host cells: receptors for the HIV-1 virus 
In 1984, a great breakthrough on HIV research came along, as it was established that the CD4 
molecule was the major cellular receptor for HIV. Initially, the viral attachment site appeared to be 
separate from the major histocompatibility complex (MHC) binding site of the CD4. Later on, 
studies showed that the MHC binding site appears to include the same CD4 region, and that this 
overlap might affect the use of inhibitors to the CD4:gp120 interaction (Kozak, Heard et al. 2002; 
Wilen, Tilton et al. 2012). For a better understanding of the interaction between the virus and the 
host immune system, several studies of cohorts using HIV infected individuals were performed to 
enlighten the sequence of events in the natural history of HIV infection. HIV-1 enters target cells by 
direct fusion of the viral and target cell membranes. The fusion reaction is mediated by env, which 
binds with high affinity to CD4, the primary receptor on the target cell surface (Dalgleish, Beverley 
et al. 1984; Miedema, Meyaard et al. 1994; Wyatt, Kwong et al. 1998; Levy 2007). 
New discoveries on the co-receptor system have given rise to a new perspective on major problems 
of HIV-1 disease, including the mechanisms of HIV-1 transmission and disease progression, and, 
most likely, new modes of therapeutic intervention. It was also found that there is a family of minor 
co-receptors which determine the cell types that different HIV strains infect (Berger, Murphy et al. 
1999). These specific types of co-receptors are present on most T cells in high levels, and also at 
lower levels on many antigen-presenting cells (APCs), such as macrophages. Studies have now 
shown that the CD4 alone would not be suffice for virus entry (Klatzmann, Barre-Sinoussi et al. 
1984; Klatzmann, Champagne et al. 1984) and that cooperative engagement of CD4 and co-
receptors, such as CCR1-CCR5, CXCR4, BoB, BONZO and STRL33, among others is needed 
(Berger, Murphy et al. 1999).  
Chemokines are small proteins with chemotactic activity for leukocytes. They are responsible for 
leukocytes activation and traffic to sites of inflammation. Receptors for chemokines comprise a 
subfamily within the G protein–coupled receptors superfamily (Murphy 1996; Baggiolini, Dewald 
et al. 1997; Berger, Murphy et al. 1999).  
At least 10 different chemokines have now been identified, along with the identification of the two 
major groups: CXC chemokines (in which the first two cysteines are separated by a single residue) 
mostly attract neutrophils and the receptors are designated CXCR; and CC chemokines (containing 
two adjacent cysteine residues) attract both monocytes and lymphocytes, and the receptors are 
designated CCR (Murphy, Baggiolini et al. 2000; Curnock, Logan et al. 2002; Giovannetti and 
Pierdominici 2008). It has also identified two other minor classes: the C class with only a single 
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cysteine residue in the motif, and the CX3C class with three residues separating the first two 
cysteines. This system is redundant, as although all the receptors are selective for one class of 
chemokines, individual receptors can bind multiple chemokines within a class, and many 
chemokines can function with more than one receptor (Berger, Murphy et al. 1999; Rollins 1999; 
Alkhatib and Berger 2007). 
The findings that lead to the discovery of these co-receptors supplied a molecular explanation for 
the ability of different strains to enter and infect different types of CD4
+
T cells. The strains 
macrophage tropic (M-tropic), generally corresponding to non-sycytium-inducing (NSI), display 
this phenotype because their envs function with CCR5 (being referred to as R5 tropic), and are 
usually non-syncytium-inducing. They are highly expressed on primary human macrophages, but 
not with the CXCR4 (a co-receptor by X4 strains of HIV-1 to gain entry into the cell). By contrast, 
envs from T cell line-tropic (TCL-tropic) strains generally correspond to syncytium-inducing (SI), 
and function with CXCR4, which is highly expressed on human continuous T cell lines, but not on 
CCR5. Because activated human primary CD4
+
T cells express abundant levels of CCR5 and 
CXCR4, they display high permissive membranes for fusion and entry of all HIV-1 isolates 
(Alkhatib, Combadiere et al. 1996; Dragic, Litwin et al. 1996; Berger, Doms et al. 1998; Cohen, 
Paolucci et al. 1998; Alkhatib and Berger 2007) . 
The discovery of fusin as a co-receptor for TCL-tropic strains provided a guide for the identification 
of the co-receptor for M-tropic isolates (Levy, Mackewicz et al. 1996; Murphy, Baggiolini et al. 
2000; Wu and Yoder 2009). Some studies have shown that these different phenotypes corresponded 
respectively to alternate phenotypic descriptions. In the end, all HIV-1 isolates were found to 
replicate in activated primary CD4
+
 T cells. Researchers also show that the env gene is the major 
viral determinant governing these phenotypic distinctions (Murphy 1996; Connor, Sheridan et al. 
1997; Alkhatib and Berger 2007). 
Particularly intriguing was the fact that these CC chemokines (RANTES, MIP-1α, and MIP-1β), 
major suppressive factors released by CD8 T lymphocytes, are potently suppressed in infection by 
M-tropic HIV-1 strains (Cocchi, DeVico et al. 1995). There are also HIV strains, which are able to 
use both CCR-5 and CXCR-4, and are referred to as R5X4 tropic. Continuous T cell lines 
abundantly express CXCR4, primary macrophages express CCR5, and primary T cells express 
both. There are two known mutations of the CCR-5 gene in humans, both of which result in failure 
of the functional receptor to appear on the cell surface. People carrying two mutant copies of the 
CCR-5 gene have a protective advantage against HIV infection, and those with one copy of the 
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mutant gene follow a long-term non-progressive disease course (Rizzuto, Wyatt et al. 1998; 
Hewson, Lone et al. 1999; Hewson, Logie et al. 2001). 
1.7 HIV Replication Cycle 
The HIV life cycle (as shown in Figure 1.6) is a complex process that occurs at the molecular level. 
The process is initiated by the binding of viral gp120 to the cellular CD4 surface molecule, forming 
a glycoprotein complex that enables the HIV to fuse with immune cells and initiate the infectious 
cycle. As HIV penetrates the T cell, a process called endocytosis starts, the virus matrix and capsid 
proteins are digested, and consequently releasing viral enzymes and RNA into the cytoplasm of the 
cell. Using host nucleotides, the HIV enzyme reverse transcriptase transforms the viral RNA into 
single-stranded DNA (Campbell and Hope 2008; Moss 2013). The single-stranded DNA again is 
reverse-transcribed and synthesized as double-stranded DNA. Following formation of linear DNA, 
a pre-integration complex consisting of viral DNA and several viral proteins is formed and 
translocated into the nucleus. This essential step in the HIV replication cycle is mediated by the 
virion-carried integrase, and once a linear copy of the viral genome has been inserted in the host 
cellular genome, the integration is for the lifetime of the cell (Freed 1998; Goto, Nakai et al. 1998; 
Freed 2001).  
The infecting virion undergoes complex structural changes before gaining access to the infected 
cells nucleus. The viral enzymes are packaged as domains within the Gag-Pro-Pol polyprotein, 
which is generated when translating ribosomes shift into the -- 1 reading frame at a site near the 3’ 
end of the gag open reading frame, and then go on to translate the pol gene. HIV-1 virion assembly 
occurs at the plasma membrane, within specialized membrane microdomains. The HIV-1 Gag (and 
Gag-Pro-Pol) polyprotein itself mediates all of the essential events in virion assembly, including 
binding the plasma membrane, making the protein–protein interactions necessary to create spherical 
particles, concentrating the viral env protein, and packaging the genomic RNA via direct 
interactions with the RNA packaging sequence (Sundquist and Krausslich 2012).  
The viral RNA provides a template for new viruses and can be used as a messenger (mRNA) to 
produce viral proteins via ribosomes in the cell cytoplasm during translation. Essentially, RNA 
polymerase (an enzyme that produces RNA) makes mRNA that encode for different viral proteins 
such as the envelope protein. The mRNA begins associating with ribosomes located on the surface 
of the rough endoplasmic reticulum, where envelope proteins are produced and shuttled to the T 
cell’s surface. There, the proteins are embedded in the cell membrane and combine with other 
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newly produced envelope proteins to form a cluster on the surface of the infected cell (Engelman, 
Mizuuchi et al. 1991; Goto, Nakai et al. 1998).  
During assembly, sets of viral proteins collect at the plasma membrane and then move to the cell’s 
surface as an unformed virus. HIV particle assembly is a multistep process that involves several 
viral and cellular proteins, lipids, and RNAs. Initially a number of proteins are minimized to be 
targeted to the plasma membrane; then the virus particles morphogenesis are regulated; the ratios 
between structural proteins are conditioned, and finally structural proteins within virus particles are 
positioned (Freed 1998; Ganser-Pornillos, Yeager et al. 2008; Briggs, Riches et al. 2009; Sundquist 
and Krausslich 2012).    
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Figure 1.6. Steps in HIV viral life cycle demonstrating all phases leading to the formation of virion: 1. 
Fusion of the HIV cell to the host cell surface; 2. HIV RNA, reverse transcriptase, integrase, and other viral 
proteins enter the host cell; 3.Viral DNA is formed by reverse transcription; 4. Viral DNA is transported 
across the nucleus and integrates into the host DNA; 5. New viral RNA is used as genomic RNA and to 
make viral proteins; 6. New viral RNA and proteins move to cell surface and a new, immature, HIV virus 
forms; 7. The virus matures by protease releasing individual HIV proteins. Figure accessed at. 
http://www.niaid.nih.gov/SiteCollectionImages/topics/hivaids/hivReplicationCycle.gif, on September 2009. 
 
1.8 Immuno-pathogenesis of HIV infection  
The immune response caused by the HIV infection contains elements of both humoral and cell-
mediated immunity involving both innate and adaptive immune responses. It is directed against 
multiple antigenic determinants of the HIV virion as well as against viral proteins expressed on the 
surface of infected cells (Weiss, Clapham et al. 1985).  Basically, it can be said that AIDS is 
essentially an infection of the immune system. Although antibody responses have a central role in 
clearing many viral infections, accumulating data suggest that this may not be true for HIV-1 
infection. In addition, the burst of HIV-1 replication that occurs in the first days after initial 
infection is contained in the infected individuals well before the development of an antibody that 
can neutralize the virus (Siliciano 2001; Letvin and Walker 2003). 
The main process of clinical progression of HIV disease is the functional abnormality and 
quantitative depletion of CD4 T lymphocytes, which lead to profound immunosuppression – a 
characteristic of advanced HIV infection (Pantaleo, Graziosi et al. 1991; McCullough, Firth et al. 
1997). It is also generally agreed that HIV itself has the primary role in the initiation and 
propagation of the pathogenic process. The observation that there is an extremely low viral burden 
in peripheral blood mononuclear cells (PBMCs) at the same time as the CD4 T lymphocytes are 
progressively depleted has raised the proposition that there are additional mechanisms of immune 
dysregulation associated with HIV infection. After primary infection and the appearance of HIV-
specific immunity most patients have a period of ‘clinical latency’ that lasts for an averageof years. 
The most obvious and quantifiable aspect of the deterioration that occurs during the latent stage is 
the depletion of CD4
+
 T cells. The inevitable outcome of the progressive deterioration of the 
immune system that occurs in most patients with HIV infection is clinically apparent disease or an 
AIDS-defining illness. HIV-induced immunosuppression results in a host defence defect that 
renders the body highly susceptible to "opportunistic" infections and neoplasm (Blattner, Gallo et 
al. 1988; Fauci 1988). 
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Over the course of several years, a striking feature of the HIV infection is the typically persistent 
decline in the peripheral blood CD4
+
 T lymphocyte count throughout the course of the disease.  
This culminates in a state of profound immunodeficiency, in which other cells in the system are 
unable to properly carry out their functions. In this regard, HIV patients have a high incidence of 
cytopenias and other hematologic abnormalities. The HIV-1 infection at its late stage is 
characterized by the occurrence of a variety of infections by bacteria, viruses and fungi that the 
immune system is no longer able to control, as a result of the CD4
+
 T cells being gradually depleted 
and host immunity becoming increasingly impaired (Siliciano 2001; Letvin and Walker 2003; 
Bosinger, Hosiawa et al. 2004). 
A complex array of multiphasic and multifactorial immunopathogenic mechanisms are involved in 
the establishment and progression of HIV disease. After primary infection, acute viremia occurs 
with wide dissemination of HIV. In addition, inappropriate immune activation and elevated 
secretion of certain pro-inflammatory cytokines occur during HIV infection. These cytokines play a 
role in the regulation of HIV expression in the tissues (Fauci, Pantaleo et al. 1996). 
 
1.8.1 Cell type association of HIV with progressive and non-progressive disease 
The virus first encounters dendritic cells (DCs), which subsequently facilitate spread of HIV-1 to 
CD4
+
 T lymphocytes. DC-SIGN, an HIV-specific DC receptor, binds HIV-1 at its gp-120 domain 
without requiring direct infection of the cell, and transports HIV-1 to lymphoid tissue. DCs act as 
potent antigen-presenting cells, priming naive T cells and enabling rapid infection of T cells 
(Kassutto and Rosenberg 2004). HIV-1 can infect T lymphocytes either as free virus particles or by 
direct transmission between infected and uninfected cells. HIV-1 spreads extensively during 
infection in vivo and is continually replicating and reinfecting new cells. Cytopathic syncytium 
inducing HIV-1 strains tend to predominate in patients progressing from lymphadenopathy to 
acquired immunodeficiency syndrome. Hence, cell-to-cell infection may represent a major 
mechanism of virus dissemination and disease progression in vivo. (Davis, Li et al. 1997). 
Previous studies have reported that an elevated proportion of CD38
+
 T cells in CD4
+
 and CD8
+
 T 
cells, as well as increased CD38 MFI on CD8
+
 T cells are associated with HIV-1 disease 
progression. Recent studies from our laboratory have found that Tregs were elevated during the 
course of HIV-1 infection and the magnitude of this elevation was associated with disease 
progression. Our studies also confirmed previous findings and further revealed that increased CD38 
intensity on CD4
+
 T cells, measured at the late stage of HIV-1 infection, is also associated with fast 
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progression to AIDS and death, independent of CD4
+
 T cell count and age. Although the co-
expression of HLA-DR and CD38 correlates with fast disease progression independently, HLA-DR 
alone was not found to be associated with the rate of progression (Cao, Jamieson et al. 2009). 
The two major cellular reservoirs in the natural host are latently infected resting CD4
+
 T cells and 
macrophages. The macrophages are widely recognized as the earlier cellular target of HIV-1, with 
the subsequent infection of T cells and the ensuing T cell depletion resulting in the immune-
pathogenesis that characterizes AIDS (Carter and Ehrlich 2008).  
Macrophages can harbor the virus for longer periods of time in vivo. In addition, to enter the blood-
brain barrier HIV infects macrophages, which then infects other tissues and organs, including the 
brain. Thus, the HIV-1-infected macrophages is of critical importance in the pathogenesis of HIV, 
as it is a major contributor to early-stage viral transmission, persistence, and virus dissemination 
throughout the body of the host (Perno, Svicher et al. 2006; Carter and Ehrlich 2008; Parikh, Huang 
et al. 2010; Van den Bergh, Florence et al. 2010). 
Depletion of CD4
+
 T cells is a hallmark of progressive HIV disease and a powerful predictor of the 
short-term risk of progression to AIDS (Munoz, Wang et al. 1989; Pantaleo and Fauci 1995). In 
addition to their role as predictors of the clinical outcomes of HIV infection, CD4
+
 T cell count and 
plasma HIV RNA level are commonly used as markers of the success of HAART. Both cross-
sectional analyses and longitudinal studies suggest that plasma HIV RNA level, categorized in 
broad strata, is inversely associated with rate of CD4
+
 T cell depletion. This suggests that HIV 
replication within CD4
+
 T cells lead to their accelerated destruction and eventual depletion. Yet, 
observations on the proportion and phenotype of infected cells suggest a much more complex 
scenario, in which preferential infection of HIV-reactive cells, widespread immune activation, and 
selective inhibition of HIV-specific immune responses each play a role in the pathogenesis of HIV-
related immunodeficiency (Hazenberg, Stuart et al. 2000; Hazenberg, Otto et al. 2003; Rodriguez, 
Sethi et al. 2006).  
Both innate and adaptive immune responses, including natural killer cell responses, HIV-1-specific 
CD4
+
 and CD8
+
 T cell responses, and neutralizing antibodies have been associated with the 
subsequent resolution of the clinical symptoms and the decline of HIV-1 RNA levels to so-called 
viral set point levels. In particular, the first appearance of HIV-1-specific CD8
+
 T cells in the 
peripheral blood has been shown to be temporally associated with the initial decline of HIV-1 
viremia during primary infection, suggesting a crucial role of these early virus-specific T cells in 
the control of viral replication (Altfeld, Kalife et al. 2006). 
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1.8.2. Viral and host factors in HIV disease 
The clinical outcome of HIV-1 infection is highly variable and determined by complex interactions 
between virus, host and environment. Several host and viral factors have been implicated in the 
outcome of the progression to AIDS (Langford, Ananworanich et al. 2007).  
 
- Viral factors: 
Among viral factors studied for their association with HIV-1 disease progression, viral phenotypes 
related to clinical progression include the CXCR4 or CCR5 co-receptor usage. Since CXCR4 use is 
associated with more rapid progression to AIDS, it seems to be linked to increase 
cytopathogenicity, resulting in enhanced T-cell depletion, which is lower for M-tropic (R5) viruses 
(Groenink, Fouchier et al. 1993; Grivel and Margolis 1999; Casado, Colombo et al. 2010). 
Associations between HIV-1 disease and genetic variants of the ligands for chemokine co-receptors 
have been described before by several studies which also that there is a strong correlation between 
disease progression and the extent of HIV-1 genetic variation (Ganeshan, Dickover et al. 1997; 
Zimmerman, Buckler-White et al. 1997; Michael 1999; Shankarappa, Margolick et al. 1999; Joos, 
Trkola et al. 2005).  
HIV-1 accessory proteins are known to play an essential role in viral replication within the human 
host, by regulating the several steps of the viral life cycle or counteracting inhibitory host factors 
(Cruz, Amorim et al. 2013). Several works have demonstrated that nef, vif, tat, rev and gag proteins 
have been classically associated with progression to disease (Rodes, Toro et al. 2004; Saksena, 
Rodes et al. 2007). Nonetheless, mutations in the proteins are not necessarily involved in the 
impairment of the viral replication to the extent of altering the rate of disease progression, with the 
exception of the structural, enzymatic and regulatory proteins, to which loss of function abolishes 
viral replication completely (Miura, Brockman et al. 2008; Rachinger, Navis et al. 2008; O'Connell, 
Brennan et al. 2010).  In certain patients who naturally controlled the progression of the disease, the 
most accepted explanation is the existence of host polymorphisms in the genes that will interfere 
with the fate of the infection. 
In regards to host factors, several studies have demonstrated that a number of host genetic, immune 
and virological factors have been associated with various patterns of disease progression. A recent 
review by Chatterjee and collaborators in 2010 stated that host genes suspected to influence the rate 
of AIDS progression could be divided into three categories: (i) genes encoding cell-surface 
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receptors or ligands for these proteins; (ii) genes within human leukocyte antigens (HLA) that 
regulate host immune response to infection; and (iii) other cytokine or immune response genes 
(Chatterjee 2010).  
 
i. Screening of the entire CCR2 gene has revealed a G→A transition at DNA position 190, resulting 
in a change of valine to isoleucine at amino acid position 64 (CCR2-V64I). This transition has a 
dominant effect and results in a slower progression to AIDS compared to normal CCR2 (Smith, 
Dean et al. 1997; Kostrikis, Huang et al. 1998; Chatterjee 2010). Other CCR5 polymorphisms were 
found to either reduce or increase protein expression on cell surface, resulting in an accelerated or 
delayed progression to AIDS in HIV-1 infected individuals, depending on the gene. Extensive 
studies have been made in order to better understand this process and target the key point of disease 
progression, and eventually develop better treatment.  
As extensively studied by Winkler and partner in 2004 and others before, the gene polymorphisms 
in the CCR5 receptor have important roles in HIV-1 resistance and pathogenesis (Alkhatib, 
Combadiere et al. 1996; Deng, Liu et al. 1996; Winkler, Hendel et al. 2004). A 32-bp deletion, 
CCR5Δ32, was found in the main chemokine co-receptor in R5 HIV-1 strains, which introduces a 
premature stop codon, resulting in a truncated protein not expressed on the cell surface and 
associated with resistance to HIV-1 infection (Dean, Carrington et al. 1996; Cohen, Paolucci et al. 
1998; Berger, Murphy et al. 1999; Carrington, Nelson et al. 2001).  A 32-bp deletion in the CCR5 
gene results in a truncated protein product that does not function as a co-receptor. This defective 
CCR5 gene affords near total protection against HIV infection in homozygotes and partial 
protection against disease progression in HIV-infected CCR5 heterozygotes (Dean, Carrington et al. 
1996; Cohen, Vaccarezza et al. 1997; EugenOlsen, Iversen et al. 1997). 
Berger, Murphy & Farber in 1999 reviewed the role of the CC chemokine designated MDC 
(macrophage-derived chemokine) which has been purified based on its ability to block both R5 and 
X4 HIV-1 replication in PBMCs. Also, RANTES, a chemokine ligand for CCR5, was found to 
suppress infection of R5 strains of HIV-1 by blocking it (Arenzana-Seisdedos, Virelizier et al. 
1996; Paxton, Martin et al. 1996). 
ii. The HLA class I loci it has been studied in multiple study cohorts, and has been set as the 
strongest effects on HIV disease progression (Carrington and O'Brien 2003; Fellay, Shianna et al. 
2007; Fellay, Shianna et al. 2010). Most recent HIV-1 host genetic studies have interrogated human 
genetic variants for their association with viral load and CD4
+
 T cell decrease, but only a few 
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confirmed genetic associations have been established in terms of the responsible causal sites. 
However, fundamental questions remain about the exact mechanisms involved in viral control 
(Dalmasso, Carpentier et al. 2008; Le Clerc, Limou et al. 2009; Limou, Le Clerc et al. 2009). The 
complete comprehension of the genetic differences in host factors between patients who differently 
develop the disease may provide an insight into the history of the HIV disease. It is general 
knowledge that viral factors acting together with some host-genetic factors may contribute to non-
progression or slowly progressing HIV disease (Saksena, Rodes et al. 2007). Although a variety of 
host factors have been examined, a significant correlation has been observed between HLA genes. 
Heterozygosis at all HLA class I loci appears to be protective against HIV infections. The alleles 
B57, B27 and *5701 is correlated with the control of HIV-1 replication and disease progression 
(Saksena, Rodes et al. 2007; Hunt and Carrington 2008; Chatterjee 2010). However strong virus-
specific T helper cell responses are more frequent and certain HLA alleles are preferentially 
expressed in individuals who spontaneously control HIV-1 (Frahm, Kiepiela et al. 2006; Bailey, 
Zhang et al. 2007; Singh, Kaur et al. 2008; Miura, Brockman et al. 2009). 
 
iii. Cytokine and immune response genes 
Involvement of host genetics has also been explored recently in several studies. With the advent of 
genome-wide microarray platforms, several genome wide studies have been carried out (Jiang, 
Willner et al. 2013). 13% of the observed variability in HIV-1 viremia is attributed to genetic 
variants, as several genome-wide association studies (GWAS) validated. The addition of gender, 
age and residual population structure to the genetic model increases the figure up to 22% (Fellay 
2009; Okulicz, Marconi et al. 2009; Fellay, Shianna et al. 2010). Despite recent advances in the 
treatment of the HIV-1 infection, there remains great variability in the course of this disease among 
patients. The determination of factors associated with progression may enable the development of 
therapeutic or prophylactic vaccines to control disease or prevent infection (Pantaleo and Fauci 
1996; Graziosi, Soudeyns et al. 1998; Leserman 2003; Mandalia, Westrop et al. 2012). Although 
the vast majority of those who are infected with HIV-1 will develop AIDS, there is mounting 
evidence that some people are able to live with the virus for extended periods of time without 
developing clinical disease (Hewson, Lone et al. 1999). There comes the interplay of host factors 
with the virus. 
Various studies that included collection of data in patients, regarding every aspect of the AIDS 
progression, such as CD4
+
T cells count, viral load and manifestations of clinical symptoms and host 
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genetic factors, came to the conclusion that there are three major types of patients which are 
differently presented, as shown in Figure 1.7 (Carrington and O'Brien 2003; Chatterjee 2010):  
 
- Slow progressors (SP) or long-term survivors present lower CD4+ T-cell levels (<500 cells 
ml) and higher viral loads (Betts, Krowka et al. 1999; Levy 2009), in whom AIDS develops 
slowly between a spam of 3 and 10 years after sero-conversion; 
-  Long-term non progressors (LTNP) or ‘elite controllers’ (EC), who mainly maintain the 
levels of viral load under detection (<50 copies/mL) for more than 10 years, they account 
for 5% – 15% of individuals infected with HIV (Saksena, Rodes et al. 2007; Piacentini, 
Biasin et al. 2009); the HIV Controller Consortium estimates that roughly 1 in 300 HIV-
infected persons meet the criteria for being an EC (Okulicz, Marconi et al. 2009);  
- Rapid progressors (RP), those in whom AIDS develop within 2–3 years of infection. 
 
It is still uncertain whether all of the above or only some of these factors would occasionally result 
in a truly protective status against the disease, or whether they would just delay the progression. 
Evidence in favour of further damage has been reported recently in patients naturally controlling the 
disease for long periods of time (Greenough, Sullivan et al. 1999; Birch, Learmont et al. 2001), 
although it does not exclude the possibility that the infection could be non-pathogenic in some 
individuals. 
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Figure 1.7. Disease progression in HIV-1-infected typical progressors, LTNPs and rapid progressors 
according to CD4
+
 T-cell counts and viraemia. Source: Poropatich et al (2011). 
 
1.9 Long term non progressors (LTNP) 
According to the review article by Gaardbo and collaborators (2012) prior to the introduction of 
combination antiretroviral therapy (cART) it was observed that a minority of the individuals 
infected with HIV-1, did not progress to AIDS or death. This minority maintained normal CD4
+
 cell 
counts in the absence of treatment for several years—in some cases for more than two decades and 
therefore the terminology Long-Term Nonprogressors (LTNP) was proposed. When the technique 
for measuring the viral load was introduced it became evident that some of these patients, who did 
not clinically progress, had low or even nondetectable viral replication. This phenomenon leads to 
the additive definition of the non progressor-phenotype referred to as controllers due to their ability 
to control viral replication in the absence of cART. 
HIV-1 infection does not always progress to AIDS. An interplay of viral, genetic and immunologic 
factors guide the non-progressive phase of HIV disease (Figure 1.8). A small number of infected 
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individuals spontaneously control HIV-1 replication in the absence of antiretroviral treatment and 
maintain a healthy status in the long term (Okulicz, Marconi et al. 2009; Mandalia, Westrop et al. 
2012; Le, Wright et al. 2013). Less than 0.2% of HIV-1 seropositive patients show stringent HIV 
control, as defined by a viral load <50 copies HIV-1 RNA/ml for over 10 years, but these rare 
individuals have a remarkably low risk of progression to AIDS. Patients with spontaneous HIV 
control have been termed HIV controllers or, in other words, Elite Controllers (EC) (Carrington and 
O'Brien 2003; Chakrabarti and Simon 2010; Chatterjee 2010). The Elite controllers (EC) are the 
individuals with <50 HIV-RNA copies/ml, differently from the viremic controllers (VC), who are 
those with detectable but low-level plasma HIV-RNA (always below 5000 copies/ml). The LTNPs 
are the ones with very low or undetectable viral replication, and sustain very slow disease 
progression or a complete lack of it. These individuals provide a unique opportunity for identifying 
potential factors associated with spontaneous control of HIV replication. Multiple factors both from 
the host and the virus seem to result in the favourable outcome of LTNPs (Easterbrook 1999; Deeks 
and Walker 2007; Okulicz, Marconi et al. 2009; Lopez, Soriano et al. 2011).  
Since the 80’s, a variety of definitions have been used to categorize these individuals, who were 
also defined as subjects with lack of disease progression. That description was primarily based on 
the stability of CD4 cell counts and the duration of symptom-free HIV infection (Lifson, Rutherford 
et al. 1988; Munoz, Wang et al. 1989; Pantaleo, Graziosi et al. 1993). Published analyses of LTNP 
patients differ in defining CD4 cell count thresholds as well as the duration of clinical and 
immunologic stability, with most studies ranging from 7 to 10 years or more of follow-up. In the 
mid-90’s technology made a huge different in science and the test with HIV RNA brought insights 
in this group, showing that most of them display low to intermediate plasma viral load and 
magnitudes of HIV RNA  (Cao, Qin et al. 1995; Pantaleo, Menzo et al. 1995; Okulicz, Marconi et 
al. 2009). Through the years, the ECs became the study focus of various specialists; many believed 
that they are the key to important information on the determinants of non-progression, and the use 
of such information in designing new interventional strategies will be able to contain the disease. 
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Figure 1.8. Overview of the viral, genetic and immunological factors associated with long-term control of 
HIV-1 infection. Source: Poropatich et al (2011). 
 
Others studies have suggested that LTNPs and EC are infected with defective virus, which could 
potentially explain their clinical status (Wang, Dyer et al. 2002; Saksena, Rodes et al. 2007). In the 
first study to sequence the entire genome of HIV-1 isolates from EC, they were only able to find 
minor mutations that did not affect the function of HIV-1’s genes and thus could not explain the 
subjects’ elite suppression of infection. In a subsequent experiment, the investigators sequenced the 
viral isolates of one of the ECs before and after virologic breakthrough in order to determine 
whether any mutations were associated with their disease non-progression (Mikhail, Wang et al. 
2003; Shepard, Loutfy et al. 2008). They found that the subject retained the same detectable 
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mutations at all-time points. This demonstrates that their mutations do not explain a mechanism for 
the control of infection and other mechanisms must play a part in their long-term control of 
infection. If the same can be shown for the remaining three ECs from the original, this would 
potentially rule out viral attenuation as the cause of their disease non-progression, which would 
shift the focus to immunological and genetic modes of control (Poropatich and Sullivan 2011; 
Barton, Burch et al. 2013; Cruz, Amorim et al. 2013). 
Apart from that, as Lambotte and Okulicz describe in their review, these patients differ from 
traditional LTNPs in that the definition of elite controllers is based on an undetectable viral load, 
rather than stable CD4
+
 T-cell counts. The incidence of ‘elite’ control is much lower (approximately 
1% in most cohorts) than the incidence of immunologic non-progression. Importantly, some 
controllers progress immunologically and many non-progressors have detectable levels of viremia 
(Blankson 2010; O'Connell, Brennan et al. 2010; Blankson 2011).  
 
HIV-1, in common with all viruses, requires the concerted contributions of numerous positively 
acting cellular factors and pathways to achieve efficient replication (Bushman et al. 2009).  
Conversely, mammalian cells also express a number of diverse, dominantly acting proteins that are 
widely expressed and function in a cell-autonomous manner to suppress virus replication. These 
have been termed restriction factors and/or intrinsic resistance factors, and they provide an initial 
(or early) line of defense against infection as a component of innate antiviral responses. This factors 
are the apolipoprotein B messenger RNA (mRNA)-editing enzyme catalytic polypeptide-like 3 
(APOBEC3) family of proteins (in particular,APOBEC3G), tetherin/bone marrow stromal cell 
antigen 2 (BST2)/CD317 (hereafter called tetherin), and tripartite-motif-containing 5α (TRIM5α) 
(Perera 2012; Malim 2012). 
 
A fundamental concept to the biology of restriction factors is thatHIV-1 generally evades their 
potent inhibitory activities in human cells, thereby allowing virus replication to proceed efficiently. 
The mechanisms for evasion from restriction factors are virus encoded and frequently involve HIV-
1’s regulatory/accessory proteins (Malim 2012). Aside from restriction factor evasion, the vpu and 
nef proteins regulate the expression and localization of a number of host proteins important during 
HIV-1 replication. Prominent among these interactions, vpu and nef both inhibit the cell surface 
expression of the primary entry receptor CD4, as well as major histocompatibility class I complexes 
(MHC class I), whereas Nef also helps promote T-cell activation and HIV-1 particle infectivity 
(reviewed by Kirchhoff 2010). 
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1.10 Prevention and treatment of the HIV infection  
1.10.1. Prevention 
In 2012, the Food and Drug Administration (FDA) approved emtricitabine/tenofovir disoproxil 
fumarate (FTC/TDF) as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in adult men 
and women. Although no single tool will be enough to stop the spread of HIV, PrEP should now 
become a vital part of a comprehensive, global strategy to end the epidemic.  
There is now an array of interventions to choose from to prevent HIV transmission and acquisition. 
The Centers for Disease Control and Prevention’s (CDC’s) strategy of ‘High Impact Prevention’ 
involves a combination of HIV prevention interventions, including: antiretroviral therapy (ART) for 
all HIV-infected adults; antiretroviral prophylaxis in the form of PrEP and/or post-exposure 
prophylaxis (PEP) for HIV-exposed persons; treatment of sexually transmitted infections (STIs); 
circumcision; wide-scale condom distribution; adherence counselling; behavioural change 
interventions; wide-scale HIV testing programs, and linkage and retention to care. Numerous 
studies have now demonstrated that PrEP also dramatically reduces the risk of HIV acquisition, 
including among women, with minimal risk of incident ART resistance (Aaron and Cohan 2013). 
HIV prevention efforts have relied on advancements in treatment, with the development of a 
preventive vaccine a truly daunting challenge. The concept that the treatment of the infection may 
act as prevention has garnered tremendous interest and hope and inspired a series of population-
level HIV-1 treatment-as-prevention studies (Cohen and Gay 2010; Baeten, Donnell et al. 2012). 
The early beginning of antiretroviral therapy has a clinical benefit for both HIV-1 infected persons 
and their uninfected sexual partners. It is known that the treatment may act as part of a public health 
strategy to reduce the spread of HIV-1 infection, and a reduction of 89% in the total number of 
HIV-1 transmissions was observed, resulting from the early initiation of antiretroviral therapy, 
regardless of viral linkage with the infected partner (Joos, Trkola et al. 2005; Graham, Holte et al. 
2007; Alter, Rihn et al. 2008; Cohen, Chen et al. 2011).  
Antiretroviral treatment for persons infected with HIV-1 provides important clinical benefits and 
substantially reduces infectiousness. This type of prophylaxis is a potential type of prevention 
strategy for those not yet infected with HIV-1, administered either as post-exposure prophylaxis 
after high-risk occupational or non-occupational exposure or as pre-exposure prophylaxis in those 
with ongoing HIV-1 exposure. In perinatal transmission studies, the protective benefits of 
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antiretroviral prophylaxis were maximized when the antiretroviral medication was administered 
both before and after HIV exposure (Groenink, Fouchier et al. 1993; Arhel and Kirchhoff 2010; 
Karim and Karim 2011).  
ART use by the infected person was accompanied by a 92% reduction in risk of HIV-1 transmission 
to their partner. ART substantially reduces HIV-1 infectiousness and transmission risk (Chaisson, 
Keruly et al. 2000; Donnell, Baeten et al. 2010). Plasma HIV-1 RNA concentrations decreased 
significantly after ART initiation, probably serving as the mechanism by which ART reduced risk 
of HIV-1 transmission. We also recorded a small but significant increase in condom use after 
treatment was initiated. The greatest effect of ART on HIV-1 transmission risk was in participants 
with CD4 cell counts lower than 200 cells per μL, emphasising the potential synergy of clinical and 
prevention benefits of ART in those with CD4 cell counts lower than this threshold (Chaisson, 
Keiser et al. 1997; Quinn, Wawer et al. 2000; Madani, Hubicki et al. 2007). 
 
1.10.2  Highly active antiretroviral therapy  
Antiretroviral therapy began in the mid-1980s, with the first study conducted on the use of 
zidovudine (AZT) in 282 subjects affected with AIDS or AIDS-related complex. This study 
analysis showed a reduction in the frequency of opportunistic infections and increased survival 
among the treated patient groups, when compared with the placebo group (Mitsuya, Weinhold et al. 
1985; Fischl, Richman et al. 1987; Volberding, Lagakos et al. 1990). 
The enthusiasm that followed the first success with two drug combination therapies grew with the 
introduction in clinics of new classes of antivirals, such as non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) and protease inhibitors (Pls).  PIs are the drugs that have shown the best results 
and, at present, triple combinations of drugs including a protease inhibitor are the gold standard of 
antiretroviral therapy. The HIV protease, encoded by the pol gene and composed of 99 amino acids, 
is responsible for the cleavage of the non-functional polyprotein precursor. Its inactivation (due to 
interactions with the active site) causes the production of immature virions, incapable of infecting 
new cells (Moyle and Gazzard 1996; McDonald and Kuritzkes 1997; Bonfanti, Capetti et al. 1999; 
Arhel and Kirchhoff 2010). 
The introduction of highly active antiretroviral therapy (HAART) in 1996, comprising 
combinations of HIV reverse transcriptase and protease inhibitors, resulted in dramatic decreases in 
HIV-related morbidity and mortality in the United States. The treatment increased CD4
+
 T-cell 
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counts and suppressed viral load to undetectable in most patients in the trial (Gulick, Mellors et al. 
1997; Hammer, Squires et al. 1997; Angel, Parato et al. 2001).  
The increase in CD4
+
 T cells observed during HAART is usually strongly correlated with the 
degree of viral load suppression, and is key to long-term control of HIV replication. Recovery of 
immune function with HAART occurs in two distinct phases. The first phase begins within 1 to 3 
months of therapy and is characterized by rapid increases in the levels of circulating naive and 
memory CD4
+
 T cells, naive CD8
+
 T cells, and B cells. T. The second phase of immune recovery is 
characterized by a slower increase in levels of circulating CD4
+
T-cells, as new T cells proliferate 
(Lederman, Connick et al. 1998; Lederman 2001; Verheggen 2003). This treatment combines 
inhibitors of HIV-1 protease and reverse transcriptase, greatly decreases plasma HIV-1 viral RNA 
concentrations and increases CD4 counts even in patients at advanced stages of the disease (Table 
1.2) (Collier, Coombs et al. 1996; Hogg, O'Shaughnessy et al. 1997; Perelson, Essunger et al. 1997; 
Li, Tubiana et al. 1998). 
More people initiated antiretroviral therapy in 2011, with the number of people living with HIV 
receiving treatment rising by 21% compared with 2010, based on data from country progress 
reports. Antiretroviral therapy reached 8 million people by the end of 2011 – a 20-fold increase 
since 2003. Since 1995, antiretroviral therapy has added 14 million life-years in low- and middle-
income countries, including 9 million in sub-Saharan Africa (UNAIDS 2012). 
Transient administration of HAART early during seroconversion may preserve the HIV-specific 
immunity. Several studies have shown that HAART during primary HIV infection results in 
development of p24 specific CD4
+
 T-cell responses. In contrast, delayed initiation of HAART is 
associated with a progressive loss of HIV-specific CD8
+
 T cells and the absence of HIV-specific T-
cell help. HAART in chronically infected patients with few exceptions fails to induce p24 specific 
CD4
+
 T-cell responses (Bostrom, Hejdeman et al. 2004). 
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Table 1.2. Antiretroviral Agents Used in the Treatment of HIV Infection. Reproduced with permission from Clavell (2004), Copyright Massachusetts 
Medical Society 
Drugs Mechanisms of Action Mechanisms of Resistance 
Nucleoside analogues 
Zidovudine 
Stavudine 
Lamivudine 
Didanosine 
Zalcitabine 
Abacavir 
Analogues of normal nucleosides 
Active as triphosphate derivatives 
Incorporated into nascent viral DNA 
Prematurely terminate HIV DNA synthesis 
Thymidine analogue mutations promote 
ATP-mediated and pyrophosphate-mediated 
excision of the incorporated terminator 
M184V or Q151M complex mutations impair 
incorporation of nucleoside analogues 
Nucleotide analogues 
Tenofovir 
Same as nucleoside analogues K65R impairs incorporation of tenofovir into 
DNA 
Thymidine analogue mutations often associated 
with cross-resistance 
Nonnucleoside reverse-transcriptase 
inhibitors 
Nevirapine 
Efavirenz 
Delavirdine 
Bind a hydrophobic pocket of HIV type 1 
reverse transcriptase 
Block polymerization of viral DNA 
Inactive against HIV type 2 
K65R impairs incorporation of tenofovir into 
DNA 
Thymidine analogue mutations often associated 
with cross-resistance to tenofovir 
Mutations reduce affinity of the inhibitors for 
the enzyme 
Single mutations generally sufficient to induce 
high level of resistance 
Protease inhibitors 
Saquinavir 
Ritonavir 
Indinavir 
Nelfinavir 
Amprenavir 
Lopinavir 
Structure derived from natural peptidic 
substrates of the HIV type 1 protease 
Bind the active site of the protease 
Mutations reduce affinity of the inhibitors for 
the enzyme 
High-level resistance requires accumulation 
of mutations 
Fusion inhibitors 
Enfuvirtide 
36-Amino-acid peptide derived from the HR2 
domain of glycoprotein 41 
Interferes with glycoprotein 41–dependent 
membrane fusion 
Mutations affect HR1, a domain of glycoprotein 
41 whose interaction with HR2 
promotes membrane fusion 
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1.10.2.1 Nucleoside analog RT inhibitors (NRTI) 
Although the different nucleoside analog RT inhibitors act by similar mechanisms, they have 
different potencies, toxicity effects, and drug-resistance profiles. When administered as single 
agents, the nucleoside analogs cause either weak or transient HIV- 1 suppression. When 
administered in certain two drug combinations, their antiviral activity is significantly increased and 
prolonged. However, even when used in two-drug combinations, complete HIV-l suppression is 
rare and viral rebound towards baseline eventually occurs along with the development of drug 
resistance. The activity of NRTIs depends on two factors: (1) the intracellular concentration of their 
triphosphorylated moiety, since NRTIs require triphosphorylation by cellular kinases to act as 
competitors of the natural 2-deoxy-nucleoside trisphosphates (dNTPs); (2) the concentration of the 
cellular dNTP pools. M/M are resting cells, characterized by a limited DNA synthesis and, 
consequently, by low intracellular level of dNTPs (Perno, Svicher et al. 2006). 
1.10.2.2. Non-nucleoside RT inhibitors (NNRTI)  
The non-nucleoside reverse transcriptase inhibitors (NNRTI) inhibit reverse transcription 
allosterically by binding to a hydrophobic pocket of HIV-l RT. There are three approved NNRTIs 
in the US (nevirapine, delavirdine, and efavirenz) and two approved in Europe (nevirapine and 
efavirenz). When used alone or with only a single nucleoside analog, the NNRTI rapidly elicit drug 
resistance by selection of HIV-l variants with at least one or two mutations in the hydrophobic 
NNRTI-binding pocket. Differently from the NRTIs, NNRTIs are non-competitive inhibitors of 
HIV-1 reverse transcriptase that bind at a hydrophobic pocket near the polymerase active site. 
These compounds do not prevent the binding of nucleoside triphosphate substrates to reverse 
transcriptase, but block the polymerization reaction and thus the ability of reverse transcriptase to 
synthesize viral DNA (Perno, Svicher et al. 2006). 
1.10.2.3. Protease inhibitors (PI) 
Protease inhibitors, acting at a post-integrational step of HIV-1 life-cycle, are the only drugs able to 
suppress HIV-1 replication in chronically infected M/M, characterized by the proviral DNA already 
integrated into the genome (Perno, Svicher et al. 2006). Each of the approved protease inhibitors 
were designed to fit into the HIV-l protease substrate cleft, thereby inhibiting post-translational 
cleavage and viral maturation. Five protease inhibitors (saquinavir, indinavlr, ritonavir, nelfinavir 
and amprenavir) have been approved. The HIV protease inhibitors are a newer class of agents with 
potent antiretroviral activity. Early dose-escalation studies showed that monotherapy with indinavir 
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or ritonavir affected HIV RNA levels and CD4 cell counts markedly. These antiretroviral effects 
were transient in some patients at lower drug doses and were associated with the emergence of 
drug-resistant virus. The three-drug combination of indinavir, zidovudine, and lamivudine reduced 
the viral load in serum to less than 500 copies per millilitre for up to one year in more than 80 
percent of the HIV-infected patients we studied, all of whom had prior antiretroviral therapy 
(Gulick, Mellors et al. 1997). 
1.10.2.4 Fusin inhibitors (FI) 
Peptide fusion inhibitors were designed based on the discovery of two homologous domains (the 
gp41 ectodomain and of the ectodomain) partnered with an inhibitory peptide (C34) (Wilen, Tilton 
et al. 2012). Studies have shown that resistance mutations in gp41 decrease fusion efficiency and 
reduce viral fitness (Labrosse, Labernardiere et al. 2003). Mutations in the co-receptor binding site 
that reduced gp120 affinity for CCR5 resulted in viruses with reduced fusion kinetics (Derdeyn, 
Decker et al. 2000).  
 
1.10.2.5 CCR Antagonist 
Small-molecule CCR5 antagonists bind to hydrophobic pockets within the transmembrane helices 
of CCR5 (Dragic, Trkola et al. 2000; Tsamis, Gavrilov et al. 2003). This site does not overlap the 
binding sites of either CCR5 agonists or HIV-1 envelope. Instead, drug binding induces and 
stabilizes a receptor conformation that is not recognized by either (Arts and Hazuda 2012). 
1.10.2.6 Integrase inhibitors 
Integrase was the most recent HIV-1 enzyme to be successfully targeted for drug development 
(Espeseth, Felock et al. 2000; Hazuda, Anthony et al. 2004). Raltegravir (RAL) was approved by 
the FDA in 2007, and other integrase inhibitors are progressing through clinical development. All 
integrase inhibitors in development target the strand transfer reaction. Selective effect on strand 
transfer is a result of a now well-defined mechanism of action, in which the inhibitor binds only to 
the specific complex between integrase and the viral DNA, and interacts with the two essential 
magnesium metal ion cofactors in the integrase active site and also the DNA (Grobler, Stillmock et 
al. 2002). Due to this new action, they are considered to be the only ARV class that interacts with 
two essential elements of the virus, the integrase enzyme as well as the viral DNA, which is the 
substrate for integration (Arts and Hazuda 2012).  
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2.1 Genomic Basis of HIV Disease Progression and Non-Progression 
There has been a considerable  effort in identifying genomic determinants of susceptibility to 
HIV-1 infection, natural control of viral replication and disease progression. Genetic analyses 
have identified over the years a number of validated variants in candidate genes, while a 
recent genome-wide association study highlighted the dominant role of variants in the MHC 
region, in the control of viral set point (the steady state of viral replication after infection) and 
disease progression. There have been a number of transcriptome studies on CD4
+
 , CD8
+
 T 
cells, monocytes/macrophages, NK cells and B cells, and of dendritic cells and total 
peripheral blood mononuclear cells (PBMCs) (Telenti and Goldstein 2006; Wu, Dwyer et al. 
2011; Saksena, Conceicao et al. 2013).These studies have provided deeper insights into gene 
expression changes, associated with virus replication and persistence, thereby defining the 
genetic basis of HIV disease staging. Several studies are limited by the number of individuals 
investigated, due to lack of non-progressors. These limits notwithstanding, microarray data 
have yielded novel mechanisms on HIV-mediated pathogenesis. Transcriptome analyses of 
variety of primary cell types from HIV patients has further revealed the genetic segregation 
of HIV disease stages, based on individual cell types, thereby highlighting cell-specific 
disease changes at the level of host genes during HIV infection. Integrating gene expression 
data with results from genome-wide association studies may help prioritize fine mapping 
efforts and provide shortcuts to disease biology (Nica and Dermitzakis 2008; Rotger, Dang et 
al. 2010).  
 
2.1.1 Contribution of high throughput genomic studies  
Recent developments in high-throughput screening with the addition of gene array genomic 
and proteomic based technologies, the understanding of virus–host interaction and genome-
wide dysregulation during HIV infection has greatly increased (Geiss, Bumgarner et al. 2000; 
Giri, Nebozhyn et al. 2006; Saksena, Conceicao et al. 2013). Gene arrays have revolutionized 
the way host cellular pathways are assessed, in the context of not only HIV, but also other 
viruses’ diseases, as it can be used to better interpret the role of host genes during HIV 
infection. The beginning of cDNA microarrays studies have changed the focus from the 
characterization of isolated genes to global gene expression analysis (Mehla and Ayyavoo 
2012). The advent of this genome-wide approaches marked a significant change in genetic 
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studies, now global host influences on HIV are assessed in single experiments, and individual 
contributions of numerous genetic variants can be ranked and compared for a comprehensive 
view of the impact of human genomic variation on HIV-1 infection (Telenti and Goldstein 
2006). 
Several genome-wide association studies explored the influence of human genetic variation 
on HIV-1 replication and disease progression. These GWAS have recently become the 
approach of choice to search for host factors involved in HIV-related outcomes, and to assess 
their relative contribution. They may also provide new insights into the molecular aetiology 
of complex diseases, by discovering unsuspected genetic risk factors and, as a consequence, 
identifying new diagnostic or therapeutic targets. Genetic variants play critical role in the 
inter-individual variability of HIV phenotypes. Targeted or whole-genome re-sequencing 
strategies will prove essential to better appreciate the global contribution of the human 
genome to HIV-1 control (Telenti and Ioannidis 2006; Fellay, Shianna et al. 2007; Bushman, 
Malani et al. 2009; Fellay 2009; Fellay, Ge et al. 2009; Fellay, Shianna et al. 2010; Messiaen, 
De Spiegelaere et al. 2012). Although it is been stated by Felay et al (2009) that some 
technical limitations to genetic studies were mostly overcome, there are still great amounts of 
new directions that could be changed, such as: clinical outcomes and biological phenotypes, 
that should be very precisely defined; the insertion of a rule for the use of ancestry markers to 
correct population stratification; and finally large cohorts of ethnically diverse origin should 
be analysed to decrease the likelihood of false positive findings and increase the coverage of 
human diversity.  
In the end, the genomic analyses have advanced to the point that a comprehensive analysis of 
the role of genetic variation in viral control is available. Microarray studies provide global 
view of gene expression and group differentially expressed genes according to the similarity 
of their expression profiles (Giri, Nebozhyn et al. 2006).  
As a consequence of this whole new side of genetic analysis, the detection of differentially 
expressed genes from expression data was an insight into the functional mechanisms that 
might influence the HIV-1 infection (Emmert-Streib and Glazko 2011). As it was supported 
before, the HIV-1 virus has the power to manipulate the host gene machinery at a very 
profound level. The data of different pathways analysis into the context of biological 
knowledge will change the way HIV infection is studied. Most of the current efforts are now 
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focused on the genomic influence of HIV on the host genome (Emmert-Streib and Glazko 
2011; Saksena, Conceicao et al. 2013).  
2.1.2. Host Cellular Transcriptome mapping and HIV disease  
The recent literature shows that gene array technology has been used for a better 
understanding of the host gene expression in HIV infection. Through the use of microarray 
techniques and other high-density gene array technology, it is possible to examine the 
expression profiles of thousands of cellular genes simultaneously, to monitor the full 
spectrum of gene expression in cells subsequent to infection by HIV-1 (Vahey, Nau et al. 
2002).  
Various groups have monitored gene expression in cell lines and primary T cells infected 
with HIV-1 in vitro, as well as the major cells in the immune system, such as macrophages 
and CD4
+
T cells that are the target of HIV-1 virus (Geiss, Bumgarner et al. 2000; Hyrcza, 
Kovacs et al. 2007; Salgado, Lopez-Romero et al. 2011). These studies ignore the fact that 
the HIV-1-induced T-cell abnormalities are systemic and affect all cells and not just the 
minor fraction of HIV-1-infected cells. Other groups have monitored gene expression from 
lymph nodes, B cells, latently infected T cells, gut tissue, etc. (Ryo, Suzuki et al. 1999; Leng, 
Borkow et al. 2002; Bosinger, Hosiawa et al. 2004; Ockenhouse, Bernstein et al. 2005; 
Hyrcza, Kovacs et al. 2007).  
Transcriptome studies performed in CD4
+
and CD8
+
T cells show how this cell types have 
important roles on progression of HIV disease. Through pathway analysis, they have 
identified a network of metabolic pathways dysfunction, by detecting up-regulating genes 
involved in apoptosis. These data provide evidence that HIV-1 induces a strong HIV-1–
specific proliferative response in persons who are controlling viremia in the absence of 
antiretroviral therapy, and suggest that early, aggressive treatment of primary infection may 
facilitate the generation of these responses. Although disease progression in HIV-1 infection 
is likely to depend on several factors, the inverse association between p24-specific CD4
+
 T 
cell proliferative responses and viral load is consistent with the hypothesis that these 
responses contribute to immunological control of virus replication.  (Rosenberg, Billingsley 
et al. 1997; Wu, Wang et al. 2007; Wu, Dwyer et al. 2008; Wu, Dwyer et al. 2011). 
Combined, these data offer new comparative insights into HIV disease progression from the 
aspect of HIV-host interactions at the transcriptomic level, for a better understanding of the 
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genetic basis of transcriptomic interaction of HIV in vivo, and how HIV subverts the human 
gene machinery at the individual cell type level. 
Extensive studies on monocytes were performed by our group, which showed strong 
evidence of gene regulation of specific pathways, when comparing HIV
+
 patients with LTNP. 
The function of these pathways was relevant to HIV disease progression, especially those 
involved in cell apoptosis, proliferation, activation and cytotoxicity. Patients that progress to 
disease were significantly associated with the down-regulation of these pathways, whereas 
the LTNP, who naturally controls the disease, are significantly associated with the up-
regulation of these pathways. From the aspect of HIV-host interactions at the transcriptomic 
level, these data facilitate the understanding of the genetic basis of transcriptomic interaction 
of HIV in vivo, and how HIV subverts the human gene machinery at the individual cell type 
level, with new comparative insights into HIV disease progression (Wu, Dwyer et al. 2008; 
Wu, Dwyer et al. 2011; Wu, Sasse et al. 2013).  
Also, studies have been investigating the B lymphocyte disorders. These cells are important 
consequences of HIV infection and can persist despite of therapy. A correlation between B 
cell growth factors and HIV disease progression was found, and B cell dysregulation appears 
throughout disease progression (Jacobson, Khayam-Bashi et al. 2002; Fontaine, Chagnon-
Choquet et al. 2011; Poudrier and Roger 2011). HIV elite controllers expresses relatively low 
levels of B cell growth factors. This suggests that therapeutic blockage of these factors in 
HIV progressors may restore balanced effector to regulatory cell ratios, and reduce both HIV 
target cells and systemic immune activation, which are the hallmarks of HIV disease 
progression  (Poudrier and Roger 2011). 
Various studies have indicated that the expression of activating receptors are decreased and 
inhibiting receptors are increased during progressive HIV infection, while others showed that 
inhibitory receptor levels are not elevated significantly (Mogensen, Melchjorsen et al. 2010). 
Genome-wide analyses are essential in identifying new candidates for HIV therapeutics and 
development of new biomarkers in predicting disease rates. The full analysis of the 
differentially expressed genes for progressive and non-progressive HIV disease will facilitate 
the understanding of genetic basis of progressive and non-progressive disease (Salgado, 
Lopez-Romero et al. 2011). A systematic genetic approach would be ideal for providing new 
leads to strategies targeting host genes and pathways that HIV tends to dysregulate (O'Brien 
and Nelson 2004; Emmert-Streib and Glazko 2011). The current global focus is on defining 
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more and more genetic and immunologic correlates of the host–pathogen interaction, with a 
view to develop possible biomarkers for infection, transmission, and disease progression, as 
well as for curative strategies for HIV. Supporting this view point, Kaur et al (2009) showed 
that structural genomic approaches aimed at defining chromosomal localization in a host of 
human genetic variants, regulate susceptibility to HIV infection, rate of CD4 decline, viral 
load, disease progression, and response to therapy, and can be very helpful in understanding 
the disease. They also showed, in a chromosomal level, that a particular set of genes that 
regulate expression of chemokines, cytokines, HIV-1 coreceptors, and immune response 
following HIV-1 infection have been defined with their genetic loci located on variable 
chromosomes (Kaur and Mehra 2009). 
Numerous studies have shown that an extensive inter-individual variability exists in response 
to HIV infection. These can vary in their viral set points, rates of decline of CD4 T cells, 
levels of viremia, emergence of CTL escape mutants, and development of opportunistic 
infections, resulting in varying incubation periods of the AIDS virus (Telenti and Goldstein 
2006; Kaur and Mehra 2009; Sakurai, Ara et al. 2011). Reports showed that multiple genetic 
factors are expected to be involved in disease pathogenesis and progression, following HIV 
infection, and the power with which RNA interferes and forward genetics can be used to 
expose the dependencies of human pathogens such as HIV (Brass, Dykxhoorn et al. 2008). A 
study carried out by O’Brien and colleagues using five different cohorts (Multicenter 
Hemophilia Cohort Study, AIDS Link to Intravenous Experience, Hemophilia Growth and 
Development Study, Multicenter AIDS Cohort Study and San Francisco City Cohort) has 
shown the existence of a number of ‘AIDS restriction genes’ that could determine the genetic 
propensity of an individual or a population and help predict survival kinetics following HIV 
infection (O'Brien and Nelson 2004; Winkler, Hendel et al. 2004; Telenti and Goldstein 
2006).  
From these studies, it is clear that the genetic make-up of an individual has been shown to 
play a role in the susceptibility to HIV-1 infection and/or the rate of disease progression. 
Some of the observed variation could be attributed to HLA types, as extensively explained 
before. Also, it is already established that the polymorphism associated with CCR5 reduce 
susceptibility to infection and sets a slower rate of disease progression. In the last couple of 
years, several GWAS have been published to reveal additional host genetic factors that are 
associated with HIV-1 control. However, all host genetic factors identified to date can 
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explain the clinical course of HIV-1 infection in only a minority of individuals. Recent 
studies have shown specific immunologic and genetic features associated predominantly with 
elite controllers, that could be correlated to their ability to resist virus (Kaur and Mehra 2009; 
Limou, Le Clerc et al. 2009; van Manen, Delaneau et al. 2011). 
It is believed that, due to the considerable heterogeneity in the AIDS epidemic showed by 
various studies, this disease should be considered genetic, as it is partially determined by 
variants in genes that moderate virus replication and immunity (O'Brien and Moore 2000; 
Carrington and O'Brien 2003; Fauci 2003). Combinations of genome-wide studies have 
widened our understanding of how gene expression modulates HIV disease progression and 
the outcome of therapy and its success to some extent. Comprehension of the complex 
behaviour some genes acting in conjunction with other genes at the pathway level will 
facilitate the identification of the new generation of biomarkers for HIV.  
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2.1 General materials and Methods 
 
2.1.1 cDNA Microarray 
 
2.1.1.1 Thawing of Frozen PBMC 
Retrospectively collected, frozen PBMCs from patients in two time points (before and after 
treatment), from The Red Cross Australia were donated for this study. The cryovials were 
thawed in a 37C water bath, and then transferred to a biosafety hood containing only a 
small amount of ice left in the tube. The vials were wiped with 70% ethanol (28mL of 
absolute ethanol (C2H6O), Chem-supply, Port Adelaide, Australia) and 12 mL of 
Dulbecco’s Phosphate Buffered Saline (PBS, Sigma-Aldrich, St Louis, MO), mixed and 
stored in a spray bottle for use before opening, and 1 mL of warm cRPMI (9mL of RPMI, 
Sigma-Aldrich, St Louis, MO) and 1mL of Foetal calf serum (FCS, CSL Biosciences, 
Parkville, Victoria, AUS) was slowly added to the cells. After that, the diluted cells were 
slowly transfered into a tube containing 8 mL of warm cRPMI and centrifuged at 250 x g 
for 7 minutes. The supernatant was decanted and the pellet gently flicked. The cells were 
gently resuspended in the 10mL of warm cRPMI, and counted microscopically using a 
haemocytometer to determine the number and cell viability. The supernatant was carefully 
removed by aspiration, as the incomplete removal of the cell-culture medium inhibits lysis 
and dilute the lysate, which eventually reduce RNA yield. The cells pellets were then 
loosened thoroughly by flicking the tube prior to disruption with 600μl of RLT lysis buffer 
(Qiagen Pty Ltd, Doncaster, Victoria, AUS), with addition of 10μl of β-mercaptoethanol 
(Amresco, Ohio, USA) per 1mL of RLT buffer, in order to extract the RNA, as per the 
manufacture’s protocol. 
 
2.1.1.2 Total RNA isolation  
Total RNA isolation was performed using RNeasy Mini Kit (QIAGEN Pty Ltd, Doncaster, 
Victoria, AUS), as per the manufacturer’s instructions. Approximately 1x106 cells from 
each patient frozen PBMC from section 2.2.1.1 were pelleted in 2mL microcentrifuge 
tubes for 5 minutes at 300 x g. These tubes were mixed by pulse vortexing before adding in 
600μl of 70% ethanol, followed by a subsequent mixing using the pipette. Each sample 
was then applied to an RNeasy mini column placed in a supplied 2mL collection tube. The 
tube was then closed gently and centrifuged in a microcentrifuge (Sigma 1-15 
microcentrifuge, Sigma, St Louis, MO, USA Sorvall RC26Plus) for 15 seconds at 10000 x 
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g. The RNeasy mini column contains silica-gel membrane, which has the binding capacity 
for 100μg RNA and allows DNA, proteins and cellular debris to pass through. After 
centrifugation, the flow through was discarded, while the collection tube was reused. 
Following this, on-column DNA digestion was performed using RNase-Free DNase Set 
(QIAGEN Pty Ltd, Doncaster, Victoria, AUS), to completely remove any possible 
remaining DNA. This was done by first adding 350μl of RW1 buffer (supplied by the kit) 
into the RNeasy mini column followed by centrifugation for 15 seconds at 10000 x g. The 
flow through was discarded, while the collection tube was reused. Concurrently, DNase I 
incubation mix was prepared in a separate 1.5mL eppendorf tube, by adding 10μl of DNase 
I stock solution to 70μl RDD buffer (supplied by kit). This was then mixed gently by 
inverting the tube, instead of vortexing, as DNase I was especially sensitive to physical 
denaturation. The mixture was then transferred directly onto the RNeasy silica-gel 
membrane and the tube was incubated for 15 minutes at room temperature. After the 
incubation, 350μl of RW1 buffer was transferred into the RNeasy mini column and 
centrifuged for 15 seconds at 10000 x g. Again, the flow through was discarded and the 
column was then washed in 500μl of RPE buffer (wash buffer supplied by kit) for 15 
seconds at 8000 x g. After discarding the flow through, the washing step was repeated 
again for 2 minutes at 8000 x g to dry the RNeasy silica-gel membrane. To eliminate any 
chance of possible RPE buffer carryover, RNeasy column was placed in a new 2mL 
collection tube and centrifuged in a microcentrifuge at full speed for 1 minute. For the 
elution step, the column was transferred to a new 1.5mL collection tube and 30μl of 
RNase-free water was added directly onto the column. This tube was then centrifuged for 1 
minute at 8000 x g to elute the RNA into the collection tube. 
 
2.1.1.3 Analysis of total RNA  
Total RNA extracted, as described in section 2.1.1.2, was analysed using Agilent RNA 
6000 Nano Kit (Agilent Technologies, Santa Clara, CA, USA), as per the manufacturer’s 
instructions. All reagents were equilibrated to room temperature for 30 minutes prior to 
use. The RNA 6000 Nano dye concentrate was mixed by vortexing for 10 seconds and then 
briefly centrifuged (Sigma 1-15 microcentrifuge, Sigma, St Louis, MO, USA Sorvall 
RC26Plus). 1μl of dye was then added into a 32.5μl aliquot of filtered gel, and this mixture 
was mixed thoroughly before centrifugation at 13000 x g for 10 minutes at room 
temperature. Concurrently, the electrode decontamination steps were performed to avoid 
any decomposition of the RNA samples. First, one of the wells of an electrode cleaner was 
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slowly filled with 350μl of RNaseZAP (Ambion, Austin, TX, USA), and then placed in the 
Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). This electrode 
cleaner was removed after 1 minute and was replaced by another separate electrode 
cleaner, which contained 350μl of RNase-free water. The second electrode cleaner 
remained in the Agilent 2100 bioanalyzer for approximately 10 seconds before it was 
removed. The final step was to let the lid of the machine open for 10 seconds in order for 
the water on the electrode to evaporate. When the gel-dye mix was ready, 9μl of the mix 
was transferred in the well marked G on the RNA 6000 Nano chip, placed on the chip 
priming station. Subsequently, the chip priming station was closed and the plunger was 
pressed until it was held by the clip. The clip was only released after 30 seconds. 9 µL of 
the remaining gel-dye mix was transferred into the wells marked G. Following this, 5μl of 
RNA 6000 Nano marker were measured into all 12 sample wells and in the ladder well. 1μl 
of prepared ladder (heat-denatured for 2 minutes at 70°C) and 1μl of sample (heat-
denatured for 2 minutes at 65°C) were transferred into their respective wells. The chip was 
then placed horizontally in the adapter and mixed on the vortex mixer for 1 minute at 2400 
rpm. The chip was now ready and was run in the Agilent 2100 bioanalyzer within 5 
minutes. When the assay was completed, the used chip was removed immediately from the 
machine. Then, the electrode was cleaned by placing an electrode cleaner filled with 350μl 
of RNase-free water for approximately 10 seconds. The water on the electrodes was left to 
evaporate for another 10 seconds before the lid was closed. The 2100 Expert software 
(Agilent Technologies, Santa Clara, CA, USA) was used to analyse the result and it 
displayed the value for the calculated RNA concentration, the ribosomal ratio and the RNA 
Integrity Number (RIN). A successful ladder run should have 1 marker peak and 6 RNA 
peaks with correct peak size assignment in the electropherogram. On the other hand, a 
successful total RNA run should have 1 marker peak and 2 ribosomal peaks. 
 
2.1.1.4 Amplification of RNA 
RNA amplification has become the standard method for preparing RNA samples for array 
analysis. The Illumina® TotalPrep
TM
 RNA Amplification Kit is a complete system for 
generating biotinylated, amplified RNA for hybridization with Illumina Sentrix® arrays. 
All the buffers and reagent were provided by the kit. First, we determine the amount of 
RNA that would be used following the manufacture’s parameters as shown in Table 2.1. 
The Illumina amplification procedure can accommodate various amounts of RNA input, 
but for reproducible and comparable results, a fixed amount of input RNA was used for all 
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experiments. After the amplification procedure, analysis by the Agilent 2100 bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA) was used to determine the amount of 
amplified RNA and its quality (as explained in section 2.1.1.3). A minimum of 25ng of 
RNA with a RIN of minimum 7.0 was used as our standard amount of input RNA. 
            
 
Table 2.1. Recommended amount of input RNA 
 
Recommended amount of input RNA 
Recommended mass amount of total RNA 50-500ng 
Minimum mass amount of total RNA 25ng 
Maximum volume of RNA 11µL 
 
 
2.1.1.4.1 Reverse Transcription to Synthesize First Strand cDNA 
A maximum volume of 11μL of total RNA was placed into a non-stick, sterile, RNase-free, 
0.5mL microcentrifuge tube. Nuclease-free water provided in the kit was used to bring all 
samples to 11 μL. At room temperature, the Reverse Transcription Master Mix was 
prepared in a nuclease-free tube. The required volumes for one reaction and the order of 
addition are shown in the Table 2.2. To achieve the quantity necessary for the 
experiments, the number of reactions was multiplied by the volume of each component 
shown in Table 2.2.  
 
  Table 2.2. Reverse Transcription Master Mix 
 
 
 
  
 
  
  
 
 
 
Reverse Transcription Master Mix (for a single 20 
μL reaction) 
Amount Component 
1μL T7 Oligo(dT) Primer 
2μL 10X First Strand Buffer 
4μL dNTP Mix 
1μL RNase Inhibitor 
1μL ArrayScript 
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The tube was mixed well by gently vortexing, followed by centrifugation 10,000 x g for 10 
seconds (Sigma 1-15 microcentrifuge, Sigma, St Louis, MO, USA Sorvall RC26Plus) in 
order to collect the Reverse Transcription Master Mix at the bottom of the tube, and then 
placed directly on ice. Each RNA sample tube received the amount of 9 μL of Reverse 
Transcription Master Mix, followed by thoroughly mixing by pipetting up and down 2–3 
times, then flicking the tube 3–4 times. The tubes were centrifuged at 10,000 x g for 10 
seconds to collect the reaction in the bottom of the tube. The samples were placed in the 
Corbett Research Palm Cycler, and the run started (as specified as Table 2.3). The 
incubation reaction last for 2 hours at 42°C and then cooled up to 16°C. After that, the 
tubes were briefly centrifuged 10,000 x g for 10 seconds to collect the reaction mixture at 
the bottom of the tube and placed in ice immediately. 
 
   
Table 2.3. Thermal cycler program 
 
 
 
 
 
 
2.1.1.4.2 Second Strand cDNA Synthesis 
This part of the experiment was all performed on ice. First, a Second Strand Master Mix 
was prepared in a nuclease-free tube in the order listed in the table below. To achieve the 
quantity necessary for the experiments, the number of reactions was multiplied by the 
volume of each component in Table 2.4.  
   Table 2.4. Second Strand cDNA Synthesis 
 
 
 
 
  
 
 
 
Temperature Time Cycles 
42C (50C lid) 2 hr 1 
16C hold - 
Second Strand Master Mix (for a single 100 μL reaction) 
Amount Component 
63μL Nuclease-free Water 
10μL 10X Second Strand Buffer 
4μL dNTP Mix 
2μL DNA Polymerase 
1μL RNase H 
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The mixture was mixed well by gently vortexing, followed by briefly centrifugation at 
10,000 x g for 10 seconds to collect the mixture at the bottom of the tube and then placed 
on ice. Each sample was added to 80 μL of Second Strand Master Mix, and mixed 
thoroughly by pipetting up and down 2–3 times, then flicking the tube 3–4 times. These 
tubes were centrifuged briefly at 10,000 x g for 10 seconds to collect the reaction in the 
bottom of the tube. The tubes were placed in a 16°C thermal cycler for 2 hours. The 
thermal cycler block was set to 16°C before adding the reaction tubes, as subjecting the 
reactions to temperatures >16°C would compromise the cRNA yield. After this incubation, 
the tubes were placed on ice or immediately frozen at –20°C.  
 
 
2.1.1.4.3 cDNA Purification 
Before initiating the process, a minimum of 20 μL per sample of Nuclease-free Water was 
preheated at 55°C. Then 250 μL of cDNA Binding Buffer (this buffer has a tendency to 
form precipitate, so in order to avoid losing concentration of the solution, the tube was 
checked and, if there was any precipitate, the tube was warmed at 37°C to redissolve the 
solution) was added to each sample and mixed thoroughly by pipetting up and down 2–3 
times, then flicking the tube 3–4 times. This was followed by a quick spin to collect the 
reaction mixture in the bottom of the tube, and then the cDNA filter cartridge supplied was 
mounted for immediate use. The cDNA sample was pippeted with cDNA Binding Buffer 
onto the center of the cDNA filter cartridge and then centrifuged for 1 minute at 10,000 x 
g, or until the mixture was through the filter. The flow-through was discarded and replaced 
with the cDNA Filter Cartridge in the wash tube. 34 mL of absolute ethanol was added to 
the Wash Buffer prior to use on each cDNA Filter Cartridge. 500 μL of the Wash Buffer 
was added to each cDNA Filter Cartridge and centrifuged for 1 minute at 10,000x g. The 
flow-through was discarded and the cDNA Filter Cartridge was spined for an additional 
minute to remove trace amounts of the buffer. Then, the cDNA Filter Cartridge was 
transferred to a cDNA Elution Tube. At this point, the Nuclease-free Water was heated at 
50–55°C for the cDNA elution, and then 20 μL of preheated Nuclease-free Water (55°C) 
was applied to the center of the filter in the cDNA Filter Cartridge. This was left at room 
temperature for 2 minutes and then centrifuged for 1 minute at 10,000x g. The double-
stranded cDNA (approximately 20 μL) was eluted at the end of the process.   
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2.1.1.4.4 In Vitro Transcription (IVT) to synthesize cRNA 
In this step, the thermal cycle was used with its lid heated at 100-105°C, so the temperature 
was maintained uniform throughout the experiment. It is known that formation of 
condensation inside the tubes could change the reagent concentrations and reduce yield. 
So, each cDNA sample was first transferred to a PCR tube compatible with the thermal 
cycler used (the program used was shown in Table 2.5. At room temperature, the IVT 
Master Mix was prepared by adding the reagents (shown in Table 2.6) to a nuclease-free 
microcentrifuge tube in the order listed below. To achieve the quantity necessary for the 
experiments, the number of reactions was multiplied by the volume of each component in 
Table 2.6. 
 
 
  Table 2.5. Thermal cycler program 
 
 
 
 
                 
    
 
    Table 2.6. Second Strand cDNA Synthesize components 
 
 
 
 
 
 
 
 
 
 
Temperature Time Cycle 
37C (default lid; 
100-105C) 
4-14 hours 1 
4C hold 4C 
IVT Master Mix for a single 25 μL reaction 
Amount Component  
2.5L T7 10X Reaction Buffer 
2.5L T7 Enzyme Mix 
2.5L Biotin-NTP Mix 
2.5L T7 10X Reaction Buffer 
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Each tube was mixed well by gently vortexing, followed by brief centrifugation for 1 
minute at 10,000 x g to collect the IVT Master Mix at the bottom of the tube, and then 
placed on ice. 7.5 μL of IVT Master Mix was transferred to each cDNA sample and then 
mixed thoroughly by pipetting up and down 2–3 times, also flicking the tube 3–4 times, 
and again centrifuged briefly to collect the reaction mixture in the bottom of the tube. Once 
assembled, the tubes were placed in the thermal cycler and the run started. For the amount 
of RNA input (25ng), the time used for the incubation was 14 hours. To stop the reaction, 
75 μL of Nuclease-free Water was added to each cRNA sample to bring the final volume 
to 100 μL and the mixture was mixed thoroughly by gentle vortexing. 
 
2.1.1.4.5 cRNA Purification 
This step was performed to remove enzymes, salts and unincorporated nucleotides from 
the cRNA. The cRNA was eluted from the filter with Nuclease-free Water. Before the 
experiment started, the Nuclease-free Water (around 200µL) was heated in the thermal 
cycler at 55°C, and the cRNA Filter Cartridge assembled.  
First, each tube was checked to confirm that the IVT reaction was brought to 100 μL with 
Nuclease-free Water. Then, 350 μL of cRNA Binding Buffer was added to each cRNA 
sample plus 250 μL of 100% absolute ethanol and mixed by pipetting the mixture up and 
down 3 times (no vortex or centrifugation was performed at this step). Immediately after, 
each sample mixture was placed onto the center of the filter in the cRNA Filter Cartridge. 
Any delay in proceeding could result in loss of cRNA, because once the ethanol is added, 
the cRNA will be in a semi-precipitated state. The samples were centrifuged for 1 minute 
at 10,000x g and the flow-through discarded and replaced the cRNA Filter Cartridge back 
into the cRNA Collection Tube. 650 μL of Wash Buffer was applied to each cRNA Filter 
Cartridge and the mixture was centrifuged for 1 min at 10,000x g. The flow-through was 
discarded and the cRNA Filter Cartridge was spined for an additional minute to remove 
trace amounts of Wash Buffer. The Filter Cartridges were transferred to a fresh cRNA 
Collection Tube and 200μL Nuclease-free Water (preheated to 55° C) was added to the 
center of the filter. The samples were incubated in a 55°C heat block for 10 minutes in 
order to obtain an 80% recovery of the cRNA. Samples were then centrifuged for 1.5 min 
at 10,000 x g. The cRNA in the cRNA Collection Tube in 200 μL of Nuclease-free Water 
then stored at -20° C for future use. 
Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) was used to 
determine the amount of cRNA was going to be used for hybridization and also its quality 
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(as explained in section 2.1.1.3). A minimum of 750ng of cRNA RIN of minimum 7.0 was 
used as our standard amount of input RNA. 
 
 
2.1.1.5 Hybridization of cRNA 
  
In this process, the cRNA was placed in the HumanHT-12 v3 Expression BeadChip 
(Illumina, San Diego, USA) to be scanned by the Illumina BeadArray
TM
 Reader The 
hybridization equipment and accessories were all provided by Illumina including the 
chambers and hybridization oven. Also, all reagents and buffers used here were provided 
in the kit. 
cRNA yields from amplification were quantified using Agilent bioanalyzer, as described in 
section 2.1.1.3, and 750 ng cRNAs were hybridized to BeadChips. Each chip contains 12 
arrays and each array targets more than 25,000 annotated genes with more than 48,000 
probes derived from the Reference Sequence (RefSeq) and the Unigene databases. Before 
hybridisation, all equipment to be used was washed with distilled H20 and dried in the 
hybridisation oven set to 58°C. The HYB (Hybridisation Buffer) and HCB (Humidity 
Control Buffer) were rocked in the 58°C hybridisation for 10 minutes to dissolve any salts 
that may have precipitated during storage, and then vortexed for 1 minute. Once cooled to 
room temperature, 200 μl of HCB was added into the humidifying buffer reservoir in the 
BeadChip Hyb Chamber. The required amount of total cRNA was then added to sterile, 
RNase-free, 0.5 ml microcentrifuge tubes and bought up to 5 μl with nuclease-free water. 
The samples were then left at room temperature for 2 minutes, after which 10 μl of HYB 
was added to each cRNA sample, and then left at room temperature for a further 2 minutes. 
The BeadChips were removed from their packages and inserted into the Hyb Chamber 
insert (as instructed by manufacturer), so that the barcode lines up with the barcode symbol 
on the insert. Each cRNA sample was then heated to 65°C for 5 minutes, briefly vortexed 
and spun down, and 15 μl of sample was loaded immediately onto the BeadChip. The lid 
on the Hyb chamber was then sealed and the chamber was incubated for 16 hours in the 
58°C hybridisation oven with the rocker on. 50 ml of High-Temp Wash Buffer (supplied 
by the kit) in 450 ml of RNase-free water was added to a water bath chamber and heated to 
55°C overnight. The scanner was turned on and left overnight to stabilize the laser beam. 
After the 16-hour incubation, the chip was transferred to a wash tray filed with E1BC wash 
(3 ml of E1BC buffer was added to 1L of RNase-free water). The solution was used the 
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same day as preparation and the cover seal on the chip was removed. The chip was then 
placed into a rack for easy transferring during the washing steps. The rack was transferred 
to the High-Temp wash buffer heated to 55°C, and left static for 10 minutes with the lid 
closed. The rack was transferred to a glass container filled with E1BC wash, agitated 10 
times and then placed on a turning tray for 5 minutes. The rack was transferred to a 100% 
ethanol wash, agitated 10 times and placed on a turning tray for 10 minutes. After 10 
minutes the rack was transferred to a fresh E1BC wash, agitated 10 times and placed on a 
turning tray for 2 minutes. The chip was then transferred to a block tray with 4 ml of Block 
E1 buffer (supplied by the kit) and rocked for 10 minutes. After 10 minutes the chip was 
transferred to a block tray with 2 ml of Block E1 buffer and 2 μl of Streptavidin-Cy3, 
covered, and rocked for 10 minutes. After 10 minutes, the chip was placed back into a rack 
and transferred to a fresh E1BC wash, agitated 10 times, covered, and placed on a turning 
tray for 5 minutes. After 5 minutes, the rack was then centrifuged at 275 RCF and left at 
room temperature for 4 minutes to dry. The chip was then scanned on the Illumina 
BeadArray Reader Confocal Scanner. 
 
2.1.1.6 Imaging the BeadChip on the Hiscan System 
Data from these images were analyzed to determine SNP genotypes using Illumina’s 
GenomeStudio Gene Expression Module. For each BeadChip, a decode content was 
downloaded from iCom provided with the BeadChip and added into the Decode folder; the 
Direct Hyb was the program selected and the scan was started. The quality of the entire 
data set was assessed by boxplot of bead intensities, density plot of bead intensities, 
density plot of coefficient of variance, pairwise MAplot, pairwise plot with microarray 
correlation, dendrogram, and NMMS using R/Bioconductor and the lumi package to 
identify any outliers. Based on the quality assessment all 24 arrays were deemed suitable 
for analysis. 
 
2.1.1.7 Analysis of Microarray 
Data normalization was performed using variance-stabilizing transform (VST) and quantile 
normalization as implemented in the lumi package for R/Bioconductor. To reduce false 
positives, unexpressed genes (based on a detection p-value cut-off of <0.01) were removed 
from the dataset. This reduced the number of probes being analyzed from 48820 to 24433, 
around 50% of the total number of probes on the Illumina human array. 
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2.1.1.7.1 GenomeStudio Gene Expression Module 
Included with the Illumina Whole-Genome Gene Expression Direct Hybridization Assay, 
is an application for analyzing gene expression data from scanned microarray images 
collected from systems. This module allows the visualization of the differential mRNA 
expression analysis as line plots, histograms, dendrograms, box plots, heat maps, scatter 
plots, samples tables, and gene clustering diagrams. The simplified data management tools 
in this software include hierarchical organization of samples, group sets, and all associated 
project analysis. 
 
2.1.1.7.2 BRB-ArrayTools 
BRB-Array Tools is an integrated software package for the analysis of DNA microarray 
data contains utilities for processing expression data from multiple arrays, visualization of 
data, multidimensional scaling, clustering of genes and samples, and classification and 
prediction of samples. BRB-ArrayTools provides powerful methods for controlling false 
discoveries. It features drill-down linkage to NCBI databases using clone, GenBank, or 
UniGene identifiers, and drill-down linkage to the NetAffx database using Probeset ids. 
SAM (Significance Analysis of Microarray) identifies genes with statistically significant 
changes in expression by assimilating a set of gene-specific t tests. Each gene was assigned 
a score on the basis of its change in gene expression relative to the standard deviation of 
repeated measurements for that gene. Genes with scores greater than an established 
threshold were deemed potentially significant. The percentage of such genes identified by 
chance was the false discovery rate (FDR). To estimate the FDR, nonsense genes were 
identified by analyzing permutations of the measurements. The threshold can be adjusted 
to identify smaller or larger sets of genes, and FDRs were calculated for each set (Tusher, 
Tibshirani et al. 2001).  
 
2.1.1.7.3 MultiExperiment Viewer (MeV) 
MeV is one member of a suite of microarray data management and analysis applications 
originally developed at The Institute for Genomic Research (TIGR). It provides functions 
for managing microarray experimental conditions and data, converting scanned slide 
images into numerical data, normalizing the data and finally analyzing that normalized 
data. This technique compares favorably to previously used methods for gene expression 
measurement, such as DNA microarrays, because of its higher sensitivity, lower 
background, and ability to detect previously unknown transcripts. 
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2.1.1.7.4 Pathway analysis 
Metacore
TM
 GeneGo is an integrated software suite for functional analysis of microarray, 
metabolic, SAGE, proteomics, siRNA, microRNA, and screening data. It is based on a 
high-quality, manually-curated database of transcription factors, receptors, ligands, 
kinases, drugs, and endogenous metabolites, as well as other molecular classes; species-
specific directional interactions between protein-protein, protein-DNA and protein-RNA 
interactions, drug targeting, and bioactive molecules and their effects and signalling and 
metabolic pathways represented on maps and networks. MetaCore
TM
 has nearly 20 
functional ontologies that can be used for filtering and enrichment, many of which were 
unique to MetaCore
TM
, interactive canonical pathway maps capturing nearly 200,000 
pathways, and over 1,000 complex formation and group relation schemas with species 
specificity. This software was used to analyze any experimental high-throughput data in 
the context of pathways, networks and maps and identify and rank important pathways. 
The Enrichment analysis in GeneGo Pathway Maps, GeneGo Diseases by Biomarkers 
(GeneGo, St. Joseph, MI), GO Processes, and GO Molecular Functions. GeneGo Pathway 
Maps represent a set of genes participating in a consecutive set of metabolic signals, or 
metabolic transformations, confirmed as a whole by experimental data or by inferred 
relationships. GeneGo Diseases by Biomarkers are groups of genes implicated in certain 
diseases based on classifications in Medical Subject Headings 
(http://www.nlm.nih.gov/mesh/). The list of genes represented on the Illumina array was 
used as a base gene list when calculating p values in the MetaCore enrichment procedures. 
MetaCore (GeneGo) uses a hypergeometric model to determine the significance of 
enrichment (Falcon and Gentleman 2007). Enrichment analysis consisted of mapping gene 
IDs of the dataset onto gene IDs in entities of built-in functional ontologies represented in 
MetaCore by pathway maps and networks for a detailed look into the most significant Map 
Folder.  
 
2.1.2 Quantitative RT-PCR 
 
2.1.2.1 First strand cDNA synthesis from RNA was performed using Roche 
Transcriptor First Strand cDNA Synthesis Kit  
To synthesize first strand cDNA, extracted RNA was added into a nuclease-free 
microcentrifuge tube, containing 1μl of 50 pmol of anchored-oligo (dT)18 and 2μl of 
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random hexamer at 600pmol/mL primers (Table 2.7). The mixture was then prepared to a 
total volume of 13μl with dH20. This mixture was gently mixed by tapping, and then 
centrifuged before being heated at 65°C for 10 minutes in the GeneAmp® PCR System 
2400 thermal block cycler with lid to minimize evaporation. This was followed by 
immediate incubation on ice for at least 1 minute. The tube containing the template-primer 
mix was then the remaining components of the RT mix were added in the order in Table 
2.8. The tube was then incubated at 25°C for 10 minutes, followed by incubation at 60°C 
for 1 hour, and finally inactivated by heating at 85°C for 5 minutes. The reaction was 
stopped by cooling down the process at 4°C or placing the tube immediately in ice. Finally, 
a total 20μl of the first strand cDNA synthesis reaction was stored at –20°C for future use.  
                 
 
Table 2.7. Preparation of Template-Primer Mix. 
Component Volume Final concentration 
Total RNA or poly (A)
+ 
mRNA 
1µg total RNA or 10ng 
poly (A)
+ 
RNA * 
Anchored-oligo (dT)18 
Primer, 50pmol/µl 
1µl 2.5µM 
Random Hexamer Primer, 
600pmol/µl 
2µl 60µM 
Water, PCR-grade to make up total 
volume = 13µl 
 
Total volume 13µl  
* These were the suggested concentrations for initial experiments. Suitable 
template concentrations may range from 10 ng to 5 µg total RNA and from 1 to 100 ng 
mRNA. 
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Table 2.8. Preparation of reaction Mix for Reverse transcription 
Component Volume Final 
concentration 
Transcriptor Reverse 
Transcriptase Reaction 
Buffer, 5x concentrated 
4µl 1X (8mM 
MgCl2) 
Protector RNase 
Inhibitor, 40 U/µl 
0.5µl 20 U 
Deoxynucleotide Mix, 
10mM each 
2µl 1 mM each 
Reverse Transcriptase 0.5µl 10 U 
Final volume 20µl  
 
2.1.2.2 Real-time PCR using Syber Green  
Real-time PCR was performed using Syber Green, which fluoresces when bound to 
double-stranded DNA, and allows the accumulation of a PCR product to be monitored over 
time.  KAPA SYBR® FAST qPCR Master Mix (KAPA BIOSYSTEMS, Boston, 
Massachusetts, USA) was designed for high performance real-time PCR. The kit contains a 
novel DNA polymerase engineered via a process of molecular evolution. The result was a 
unique enzyme, specifically designed for qPCR using SYBR® Green I dye chemistry. 
Reactions were performed using KAPA SYBR Green qPCR kit, according to the 
manufacturer’s instructions. The diluted cDNA from section 2.1.2.1 was used as the DNA 
template, while housekeeping gene GAPDH were used to normalise the real-time PCR 
results. The forward and reverse primers sequences for all 14 tested genes are listed in 
Table 2.9. Each real-time PCR reaction contained the components listed in Table 2.10. All 
reactions were performed in the Stratagene Mx3000p real-time thermal cycler, according 
to the cycling program in Table 2.11. For qPCR analysis, one-way ANOVAs were 
performed and GraphPad Prism 6.0 was used for the statistics. 
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Table 2.9. Primer sequences for the real-time PCR amplification of the significant 
regulated genes detected from Microarray study. 
GENE FORWARD (F) AND REVERSE (R) 
PRIMER SEQUENCE 5’-3’ 
TM (ºC) 
GAPDH F: CCAGGCGCCCAATACG 
R: CCACATCGCTCAGACACCAT 
66.5 
66.3 
FKBP3 F: ACCCTCATCCAGGGTCTCTT 
R: GCAGGAACACGGTTCAGATT 
63.8 
64 
CD46 F: TGGTCAAATGTCGATTTCCA 
R: TGGTCAAATGTCGATTTCCA 
63.9 
63.9 
CD47 F = AGGACTCCTGCTTCTGTGG 
R = TTATTTGGGGTTCGCTCTTG 
64 
63.7 
BIRC2 F = CAACTTTTGGGGGAAGTCAA 
R = TGCTGCAGGAAATGGAAAC 
63.9 
63.7 
MAPK3 F = CTCATCCGTCGGGTCATAGT 
R = CAGTCTCTGCCCTCCAAGAC 
63.9 
64 
OAS2 F = GCACAAGAGAGCCTCCAAAC 
R = AAGCCCTCCCTACCTACCAA 
63.9 
63.5 
FADD F = CAACCATCACTGCCCCTACT 
R = TTTGTCCCATTTCCTTGGAG 
63.9 
63.7 
CASP3 F = CAACGATCCCCTCTGAAAAA 
R = TGGAATTGATGCGTGATGTT 
63.8 
63.9 
IL-6 F = GAGGTGCCCATGCTACATTT 
R = ATGCAATAACCACCCCTGAC 
63.7 
63.5 
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STAT1 F = GGGCATTCTGGGTAAGTTCA 
R = TGCAAAACCTTGCAGAACAG 
63.7 
63.9 
THBS1 F = CGGTCTCCCACATCATCTCT 
R = AAAGGATAATTGCCCCAACC 
64.1 
63.5 
IFIT1 F = CACCTCAAATGTGGGCTTTT 
R= TCACCAGATAGGGCTTTGCT 
64 
63.7 
IFIT3 F = ATGGCCTGCTTCAAAACATC 
R= AGGAAGGGTGGACACAACTG 
63.9 
64 
  
     
 
Table 2.10. Preparation of reaction mix for real-time PCR using Syber Green. 
Components Final 
concentration 
Per 20 μl rxn 
PCR-grade water - Up to 20 μl 
KAPA SYBR® FAST 
qPCR Master Mix (2X)* 
Universal 
1X 10 μl 
Forward Primer (10 μM) 200 nM 0.4 μl 
Reverse Primer (10 μM) 200 nM 0.4 μl 
Template DNA (<20 ng/20 μl 
rxn) 
As required 
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                Table 2.11. Syber Green real-time PCR cycling program using Stratagene Mx3000p. 
Step Temperature Duration Cycles 
 
Enzyme activation 95 ºC 3 min    Hold 
 
Denature 95 ºC 1-3 sec 40 
Anneal/extend 60 ºC 30 sec 40 
Dissociation According to instrument guidelines 
 
2.1.3 Flow Cytometry 
2.1.3.1 Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
Fresh blood collection of HIV+ and HIV- individuals was performed by a 
registered nurse from the Westmead Hospital (Sydney, NSW) into lithium heparin 
vaccutainer tubes (Greiner Bio-One) and mixed well to prevent clotting. All procedures 
were carried out at room temperature unless specified otherwise. Isolation of PBMC from 
the whole blood samples for use in the assays was carried out by density gradient 
centrifugation using Ficoll-Paque plus (GE Healthcare, Uppsala). Blood was centrifuged at 
1800 x rpm for 20 minutes with no brake on an Allegra centrifuge (Beckman Coulter®). 
The blood tubes were carefully transported into a Class II bio-hazard safety cabinet and all 
the techniques were performed aseptically (in a sterile environment), inside a PC3 
(Physical Containment Level 3) laboratory facility. The buffy coat cells at the interface 
between the plasma and red blood cells were removed using a transfer pipette and 
transferred to a Falcon tube, and a volume of 50 mL of PBS was added. The diluted buffy 
coat was washed twice and centrifuged at 1500 x rpm for 7 minutes with brake. The 
supernatant was discarded and the cell pellet resuspended in the residual volume. A 50 mL 
aliquot of PBS was then added and the cells were again washed by centrifugation at 1500 x 
rpm for 7 minutes. The cell concentration was determined microscopically using a 
haemocytometer, following manufacturer’s instructions. 
 
2.1.3.2 Staining for flow cytometry  
PBMC were harvested by Ficoll separation from fresh blood as described in section 2.1.3.1 
and pipetting into 15 mL Falcon tubes (Becton Dickinson®) and centrifuged at 1500 x rpm 
for 5 minutes (Allegra X-12 R, Beckman Coulter ®). The supernatant was discarded and 
the cells were resuspended in 3 mL of FACS buffer (1x PBS and 10% Foetal calf serum 
(FCS), CSL Biosciences, Parkville, Victoria, AUS). The cell concentration was determined 
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microscopically, as explained in the section before. An aliquot containing 10
6
 cells in 
FACS buffer was then added to the FACS tubes (5 mL, polystyrene, round-bottom type 
tube, Becton Dickinson®). This was followed by the addition of each antibody (see Table 
2.12) and FACS buffer in a total volume of 100µL. For the unstained control, 100 µL of 
FACS buffer alone was added to the cells. Cells were incubated in the dark at room 
temperature for 30 minutes. Following incubation, 3 mL of FACS buffer was added to all 
the tubes, and the tubes centrifuged at 1500 x rpm for 5 minutes at 4°C. The supernatant 
was discarded carefully with a transferred pipette and 3 mL of FACS buffer was added to 
all the tubes and centrifuged at 1500 x rpm for 5 minutes at 4°C. The supernatant was 
discarded and the cells were resuspended in 1mL/tube of 2% paraformaldehyde (0.125mL 
16% Formaldehyde, ProSciTech, Kirwan, Queensland, AUS and 0.875mL of PBS) and 
incubated in the dark for 20 minutes. 3 mL of FACS buffer was added to all the tubes 
followed by centrifugation at 1500 x rpm for 5 minutes at 4°C. The supernatant was 
discarded carefully with a transferred pipette and 3 mL of FACS buffer was added to all 
the tubes and centrifuged at 1500 x rpm for 5 minutes at 4°C. The supernatant was 
discarded and the cells were resuspended in 500µL/tube of FACS buffer, and kept in the 
dark until data was acquired by flow cytometry within three days. 
 
Table 2.12 Antibodies used in the Flow cytometer 
Antigen Type Dilution 
THBS1 
(Thrombospondin) 
mouse 
monoclonal 
(PE) 
1:10 
CD14 mouse 
monoclonal 
(FITC) 
1:10 
CD16 mouse 
monoclonal 
APC 647) 
1:10 
DAPI Mouse 
monoclonal 
(violet)  
1:10 
*PE, (Phycoerythrin); FITC (Fluorescein isothiocyanate); APC (Allophycocyanin) 
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2.1.3.3 Flow cytometric analysis  
The expression of the particular molecule of interest in the samples was assessed 
using a FACSCanto II® flow cytometer (Becton Dickinson) either in the tube mode. All 
analyses were carried out using FlowJo® v.10 software. Data were presented as the 
Median Fluorescence Intensity (MFI), which was obtained for the each average of 
fluorescence of the antibody for each patient minus the value for the respective isotype 
control for the molecules of interest. 
 
2.1.4 Immunofluorescence microscopy 
 
2.1.4.1 Reagents and solutions 
 
Antibody dilution buffer 
0.1g of BSA (Sigma, USA) was dissolved in 100 ml PBS following which 50 µl of Cold 
water fish skin gelatin (CWFS) (Sigma, USA) was added to the solution. The solution was 
stored at 4°C.  
10% v/v goat serum (Blocking buffer) 
100 µl of Goat serum (Sigma, USA) was added to 900 µl of Antibody dilution buffer and 
the solution was stored at 4°C.   
4% Formaldehyde fixative in phosphate buffer 
10mL of 16% Formaldehyde (EM grade) (Electron Microscopy sciences, USA) was 
added to 24 mL of Sorensons phosphate buffer stock. The pH of the solution was adjusted 
to 7.4 using 1.0 NaOH, and the final volume was made up to 40 ml with DDW. Any 
unused solution was discarded after 5 days. 
Immersion oil (type FF) 
The 50 ml bottle of immersion oil combines non-fluorescence and good optical properties, 
and was formulated from aliphatic and allcyclic hydrocarbon.   
Mounting fluid  
The 6.0 ml bottle of mounting fluid (Micro Tak, USA) contains phosphate buffer, glycerol 
and a photobleaching retardant.  It was stored at 4°C. 
Sorensons phosphate buffer stock solution 
28.84 g of Na2HPO4.2H2O (Fluka Biochemicals, USA) and 5.93 g of NaH2PO4.2H2O 
(Fluka Biochemicals, USA) were dissolved in 900 ml of DDW with frequent shaking and 
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the final volume was made to 1200 ml with DDW. The solution was autoclaved and stored 
at 4°C. 
0.1% Triton X-100 working solution 
5 ml of 1% Triton X-100 was added to 45 ml of PBS and the solution was stored at 4°C.   
1% Triton X-100 stock solution 
1 ml of Triton X-100 (Sigma, USA) was added to 99 ml of PBS and the solution was 
stored at 4°C. 
10% Bovine serum albumin (BSA) (Fraction V) 
4.0 g of BSA (Sigma, USA) was added to 40 mL of distilled water. The solution was 
placed in a 37°C incubator until the powder dissolved.  The solution was filtered and 
stored at -20°C in 1.0 ml aliquots. 
 
2.1.4.2 Fixation of cells 
PBMCs cultured on coverslips overnight in media containing RPMI (Sigma-Aldrich, St 
Louis, MO), were washed twice in sterile PBS and then fixed in 4% formaldehyde in 
Sorensons buffer for 20 minutes at room temperature. The fixative was removed and the 
cells permeabilised in 0.1% Triton X-100 for 5 minutes. The cells were washed twice in 
sterile PBS and stored away from light at 4°C before being processed for 
immunofluorescence. 
 
2.1.4.3 Confocal microscopy 
PBMCs cultures on coverslips were incubated for 15 minutes at room temperature in 
blocking buffer to block non-specific binding. Cells were rinsed three times in PBS before 
being incubated for 45 minutes in primary antibody [Thrombonspondin (THBS1) 1, 
Abcam, AUS)] diluted 1:50 in antibody diluting buffer. After rinsing six times in PBS, the 
cells were then incubated for 1 hour with the secondary antibody (Fluorescein conjugated 
Alexa Fluor®488, goat anti rabbit, Invitrogen, USA) diluted 1:200 containing 1µL of 
Hoechst [33258, pentahydrate (bis-benzimide), Invitrogen, USA] diluted 1:100 for nucleus 
visualization. This was followed by six washes in PBS before the cells were mounted on 
glass slides. The slides were examined using Leica TCS SP5 Confocal Microscope. 
Excitation was with the 405 nm line (DAPI) and 476 nm line (FITC) from blue diode and 
multiline argon lasers. Excitation was on 20% of the power.  
Cells were examined with a HCX PL APO 63.0x1.30 37°C UV Glycerol immersion 
objective, using a FluoView FV1000 Series Confocal Laser Scanning Microscope. 
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Confocal images were acquired using Leica Application Suite (Advanced Fluorescence) 
software. The scan mode was set to xyz, i.e. the image stack was recorded from xy-
sections in the z-direction. The z-position was adjusted until the nucleus of the cell was 
clearly visualised. High resolution was achieved by setting the image size to 1024 x 1024, 
approximately 1,321,963 pixels per image. The zoom factor was set between 1 and 3 to 
allow better presentation of the cell. 
Image quality was optimized to reduce the rate of photo bleaching and the level of noise. 
Noise reduction was achieved by signal averaging-performing 4-6 scans per image. The 
levels of gain and offset were optimized for high contrast without saturating and losing 
detail. Other parameters such as pinhole size and laser power were also adjusted to acquire 
better quality images. Image cropping and brightness and contrast adjustments for 
presentation purposes were performed using Photoshop CS5.1 image editing software. 
 
2.1.4.4 DeltaVision microcopy 
PBMCs on coverslips were treated and stained the same way described in section above. 
Images were acquired using a Photometrics CoolSnap QE camera with sequential 
exposures and were deconvolved using Sedat & Agard algorithms available through the 
Deltavision SoftWoRx software, version 3.0.0. Background was subtracted post capture 
using SoftWoRx, through a single adjustment of the levels histogram. The images were 
then cropped using Adobe Photoshop CS5. 
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3.1 Summary 
Objective 
To investigate the genomic basis of HIV pathogenesis and its pharmacogenomics in HIV+ 
subjects pre- and post-Highly Active Antiretroviral Therapy (HAART) in responders. 
Design 
14 HIV+ subjects, pre- and post- HAART, were analysed. The subjects who responded to 
therapy were therefore classified as responders. Pre-HAART samples were derived from 
patients who had detectable plasma viremia and were classified as Time Point 1 (TP1). All 
the samples showed below detectable levels of HIV-1 RNA (<40 copies of HIV RNA/mL 
plasma). The CD4+ T cell counts in TP1 (pre-HAART) ranged from 300-1050/µl of blood 
and at TP2 (same subjects 2 to 3 years post-HAART) ranged from 620-1222/µL of blood. 
The HIV RNA copies/μl of plasma in TP1 ranged from 1602 to 647,095. In Time Point 2 
(TP2) patient samples, the viral loads was below detectable level across all patients (<40 
copies/mL of plasma). We performed a comprehensive genome-wide analysis to 
characterize differential gene expression of HIV-infected peripheral blood mononuclear 
cells (PBMCs) pre- and post-HAART. This was aimed at defining the underlying 
pharmacogenomic basis of HIV control during HAART, and the genomic basis of immune 
deterioration prior to HAART initiation in HIV+ individuals. 
 
Methods 
Genomic RNA extracted from the PBMCs was used in genome-wide microarray analysis 
using HT-12V3 Illumina chips. Quantile normalization was performed to normalize the 
data and inter-patient variability. Illumina
®
BeadStudio Data Analysis Software was used to 
obtain differentially expressed (DE) genes. Only the significant genes with p value <0.01 
and FDR of <5% were considered appropriate for analysis. Pathway analysis was 
performed in MetaCore
TM
 to derive functional annotations. Functionally significant genes 
were validated by quantitative real time PCR. 
 
Results 
Between TP1 and TP2, 234 genes were differentially expressed. Within these genes, 212 
were down-regulated and 22 up-regulated. Analysis of top 10 pathways showed 8 of 10 
pathways belonging to the immune response system, which is the most significant pathway 
up-regulated in TP1 against TP2.  This was comprised of genes that were involved in 
antiviral action of interferon (IFN) and their signalling function, antiviral response, 
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dendritic cell maturation and migration and cell metabolism. Further confirmation of this 
assertion came from analysis of map folders and enrichment analysis, again showing that 
the most significant pathways were all related to the immune, inflammatory and interferon 
response family. Although this data set is intuitive and expected, we stress that these 
results are unique in demonstrating the previously held belief through a genome-wide 
analysis of pre- and post-therapy timepoints of the same HIV+ individual, which has never 
been done before. 
Conclusions  
Genome-wide analysis shows that there is a considerable difference between DE genes 
pre- and post-HAART, and the therapy-mediated control of HIV plasma viremia, when the 
viral load is below detectable levels (<20 copies/mL plasma), is genomically distinct from 
the untreated phase within the same individual. During detectable viremic phase, there is 
an orchestrated and coordinated up-regulation of immune, inflammation and antiviral 
genes, fully consistent with HIV infection. In stark contrast to the viremic phase, the 
therapy-mediated control phase showed down-regulation of these pathways, suggesting 
that the reduction in viremia in plasma has a considerable bearing on the immune system, 
and that HIV has a definitive role in subverting the human gene machinery. Overall, since 
we have analysed the whole PBMC in microarray studies, they have provided a more 
holistic and profound view of host cellular transcriptome and its modulation at viremic and 
therapy-experienced aviremic phase of HIV infection. 
 
3.2 Aims  
To delineate modulation of genome-wide expression in primary peripheral blood cells 
from HIV patients, pre- and post-HAART, in order to determine what role HIV has in 
subverting and manipulating the host immune system. Also, to determine what effect 
HAART therapy-mediated suppression of HIV-1 virus has on host gene expression. 
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3.3 Background 
The AIDS pandemic is one of the greatest global health crises of our time. Since the 
human immunodeficiency virus (HIV) was identified 25 years ago, there are approximately 
34 million people currently living with HIV. Thus, HIV-1 virus infection has led to a 
worldwide pandemic (Mothe, Ibarrondo et al. 2009; Guerra, Gonzalez et al. 2010; WHO 
2011). Over the past 33 years, HIV-1 infected individuals develop a unique interaction 
with the virus, and this determines the host-virus interaction and natural history of the 
disease. This natural history is tightly governed by the plasma viral load and T cell 
modulation in the absence of HAART. The major impact of the infection with HIV-1 
results in massive destruction of CD4+ T cells by multiple mechanisms, leading to T cell 
exhaustion. HAART treatment consists of a combination of potent antiretroviral agents, 
which have been shown to produce a dramatic decrease in HIV RNA levels. It also aids to 
reduce the incidence of opportunistic infections and co-morbidities, mortality rates and to 
stop secondary transmission (Cohen, Hellmann et al. 2008; Cohen and Gay 2010).   
It is apparent that HIV not only targets CD4+ T cells, but also has the ability to infect a 
variety of blood leukocytes (Cao, Qin et al. 1995; Pantaleo, Menzo et al. 1995; Paranjape 
2005; Cohen, Hellmann et al. 2008). This shows that HIV has the inherent ability to 
subvert and manipulate the host gene machinery at the transcriptomic level (Wu, Dwyer et 
al. 2008; Wu, Dwyer et al. 2011; Wu, Sasse et al. 2013), thereby having considerable 
influence on the cell morphology, gene expression, and metabolism. Increased gene 
expression changes have also been associated with increased viral loads in viremic 
patients. Nonetheless, the global effects of viral infection on host cell gene expression 
patterns are still unknown (van't Wout, Lehrman et al. 2003).Therefore, the genomic basis 
of HIV pathogenesis still remains unclear.  
Microarray gene expression profiling has been applied to sub-categorize complex diseases, 
and it can predict treatment outcomes and disease progression using “gene signatures”, 
which represent differentially expressed genes that correlate with the appropriate 
phenotype (Nikolsky, Ekins et al. 2005).  As such, the DNA microarray based approaches 
have gained rapid acceptance in a variety of fields, for studying the roles of genes in the 
pathogenesis of infectious disease. This is achieved by allowing the simultaneous 
monitoring of differential gene expression for thousands of genes, generating a global 
picture of the transcriptional changes affected by pathogens (Blader, Manger et al. 2001; 
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Kato-Maeda, Gao et al. 2001). Thus, the high-density genome-wide microarrays have 
greatly facilitated the genomic basis of pathogen-host interactions (van't Wout, Lehrman et 
al. 2003; Chan, Qian et al. 2007) and also the studies related to pharmacogenomics. 
After the introduction of HAART, most patients who adhere to treatment show a good 
response. This is defined by a decrease in plasma viral load (pVL) to undetectable levels, 
and an immunological reconstitution with a significant increase of CD4+ T cell levels from 
baseline values, leading to prolonged survival (Hammer, Squires et al. 1997). These 
patients are termed responders, whereas patients who do not achieve complete suppression 
of virus with HAART are termed non-responders. 
 The immune reconstitution fails under the value of 200 CD4+ T cells/μl, which is 
considered as a critical threshold, and this occurs in 5–27% of patients receiving HAART 
(Knapp W 1989; Onate, Vilahur et al. 2012). In fact, CD4+T-cell counts persistently <250 
cells/μl or a percentage of CD4+ T cells <17%, has been considered a sign of poor immune 
reconstitution (Grabar, Le Moing et al. 2000). In our study, all our patients, before the start 
of therapy, showed an average of 300 CD4+ T cells/μl of blood. Therefore, we hypothesise 
that successful HAART treatment in responders can guide us to find the genomic basis of 
immunological reconstitution, and identify key immunity genes/pathways that cooperate 
during immune reconstitution upon effective therapy. To better characterize genomic 
events occurring in vivo before and after therapy in HIV+ patients, we have used genome-
wide analysis, using cDNA microarrays on frozen primary ex-vivo-derived PBMCs from 
HIV+ patients at two times points, before and after the initiation of HAART, being referred 
to as TP1 (pre-therapy with detectable plasma viremia) and TP2 (post-therapy with below-
detectable <20 copies HIV RNA/mL plasma). All patients showed rise in CD4+ T cell 
counts upon suppressive HAART and reduction in plasma viremia to below detectable 
level of HIV virus (<40 copies of HIV/ml plasma).  
In this study, we report microarray analyses of whole PBMCs, revealing, for the first time, 
host gene expression during HIV-1 infection pre- and post-therapy. We show that, 
although there is a common set of key genes associated with HIV with altered expression 
in both stages, each stage also showed unique molecular signatures. Further analysis of 
differentially expressed genes showed that the genes involved in innate and adaptive 
immunity, inflammation, apoptosis and antiviral functions were highly up-regulated pre-
therapy, while they were down-regulated post-therapy.  
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3.4 Results 
3.4.1. Clinical profiles of patients enrolled in the study  
The age range, CD4+ and CD8+ T cell counts, viral load and HAART regimen that each 
patient received are shown in Table 3.1. All the patients enrolled in this study were used 
for blood collection at two time points, pre- and post-HAART. The separation between 
time points is shown in each case in Table 3.1. As it can also be seen from Table 3.1, all 
our patients responded to treatment post-HAART, in concomitance with the rise in CD4+ 
T cell counts. Thus, these patients are classed as responders, as they all displayed below-
detectable plasma viremia post-HAART (<40 copies of HIV RNA/mL plasma). 
 
Table 3.1. Clinical profiles showing age, CD4+, CD8+ T cell counts, plasma viral load and the 
HAART regimen of patients enrolled in the study. Two time points were used, indicated as pre- 
and post-therapy in the genome-wide analysis. 
PATIENTS AGE 
TIME 
POINT 
CD4 
count 
(cell/µl) 
CD8 
count 
(cell/µl) 
VIRAL LOAD 
(COPIES/ML) 
DRUGS USED 
DURING 
TREATMENT 
SC18 
 
27 
 
20/08/96 
2 years 
07/09/98 
510-pre 
710-post 
980 
840 
112,000 
< 40 
RTV 
SQV 
d4T 
3TC 
SC19 
 
36 
day 3 
19/09/96 
3 years 
08/09/99 
610-pre 
720-pos 
1408 
720 
108634 
< 40 
SQV 
d4T 
3TC 
SC 27 
 
33 
21/12/96 
1.5 years 
06/07/98 
620-pre 
620-post 
1810 
1200 
169841 
< 40 
SQV 
d4T 
3TC 
SC35 
 
34 
19/02/97 
2 years 
23/03/99 
750-pre 
1010post 
1380 
840 
605236 
< 40 
RTV 
SQV 
d4T 
3TC 
SC39 
 
43 
04/04/97 
3 years 
05/04/00 
n/a n/a 
1602 
< 40 
RTV 
SQV 
d4T 
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3TC 
SC40 
 
34 
SC peak 
18/04/97 
on + off 
Rx 
16/03/99 
600-pre 
800-post 
400 
840 
3678 
< 40 
NVP 
d4T 
3TC 
SC51 
 
35 
pre 
28/10/97 
1 year 
28/10/98 
400-pre 
810-post 
 
680 
1130 
10117 
< 40 
RTV 
IDV 
d4T 
3TC 
SC61 
 
25 
30/03/98 
2 years  
11/05/00 
510-pre 
990-post 
930 
870 
 
6264 
< 40 
RTV 
IDV 
d4T 
3TC 
SC65 
 
26 
20/05/98 
2 years 
10/05/00 
360-pre 
620-post 
1380 
1217 
647095 
< 40 
RTV 
IDV 
d4T 
3TC 
SC70 
 
29 
16/07/98 
3 years 
23/04/01 
650-pre 
1222post 
1069 
624 
334088 
< 40 
RTV 
IDV 
d4T 
3TC 
SC71 
 
31 
05/08/98 
2 years 
13/12/00 
830-pre 
1073post 
1050 
1073 
5208 
<40 
RTV 
IDV 
d4T 
3TC 
SC75 
 
34 
14/09/98 
1 year 
23/09/99 
300-pre 
610-post 
1420 
861 
92000 
< 40 
RTV 
IDV 
d4T 
3TC 
SC64 
 
28 
14/05/98 
2 years 
21/03/00 
1050pre 
1160post 
950 
1106 
24835 
<40 
NEV 
ddI 
d4T 
3TC 
DT 73 
 
32 
13/05/98 
3 year 
26/09/00 
510-pre 
722-post 
 
831 
399 
142900 
< 40 
RTV 
IDV 
d4T 
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£
Individual drug abbreviations of the prescribed anti-HIV drugs: 3TC (lamivudine); d4T 
(stavudine); ddI (didanosine); RTV (ritonavir); SQV (saquinavir); NVP (nevirapine); IDV 
(indinavir); NLF (nelfinavir); NEV(nevirapine). Patients stayed on treatment for 2-3 years in 
average. 
The methodology of the microarray experimental techniques and the detailed terms of 
analysis by Illumina
®
BeadStudio Data Analysis Software, MultiExperiment Viewer (MeV) 
and Metacore
TM 
used in this chapter are extensively described under Methods and 
Materials (see Chapter 2). Frozen PBMCs from HIV+ patients were used for obtaining 
total RNA and then transcribed to cDNA for the microarray experiments, as stated in 
Chapter 2, under the Illumina HumanHT-12 v3 Expression BeadChip analysis. Two time 
points were analyzed by genome-wide microarray before (TP1) and after (TP2) HAART. 
Upon normalization of the data set, hierarchical clustering was performed using the entire 
normalized chip data.  
 
3.4.2. Clustering analysis of patients prior to DE gene analysis 
Following normalization of the entire chip data, which covered more than 25,000 
annotated human genes and more than 48,000 probes covering RefSeq and UniGene 
annotated genes, we performed clustering analysis in BRB-Array Tools software. This 
analysis serves to group the data set in such a way that objects in the same group (called 
clusters) are genetically more similar to each other than to the other group in the cluster. 
The statistical significance test used by the BRB-Array software was Pearson’s centred 
correlation, and the average linkage method was implemented to obtain the Figure 3.1 (as 
explained in Chapter 2). As shown in Figure 3.1, the groups TP1 and TP2 are separated 
in two clusters (TP1 = patients before treatment; TP2 = patients after treatment), clearly 
showing the formation of two different clusters based in their differently expressed genes 
list. This gave the confidence to the data set to further derive specific DE list between TP1 
and TP2 for further analysis. 
3TC 
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Figure 3.1. Clustering analysis of global gene expression profiles in PBMC at time points TP1 and TP2 of the patients enrolled in the study. Similarities in the gene 
expression patterns among individuals were evaluated and visualized with BRB ArrayTools. The Y-axis shows the correlation and the X-axis shows the time points 
of each patient. The algorithm used is named Correlation, which computes the Pearson correlation using a 1-r distance measure. The distance on the X axis 
represents the similarity in the relationships among samples. 
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3.4.3 Differential expression analysis of genes between TP1 and TP2 
The data acquired from the Illumina Microarray BeadChip, as explained in Chapter 2, was further 
used for obtaining the DE list in Illumina
®
BeadStudio Data Analysis Software. Furthermore, this 
DE gene list was analysed using the BRB-ArrayTools software, installed as an Excel package, in 
order to perform a variety of pre-processing steps, including computing probe-set expression 
summaries, normalization, filtering and calculating quality control indices (Kato-Maeda, Gao et al. 
2001; Butte 2002; Simon, Lam et al. 2007). Quantile normalization was performed to diminish the 
biological errors due to false positives, to see more clearly the systematic biological differences 
between the samples and to compensate for systematic technical differences between chips. On the 
BRB-Array Tools software, the Significance Analysis of Microarrays (SAM) was also performed to 
identify the genes with statistically significant changes in expression, by assimilating a set of gene-
specific t-tests. During this process, each gene is assigned a score on the basis of its change in gene 
expression relative to the standard deviation of repeated measurements for that gene. Genes with 
scores greater than a threshold are deemed potentially significant. The percentage of such genes 
identified by chance is the false discovery rate (FDR). To estimate the FDR, nonsense genes are 
identified by analysing permutations of the measurements. The threshold can be adjusted to identify 
smaller or larger sets of genes, and FDRs are calculated for each set (Tusher, Tibshirani et al. 2001). 
In this part of the study we used a FDR p-value threshold of <0.05 with p-value of <0.01 and -1.10 
≤ fold change ≥ 2.85, so the genes that received a fold-change value higher or equal to -1.10 were 
appointed down-regulated and the genes that received a fold change minor or equal than 2.85 were 
up-regulated. 
The final list of DE genes for the comparison between TP1 (pre-therapy) and TP2 (post-therapy) 
contained 234 genes, of which 212 DE genes were down-regulated and 22 up-regulated (see Table 
3.2 for DE genes list), suggesting significant separable biological difference between these two time 
points. This difference segregating the two biological entities based on the 234 DE genes was 
considered confident enough for downstream pathway, gene networks and gene enrichment 
analysis. 
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Table 3.2. Differentially expressed gene list derived through comparison of genes between TP1 
versus TP2, based on their observed scores. 234 genes were differentially expressed between TP1 
and TP2. 
Gene symbol 
Expected 
score 
Observed 
score 
Numerator Denominator 
Fold 
change 
OAS3 0.42675933 -5.0803823 -1.2797203 0.25189447 0.3734844 
FFAR2 -0.5644532 -4.9500237 -1.9625149 0.39646575 0.30037153 
CCL4L2 -0.9398435 -4.9085317 -3.186326 0.64914036 0.23708229 
GBP1 -0.504601 -4.6164107 -1.6606779 0.35973358 0.27789873 
CCL3L1 -0.9405141 -4.614468 -2.8382845 0.61508375 0.2062823 
CCL3L1 -0.9408498 -4.534406 -2.800703 0.617656 0.26621494 
CCL3L1 -0.9406826 -4.519408 -2.86477 0.6338816 0.2999001 
IFIT2 -0.06419801 -4.4181805 -2.7349148 0.61901385 0.25621757 
CCL3 -0.94101036 -4.3225007 -2.7621813 0.6390239 0.31335104 
C3orf14 -1.0526695 -4.25157 -0.4228077 0.09944742 0.74170494 
IL1RN -0.0532208 -4.2384005 -2.423664 0.5718346 0.19622545 
IFI27 -0.065098606 -4.19814 -1.9500985 0.46451488 0.11236938 
SAMD9L 0.7309575 -4.180682 -1.3197756 0.31568426 0.365504 
IFIT3 -0.06411307 -4.1685696 -3.0679684 0.7359763 0.15986454 
IFI44L -0.06476419 -4.127145 -1.2851315 0.31138512 0.39291248 
GBP1 -0.50449896 -4.1266117 -1.6439705 0.39838263 0.26559356 
EPSTI1 -0.62839705 -4.0719585 -1.2264242 0.30118778 0.40335783 
SAMD9 0.73082536 -4.05626 -1.3938246 0.34362307 0.3717935 
CXCL10 -0.76003265 -4.021757 -3.1006546 0.7709701 0.1341035 
IFIT3 -0.06395177 -4.0161567 -1.6345525 0.4069942 0.28886032 
GBP5 -0.50410503 -3.9744053 -1.4250298 0.35855168 0.3122645 
IFIT1 -0.06444321 -3.9705477 -2.4483986 0.61664003 0.25112563 
ETV3 -0.6194654 -3.9242573 -.70651674 0.18003833 0.5836812 
PLA1A 0.5115807 -3.8697472 -1.1976147 0.30948138 0.4194429 
IFIT3 -0.06402939 -3.8242953 -3.0442371 0.79602563 0.2485131 
MSC 0.34185186 -3.8098137 -1.1936555 0.3133107 0.41341317 
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ISG15 -0.038145613 -3.7631938 -2.3269339 0.61834013 0.31049064 
CCL8 -0.93902236 -3.754046 -2.102775 0.56013566 0.18482934 
CCL4L1 -0.94002074 -3.741667 -2.386836 0.63790715 0.31420437 
LBA1 0.02064815 -3.7316766 -0.73635674 0.19732597 0.5507719 
CCL5 -0.93951505 -3.7280154 -0.77837944 0.20879191 0.58271605 
CCL3L3 -0.9403485 -3.7213936 -2.126958 0.57154876 0.41006738 
IL1RN -0.05313881 -3.7021108 -2.2973814 0.6205599 0.26846543 
KCNJ2 -0.024531571 -3.696016 -1.4922967 0.40375817 0.44253558 
XAF1 1.487174 -3.6725726 -1.4011335 0.38151282 0.4016438 
SOD2 0.8849008 -3.6665595 -1.7177505 0.4684911 0.4575416 
MT2A 0.34545022 -3.66402 -1.445199 0.3944299 0.36470655 
KIAA0101 -0.018818974 -3.6500738 -0.81513834 0.22332107 0.5250399 
CD38 -0.91713107 -3.645084 -0.8706393 0.23885302 0.47886088 
IFI6 -0.06468714 -3.6411843 -1.3402395 0.3680779 0.30766064 
CD83 -0.9091399 -3.6375957 -1.1473904 0.3154255 0.4749613 
TLR7 1.0585091 -3.6269853 -0.8278775 0.228255 0.53850114 
IFNB1 -0.06270272 -3.6226375 -1.0422235 0.2876974 0.39908975 
CDCA7 -0.89668834 -3.6170485 -0.73892546 0.20428962 0.58981645 
PARP14 0.4595197 -3.599667 -0.7932458 0.22036643 0.55762637 
SOD2 0.8847393 -3.5959492 -2.2798367 0.6340014 0.37602705 
RNF19B 0.67937505 -3.5890775 -1.1760731 0.32768115 0.48817736 
GCH1 -0.5029993 -3.5863428 -1.0650482 0.29697335 0.4695963 
IFI6 -0.0646093 -3.5668287 -1.0072136 0.2823835 0.42085356 
GBP2 -0.5044018 -3.5198333 -0.8450451 0.240081 0.5294051 
ZBP1 1.5417188 -3.512325 -0.58825207 0.16748224 0.6483138 
OAS1 0.42598832 -3.4865394 -0.752604 0.21585989 0.58638155 
IL6 -0.050994974 -3.4754646 -2.9971752 0.86238116 0.29427785 
LY6E 0.26441905 -3.4647062 -0.9971714 0.28780836 0.4338826 
UBE2C 1.2625195 -3.4587138 -0.46288824 0.13383248 0.699815 
HSH2D -0.075736806 -3.4559553 -0.8123541 0.2350592 0.52780247 
MT1A 0.34473285 -3.4507453 -1.1660624 0.33791608 0.44624764 
PSMA6 0.5800359 -3.4336317 -0.57785034 0.1682913 0.6502408 
GBP4 -0.50420433 -3.4330473 -1.2520523 0.3647058 0.36935398 
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IFI44 -0.06484902 -3.4326754 -1.4650555 0.42679697 0.3603535 
LOC730249 0.24238099 -3.4314592 -1.8182669 0.52988154 0.14167856 
CD83 -0.90929866 -3.4306986 -1.0062847 0.29331774 0.5584771 
FPR2 -0.5278663 -3.43036 -0.68151426 0.19867136 0.6079879 
IFITM3 -0.063616134 -3.418472 -1.4453506 0.42280605 0.33314458 
NUSAP1 0.42417964 -3.4179163 -0.49759436 0.14558412 0.68396235 
STAT1 0.9362078 -3.4050975 -0.99912643 0.2934208 0.5411204 
LOC400759 0.07213392 -3.3992145 -0.88064146 0.25907204 0.4837633 
TYMS 1.2502244 -3.3480518 -0.6773577 0.20231397 0.5908364 
PSMA6 0.5801418 -3.342626 -0.78498745 0.23484154 0.58253014 
LRRC50 0.25834143 -3.3350925 -2.088745 0.626293 0.38605222 
KLF6 0.003711841 -3.3349445 -0.6727071 0.20171462 0.63519365 
PTTG1 0.60013187 -3.3137422 -0.49916553 0.15063499 0.69452864 
HBB -0.44289204 -3.312816 -1.2503223 0.3774198 0.48730302 
IL1B -0.054126855 -3.309459 -1.7789259 0.5375277 0.48973417 
PTPRJ 0.5985735 -3.3067906 -0.2056756 0.062197953 0.8639993 
LOC654346 0.22850724 -3.3059611 -0.40951014 0.123870224 0.73209304 
FBXO6 -0.5733568 -3.29039 -0.46081352 0.1400483 0.721025 
NFS1 0.3875634 -3.259498 -0.656291 0.20134728 0.6669095 
PARP12 0.45942268 -3.2430842 -0.8509655 0.2623939 0.4851226 
OAS2 0.42656448 -3.2389882 -1.341341 0.41412348 0.4083785 
PARP9 0.4607717 -3.230047 -0.80021 0.24773943 0.53216743 
PTTG1 0.60002154 -3.2259624 -0.47765923 0.1480672 0.71703345 
OTOF 0.44560736 -3.224663 -0.91716146 0.28442088 0.40973353 
APOL3 -1.488796 -3.2170537 -0.9260073 0.2878433 0.50424623 
TMEM155 1.0786825 -3.215469 -0.20744467 0.06451459 0.8626798 
TNFSF10 1.1214488 -3.2112827 -1.6090012 0.50104624 0.31774375 
ADAR -1.8603022 -3.1969717 -0.72576237 0.22701558 0.59331834 
FPR2 -0.52797174 -3.1962204 -0.6374574 0.19944099 0.6590889 
TIMD4 1.0469642 -3.18891 -0.32158947 0.1008462 0.78602266 
ZBTB32 1.5491271 -3.1869264 -0.62415266 0.19584784 0.5841406 
TNFAIP8 1.1154293 -3.1658072 -0.95710564 0.30232593 0.4711884 
PSMA4 0.579815 -3.1372805 -0.4705782 0.14999558 0.7016273 
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CDCA5 -0.8968436 -3.1360571 -0.51769686 0.1650789 0.6618505 
OAS2 0.42646512 -3.135491 -0.8076601 0.25758648 0.513324 
RSAD2 0.7152234 -3.128006 -1.2728581 0.40692317 0.3136008 
TAP2 0.9856252 -3.1249948 -0.59969234 0.19190188 0.6277214 
XAF1 1.4876466 -3.1228774 -0.99207497 0.31767976 0.46484175 
IFIH1 -0.064525485 -3.121719 -1.0734649 0.3438698 0.40213183 
NBN 0.3686791 -3.1144345 -0.7322626 0.23511897 0.5582653 
LAP3 0.01751892 -3.1143086 -0.91018105 0.29225782 0.49493554 
OASL 0.42694467 -3.106628 -1.9805574 0.63752645 0.34732276 
LAG3 0.015447804 -3.098014 -1.179234 0.3806419 0.31881177 
BIRC5 -1.2440537 -3.0928712 -0.19627857 0.06346161 0.872191 
STEAP4 0.939546 -3.0919583 -0.60287476 0.19498153 0.6420472 
MAFA 0.2701851 -3.087104 -0.5638318 0.18264101 0.64719933 
HBA2 -0.44298798 -3.086008 -1.4379082 0.4659444 0.4566744 
TRIM22 1.1695155 -3.0740912 -0.7305336 0.23764214 0.5921833 
OAS2 0.42627576 -3.070014 -0.47762632 0.1555779 0.68688357 
ISG20 -0.038061373 -3.0673218 -1.018199 0.3319505 0.45157266 
OAS2 0.4263685 -3.0623052 -1.2564921 0.41030926 0.4620832 
UBE2L6 1.2725362 -3.0616794 -.64707184 0.21134539 0.66142195 
TXN 1.2415017 -3.053 -.75183487 0.24626102 0.61039346 
WARS 1.4099236 -3.0514135 -1.2479172 0.40896365 0.30912063 
TNFAIP6 1.1149546 -3.048315 -1.571579 0.51555663 0.31398633 
IRF9 -0.0394065 -3.0399346 -.52831554 0.17379175 0.6866199 
TXN 1.2417754 -3.039867 -.73644066 0.24226083 0.59636915 
NCOA7 0.37426957 -3.032179 -1.0827312 0.35708025 0.47810298 
MARCKS 0.28404266 -3.0305226 -0.9809265 0.3236823 0.5996619 
RNF213 0.6796081 -3.0290391 -.28264952 0.09331326 0.81055146 
IRF7 -0.0395729 -3.0225742 -0.9853792 0.32600662 0.46420413 
TDRD7 1.0171225 -3.0168214 -0.8000927 0.2652105 0.5338549 
C1orf97 -1.0846637 -3.0165353 -.22026396 0.07301886 0.8527123 
NFKBIZ 0.38729304 -3.0157874 -0.7810879 0.25899965 0.51715183 
STAT1 0.93603957 -3.0129788 -.90178394 0.2992998 0.5234202 
MX2 0.3543741 -3.0050066 -1.0762224 0.35814312 0.4199904 
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NA -0.27473208 -2.995216 -0.5131979 0.1713392 0.693166 
MX1 0.35428262 -2.994807 -1.3634386 0.4552676 0.37525997 
PSME2 0.58569604 -2.9932623 -0.5481138 0.18311587 0.7043533 
IFI35 -0.06493276 -2.9897797 -1.0024805 0.33530247 0.41527668 
CKAP2L -0.84843785 -2.9789152 -0.26414204 0.088670544 0.82421356 
IFITM2 -0.06370018 -2.9764738 -0.80049706 0.2689414 0.5377348 
PTTG3 0.60056764 -2.9629462 -0.3696618 0.12476157 0.76906383 
NBN 0.36876827 -2.956436 -0.20860624 0.070560046 0.8621067 
NMI 0.3975871 -2.9504156 -0.60336685 0.20450233 0.63301134 
LMNB1 0.035099853 -2.9482322 -0.6730685 0.22829562 0.6016637 
NA -0.37895456 -2.946444 -0.55527735 0.18845677 0.64102256 
NFKBIA 0.38673994 -2.9453695 -0.35041523 0.11897157 0.79686767 
WARS 1.410312 -2.9430494 -1.1306973 0.3841924 0.36755747 
MSL3L1 0.34310973 -2.9332507 -0.23070955 0.0786532 0.84890777 
NA -0.1366471 -2.9313598 -0.26527834 0.09049668 0.82100743 
CYP26A1 -0.74883944 -2.9243166 -0.9719424 0.33236566 0.53781015 
OBFC2A 0.427519 -2.9228666 -0.7183533 0.24577013 0.5543896 
NA -0.08248609 -2.922572 -0.22222137 0.07603624 0.8518171 
IFIT1 -0.06435794 -2.921479 -1.1730065 0.4015112 0.3474283 
AIM2 -1.7190115 -2.9182653 -0.47119045 0.16146252 0.73248047 
LOC652694 0.20519401 -2.9135387 -1.0439568 0.3583123 0.41600358 
YEATS2 1.5121676 -2.90025 -0.36150312 0.12464551 0.7614019 
LOC26010 0.047647182 -2.8996515 -0.71855545 0.24780752 0.5185895 
PLAC8 0.5129178 -2.89236 -0.823555 0.2847346 0.5947455 
CD276 -0.9205053 -2.8922212 -0.13680553 0.0473012 0.9081713 
SUCNR1 0.95365775 -2.8911238 -0.23179197 0.08017366 0.8430079 
IRF7 -0.039733853 -2.8893933 -0.9255152 0.3203147 0.4855806 
CD274 -0.920663 -2.8890505 -0.5298605 0.18340299 0.639894 
IL1F7 -0.05379533 -2.886481 -0.8392725 0.29075974 0.5299799 
TNFRSF9 1.1212257 -2.8831277 -0.39218664 0.13602819 0.75422376 
PSMB8 0.5812234 -2.870589 -0.5471363 0.19060071 0.6893601 
EZH2 -0.6126608 -2.8692281 -0.41121006 0.14331731 0.7369426 
PELI1 0.48076856 -2.8682275 -1.3183756 0.4596482 0.44151935 
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AQP9 -1.4782128 -2.8666112 -1.493433 0.52097505 0.42546812 
BATF3 -1.2814198 -2.8593025 -0.9640889 0.33717626 0.5655858 
CMPK2 -0.828136 -2.8584173 -0.84870195 0.29691324 0.49515393 
ZKSCAN2 1.6314819 -2.8583496 -0.3025174 0.1058364 0.80914736 
SAMD4A 0.7304414 -2.8533995 -0.6032939 0.21142988 0.61429363 
SP110 0.89064187 -2.8530369 -0.4809413 0.16857171 0.6897933 
CCL5 -0.9393529 -2.8444417 -0.4135027 0.14537218 0.761383 
UBE2J1 1.270717 -2.842738 -0.45941067 0.16160852 0.75224686 
DNAJA1 -0.6976562 -2.8344507 -0.60028076 0.21178028 0.65540725 
MSL3L1 0.34319794 -2.8338985 -0.2962594 0.10454129 0.8121099 
CDKN3 -0.88744575 -2.8259933 -0.21701097 0.07679104 0.853511 
UBE2C 1.2628146 -2.8215623 -0.3749051 0.13287146 0.74337333 
PI4K2B 0.49821132 -2.811212 -0.7919054 0.28169537 0.48544598 
OASL 0.42685512 -2.8059611 -1.626173 0.5795422 0.33726895 
DMXL2 -0.69850266 -2.8039422 -0.4635954 0.165337 0.72824186 
LOC647450 0.15991324 -2.7987826 -1.1905851 0.42539394 0.4474752 
TNFAIP2 1.1145047 -2.7965589 -0.8010187 0.28643012 0.590673 
NA -0.26471645 -2.79476 -0.35224247 0.12603675 0.7554469 
HERC6 -0.43410146 -2.7904859 -0.7371421 0.26416263 0.5163029 
IL15RA -0.055787712 -2.788209 -0.588109 0.21092717 0.62359124 
MCOLN2 0.29249647 -2.7840424 -0.6891155 0.24752337 0.5741496 
RIN2 0.6676488 -2.7824187 -1.4597206 0.5246229 0.40066493 
MGC39372 0.3095949 -2.7766402 -1.07199 0.3860745 0.45362768 
CH25H -0.8659307 -2.7751105 -1.2173233 0.4386576 0.2958307 
UBE2L6 1.2728497 -2.7749603 -0.72933674 0.2628278 0.6526403 
DUSP5 -0.6712507 -2.7710962 -1.0294533 0.37149677 0.5710575 
GRAMD3 -0.46445507 -2.7702954 -0.44886494 0.16202782 0.71274096 
HIST1H4K -0.42433366 -2.7699432 -0.34911346 0.12603633 0.7857145 
HIST1H2BN -0.42585063 -2.768297 -0.1362729 0.04922626 0.9082275 
GINS2 -0.49376842 -2.765965 -0.42301178 0.15293461 0.7148175 
BPGM -1.2295699 -2.764425 -0.386086 0.13966231 0.74483824 
CDC45L -0.8981064 -2.7634597 -0.4356451 0.15764482 0.7001552 
HERC5 -0.43419352 -2.7576168 -1.6692114 0.6053094 0.2874709 
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C11orf75 -1.1775552 -2.757115 -0.5849128 0.21214668 0.64473075 
APOL6 -1.4878733 -2.7534676 -0.49040222 0.1781035 0.6653048 
NCAPG 0.37095085 -2.7506695 -0.2678547 0.097378 0.81766313 
TRIM21 1.1692727 -2.7364476 -0.6540365 0.23900934 0.59627193 
CCNB2 -0.93751544 -2.7305439 -0.38956213 0.14266834 0.74407065 
OXSR1 0.44805205 -2.7274585 -0.42287827 0.15504481 0.73770237 
LOC441019 0.08445239 -2.722548 -0.6378555 0.23428623 0.6014139 
NA -0.40303454 -2.7220407 -0.6016073 0.22101335 0.6181926 
CASP7 -0.9724967 -2.715913 -0.51755285 0.19056311 0.6649754 
MR1 0.32889488 -2.7158763 -0.42372656 0.15601836 0.7217215 
C15orf48 -1.142984 -2.7158601 -1.3522272 0.49790016 0.45400542 
STAT2 0.93654346 -2.7146766 -0.7467108 0.27506435 0.5976397 
CFLAR -0.8675699 -2.7131095 -0.5594406 0.20619905 0.68020916 
IFNG -0.062456194 -2.7105718 -1.2162476 0.44870517 0.44437358 
NLRC5 0.39460063 -2.7065458 -0.42261314 0.15614483 0.76349324 
CASP4 -0.97354424 -2.7049656 -0.47670078 0.17623174 0.7118474 
SLC43A3 0.8365588 -2.7026854 -0.3796525 0.14047232 0.74895483 
TK1 1.0537102 -2.7023575 -0.3347106 0.12385874 0.7746922 
EIF2AK2 -0.64998466 -2.7007682 -0.9589453 0.3550639 0.45914164 
LOC643997 0.12164942 -2.699231 -0.29249477 0.108362265 0.8085494 
MGC29506 0.30818275 -2.6942391 -0.7766876 0.28827718 0.4883514 
MXI1 0.3548203 3.336374 0.21884489 0.06559363 1.1678367 
CXXC5 -0.75460875 3.355098 0.75873184 0.22614297 1.6827801 
GLTP -0.48851326 3.374232 0.52899647 0.15677537 1.4240466 
CTDSP2 -0.7726914 3.3758397 0.69990253 0.20732695 1.6576083 
LOC653103 0.20998333 3.383266 0.37982464 0.112265676 1.3129019 
LOC730316 0.24280547 3.386709 0.4444132 0.13122272 1.3697579 
HBEGF -0.4426067 3.3967972 1.402669 0.41293868 2.8503883 
TSPAN4 1.2053695 3.5200386 0.56306267 0.15995923 1.4950634 
PTDSS1 0.58929396 3.537718 0.4015255 0.11349844 1.3212758 
MRPL45 0.33522627 3.5413284 0.3730712 0.10534781 1.2918046 
ZNF34 1.7846655 3.561116 0.35599804 0.09996811 1.2875334 
CABC1 -0.99779123 3.566188 0.5301933 0.14867228 1.4451729 
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VEGFB 1.3720226 3.657623 0.5577736 0.15249619 1.4445028 
ZDHHC7 1.5936121 3.6603582 0.7073345 0.19324188 1.7052039 
MEF2D 0.2981564 3.6701992 0.6924658 0.18867254 1.5831358 
PIK3IP1 0.5036851 3.7065449 0.6473732 0.17465678 1.5731415 
ARRDC2 -1.4073013 3.8193815 0.5582261 0.14615615 1.4492002 
TOB1 1.1313546 3.9774272 0.90807724 0.2283077 1.975464 
ING1 -0.047008947 4.077989 0.46914577 0.11504341 1.4024422 
AXIN2 -1.3070259 4.126832 0.5361223 0.12991135 1.4615514 
FOXJ2 -0.530525 4.7123027 0.5525303 0.117252715 1.4846911 
KBTBD11 -0.027755639 4.726356 0.665823 0.14087449 1.5950197 
- Down-regulated gene; No sign- Up-regulated gene 
 
This process obtained a DE list of >25,000 genes that needed further analysis to reduce the number 
of genes for more practical analysis. MultiExperiment Viewer (MeV) was then used to address the 
differences in analysis requirements between this data type and traditional gene expression data. Its 
tools include automatic conversion functions, from raw count data to processed values, and 
differential expression detection and functional annotation enrichment detection, based on 
published methods (Howe, Sinha et al. 2011). From this method, we derived a heatmap shown in 
Figure 3.2. Biological heat maps are typically used in molecular biology to represent the level of 
expression of the differentially expressed (DE) genes across different groups or contrasts. 
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Figure 3.2. Heatmap comparison of gene expression modulation between TP1 and TP2 groups. This is a 
graphical representation of the data based on 234 DE genes, where the individual values contained in a 
matrix are represented as colours: red means down-regulation and green up-regulation. 
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3.4.4 Pathway Enrichment Analysis 
 
3.4.4.1 Pathway map prediction reveals dysregulation of intrinsic Immune response pathways 
during HIV-1 infection 
Next, we analysed the functional importance of the DE gene list at the pathway level, in order to 
derive functionally annotated genes relevant to TP1 and TP2. Genetic pathway map folders were 
evaluated using the MetaCore Analytical Suite (GeneGo Inc). The main aim of this work was to see 
the effect of gene expression in the absence (TP1) and presence (TP2) of antiretroviral drugs. These 
experiments determined what effect virus has on the immune system and how antiretroviral drugs 
ease the heightened gene expression (seen in TP1) when plasma virus is suppressed to below 
detectable levels with therapy. In Appendix 1, the legend for MetaCore
TM
 is displayed to identify 
the genes in the pathways. 
Initial analysis of the DE genes between TP1 and TP2 was performed in order to define the 
functional distribution of DE genes using MetaCore. Through these analyses, 32 pathway map 
folders were detected (Appendix 2). Among the top 10, the overrepresented and statistically 
significant pathway map folders belong to Immune system response (20%) cell cycle and 
inflammatory response (each 17%), vascular development (12%), tissue remodelling (8%), 
apoptosis and mitogenic signalling (6%), and transcriptional regulation (5%) (Figure 3.3). 
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Figure 3.3. Representation of the Top 10 GeneGo Pathway Maps from Metacore. Significant pathways are represented in the form of a pie chart, where each part 
represents -log10 of the P-value of that pathway from the set of over represented pathways, where the total of these -log10 p values is 1. The p values were determined 
by Metacore Pathway analysis, based on the chi-squared value for the expected compared with the observed number of genes identified from that pathway.
20% 
17% 
17% 
12% 
8% 
6% 
6% 
5% 
5% 4% 
Immune system response
Cell cycle and its regulation
Inflammatory response
Vascular development
Tissue remodeling and wound repair
Apoptosis
Mitogenic signalling
Transcription regulation
Cell differentiation
Hypoxia response regulation
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Further, we used the MetaCore package to analyse the differentially expressed genes included 
in Table 3.2. A 5% FDR (p value < 0.01) analysis produced 50 pathway maps (See Appendix 
3 for the full list of pathway maps). Of these, the top 10 gene maps are summarized in Figure 
3.4 and Table 3.3 and assembled according to and in order of significance levels. As seen in 
the Pie Chart, the immune response system was the top ranked category. The pathway 
enrichment concurred with the map folders and we obtained 8 of top 10 significantly enriched 
pathways between TP1 and TP2, predominantly in the immune response category (Figure 
3.4), with strong p values (Table 3.4). This immune response category comprised of antiviral 
actions of interferons and their signalling, stress-induced antiviral response, dendritic cell 
maturation and migration, TLR signalling and metabolism. Two additional maps that were 
also significant were Transcriptional Regulation of cellular metabolism and Development of 
PEDF signalling.  It is apparent, from the data in Table 3.4 and Figure 3.4, that of all 
immune responses, the involvement and up-regulation of interferon-related genes and genes 
related to inflammation predominated in TP1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.4. Top 10 significantly enriched pathways derived through comparison of DE genes between 
time point 1 (TP1) and time-point 2 (TP2) of the same patients, before and after treatment (FDR < 
0.05). 
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Table 3.3. MetaCore Map Folders and Pathways identified in the comparison between TP1 and TP2 
(p<0.01, FDR< 0.05). P-values and ratios of differentially expressed genes are shown. 
Map Folder 
╟
p-value †Ratio Pathway Maps 
╟
p-value †Ratio 
Immune 
system 
response 
2.824e-7 21/1000 
Immune response_IFN 
alpha/beta signalling 
pathway 
8.104e-5 5\24 
Cell cycle and 
its regulation 
3.224e-6 14/516 
Development_PEDF 
signalling 
2.255e-2 6\53 
Inflammatory 
response 
3.794e-6 17/775 
Immune 
response_HMGB1/TLR 
signalling pathway 
6.734e-4 5\36 
Vascular 
development 
(Angiogenesis) 
1.478e-4 12/543 
Development_PEDF 
signalling 
1.689e-2 4\49 
Tissue 
remodelling 
and wound 
repair 
 
1.882e-4 
12/557 
Cell adhesion_Cell-
matrix glycoconjugates 
4.201e-2 3\38 
Apoptosis 2.491e-3 14/953 
Development_PEDF 
signalling 
4.224e-3  
 
4\49 
Mitogenic 
signalling 
1.015e-2 9/562 
Development_PEDF 
signalling 
 
4.656e-3 4\49 
Transcription 
regulation 
1.137e-2 3/71 
Apoptosis and 
survival_Role of PKR 
in stress-induced 
apoptosis 
4.099e-1 3\53 
Cell 
differentiation 
1.656e-2 12/940 
Some pathways of 
EMT in cancer cells 
2.340e-2 3\51 
Hypoxia 
response 
regulation 
3.269e-2 2\43 
Development_EPO-
induced PI3K/AKT 
pathway and Ca(2+) 
influx 
1.000e+0  
 
2\43 
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╟
p-value calculated by MetaCore
TM
 from GeneGo, Inc. Pathway analysis; † ratio meaning the number 
of differentially regulated pathway genes versus total number of genes comprising the pathway; IFN 
(Interferons); PEDF, (Pigment epithelium-derived factor); HMGB1 (High mobility group 1); PKR, 
(Protein kinase R);EMT (Epithelial to Mesenchymal Transition); EPO (Erythropoietin); PI3K, 
(Phosphoinositide 3-kinase);  AKT, (Protein Kinase B); Ca (Calcium).  
 
3.4.4.2 Scoring and prioritization of networks/pathways according to the relevance to input 
data  
In most cases, high-throughput experiments such as ours result in lists of genes of interest. In 
our case, the list of genes was the differentially expressed between pre-and post-therapy time 
points (TP1 and TP2) of the same patient. Next, we analysed the DE genes in MetaCore 
networks, in order to address the issue of how different networks and pathway modules in 
MetaCore can be prioritized, based on their statistical significance (Figure 3.5) with respect 
to our experimental datasets. Significance was evaluated based on the size of the intersection 
between user’s dataset and set of genes/proteins corresponding to a network module/pathway 
in question.  
a) Pathway Maps     
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b) Process Networks 
 
 
 
  
 
 
 
c) Diseases (by Biomarkers)  
 
 
 
 
 
 
 
d) Metabolic Networks 
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e)  GO Processes 
 
 
 
 
 
 
 
Figure 3.5. Enrichment in functional ontologies for the comparison between patients before and after 
treatment. Enrichment analysis across five ontologies in MetaCore: (a) GeneGo pathway maps; (b) 
GeneGo processes; (c) GeneGo disease by biomarkers and (d) GO processes. The associated false 
discovery rate is less than 0.01 for a P value threshold less than or equal to 0.01. 
The resulting networks, if significant, will mean that the algorithm has succeeded in creating 
modules that have higher than random saturation with the genes of interest, which was the 
case with our dataset shown in Figure 3.5(b) under process networks. As it can be seen in 
Figure 3.6, of the top 10 process networks, 5 belonged to inflammation (all involved in 
interferon signalling) and immune response to virus infection, whereas other 5 were in the 
development, cell adhesion and cell-proliferation. Thus, the top ranked network was in 
inflammation of Interferon signalling.  
Furthermore, the examination of disease by biomarker folder was also consistent with top 3 
maps related to RNA virus infection, which was again consistent with the GO processes 
(Figure 3.5e) and the top 2 maps in the defence response and response to virus. Thus, the 
process networks, disease by biomarkers and GO processes were all in concordance with the 
DE genes relevant to immune response to viral infection and RNA virus, which in our case is 
HIV. 
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Figure 3.6. Process Networks by Enrichment analysis in MetaCore
TM
 software. These are the top 10 process network pathways 
according to their p-value- the hierarchy of significance as calculated by the program. 
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To further verify these findings, we carried out gene enrichment analysis, which consisted of 
mapping gene IDs of the dataset onto gene IDs in entities of built-in functional ontologies, 
represented in MetaCore by pathway maps and networks. The DE list provided by MeV was 
uploaded in the website of MetaCore
TM
 from Thomson Reuters Systems Biology Solutions. 
The enrichment analysis of the pathways provided by the MetaCore
TM
 system was also used 
on samples, in order to compare them and learn what is overrepresented among their genes 
represented in the pathways. This analysis assessed the overall functional character of the 
sample set, providing a ranked representation of ontologies that are most saturated or 
"enriched" with the input data. Each GeneGo Process Network represents a comprehensive 
biological process with a specific functional theme. The Figure 3.6 shows the ten most 
enriched GeneGo processes for the sample set, as by their p value represented in the Figure. 8 
of 10 enrichments, which fully represent only the genes from our DE list between TP1 and 
TP2, were in inflammation/signalling and immune response. A lot of these DE genes are 
overlapping between the networks, as most of them are involved in the immune system 
response and inflammation. The representation of all significant genes in the top ranked 5 
pathways is shown in Figure 3.7 a-e.  
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d)            
Figure 3.7. Canonical pathway maps represent a set of 
about 650 signalling and metabolic maps covering human biology 
(signalling and metabolism) in a comprehensive way. All maps are 
drawn from scratch by GeneGo annotators and manually curated 
and edited. Experimental data is visualized on the maps as blue 
(for down-regulation) and red (up-regulation) histograms. The 
height of the histogram corresponds to the relative expression 
value for a particular gene/protein (MetaCore 
TM
). a) Immune 
response_Antiviral actions of Interferons pathway; b) Immune 
response_IFN alpha/beta signalling pathway; c) Immune 
response_Role of PKR in stress-induced antiviral cell response; d) 
Immune response_HMGB1/TLR signalling pathway; e) Immune 
response_Role of HMGB1 in dendritic cell maturation and 
migration. 
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Another significant and the most notable feature in our analyses was the predominance and 
up-regulation of genes related to immune response and inflammation, which were apparent 
from map folders, process networks and GO processes (Figure 3.5). In Table 3.4, we 
visualized the GO process network and the functional annotation of our DE genes in defence 
response (the top ranked category). It showed the large majority of genes comprising of 
interferon, interferon-induced and interferon-associated genes (involved in innate immune 
response, defence response, regulation of innate immune and defence response, surface 
receptor signalling, cytokine-mediated pathways, etc), which were highly up-regulated in TP1 
when compared to TP2. All these networks shown in Table 3.4 were highly statistically 
significant.  
Thus, the immune and inflammatory systems with possible involvement of the interferon 
(IFN) family and also the STAT (signal transducers and activators of transcription) family 
were significant in this comparison (Table 3.4). 
 
Table 3.4 This table content shows the genes of the uploaded file, which was used as the input list for 
generation of biological networks by MetaCore 
TM
, for the defence response for the disease section of 
the enrichment analysis. This is a variant of the shortest paths algorithm, with main parameters of 
relative enrichment with the uploaded data and relative saturation of networks with canonical 
pathways. These networks are built on the fly and unique for the uploaded data. In this workflow the 
networks were prioritized based on the number of fragments of canonical pathways on the network.  
Key network objects GO Processes p-Value 
AKT(PKB), Caspase-9, 
HMGB1, Bcl-XL, 
IKK-beta 
Regulation of defence response (74.0%), 
regulation of response to stress (80.0%), 
regulation of immune system process (82.0%), 
regulation of response to stimulus (92.0%), 
toll-like receptor 1 signalling pathway (40.0%) 
1.31e-16 
ATM, p21, MLL/MEN 
fusion protein, E1B-AP5, 
HEXIM1 
Regulation of cell cycle (38.0%), cell cycle 
checkpoint (24.0%), chromatin organization 
(30.0%), negative regulation of cellular process 
(60.0%), chromatin modification (28.0%) 
4.22e-39 
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From these 5 pathways, we observed 28 of the DE genes (Table 3.5) belonging to genes 
related to interferons, antiviral function, interferon signalling, interferon-induced genes and 
immune-response/activation genes with high statistical significance. Thus, these analyses 
unambiguously confirmed the involvement and up-regulation of genes involved in immune 
response, with inflammation being the most significant one in driving the viremic (TP1) 
phase. Interesting to note was that there was a mirrored regulation in TP2, where there was 
systematic down-modulation of all the very genes/pathways, which possibly led to plasma 
viremia in TP1.  
  
 
 
 
 
 
 
CD19, CD79 complex, 
MHC class II, CD79B, 
IL-8 
Immune response-regulating cell surface 
receptor signalling pathway (53.1%), positive 
regulation of T cell activation (55.1%), T cell co-
stimulation (44.9%), lymphocyte co-stimulation 
(44.9%), response to interferon-gamma (49.0%) 
1.82e-32 
G3BP1 (hdhVIII), 
H-Ras, GPIAP1, ACSL3, 
IFNAR2 
Leukocyte migration (46.0%), cell activation 
(54.0%), cell migration (52.0%), hemostasis 
(48.0%), localization of cell (52.0%) 
2.05e-29 
Casein kinase II, alpha 
chains, CD4, HSP27, 
IRF4, HDAC6 
Regulation of macromolecule metabolic process 
(87.8%), regulation of primary metabolic process 
(87.8%), developmental process (87.8%), 
regulation of cellular metabolic process (87.8%), 
regulation of cellular biosynthetic process 
(79.6%) 
1.40e-29 
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Table 3.5. Overrepresentation of genes, significant for TP1 versus TP2 comparison, in the top 5 
significant pathways. 17 genes from the DE list were found to be involved across 5 pathways. Of the 
17 genes, 9 were validated by qRT-PCR shown, with their respective p-value, function, regulation and 
expression trend. 
GENE 
ANNOTATION 
p-value CELL FUNCTION REGULATION 
IFI6 p <= 0.001198 Regulation of apoptosis down 
IFN- β* p <= 0.001647 
antiviral activity which is 
Mainly involved in innate 
immune response 
down 
IFN-γ* p <= 0.008242 
critical for innate and 
adaptive immunity against 
Viral and intracellular 
bacterial infections and for 
tumor control 
down 
IL-1β* p <= 0.005439 
An important mediator of 
the inflammatory 
response, and is involved 
in a variety of cellular 
activities, including cell 
proliferation, 
differentiation, and 
apoptosis 
down 
IL-6* p <= 0.002616 
Acts as both a pro-
inflammatory and anti-
inflammatory cytokine; 
stimulate immune 
response 
down 
IL1RN p <= 0.0007325 
Inhibits the activity of IL-
1 by binding to its 
receptor 
down 
ISG15 p <= 0.0007325 
Antiviral activity during 
viral infections 
down 
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ISG54 p <= 0.0004398 
Restrict virus infection 
through alteration of 
cellular protein synthesis 
down 
MIP-α p <= 0.0003696 
Involved in the acute 
inflammatory state in the 
recruitment and activation 
of polymorphonuclear 
leukocytes 
down 
OAS1* p <= 0.002616 
involved in the innate 
Immune response to viral 
infection 
up 
OAS2* p <= 0.004717 
involved in the innate 
Immune response to viral 
infection 
up 
OAS3* p <= 2.622e-05 
involved in the innate 
Immune response to viral 
infection 
up 
PKR* p <= 0.01396 
inhibits further cellular 
mRNA translation, 
thereby preventing viral 
Protein synthesis; induce 
cellular apoptosis, to 
prevent further viral 
spread 
down 
STAT1* p <= 0.002616 
Signal transducer and 
activator of transcription 
that mediates signalling by 
interferons 
up 
STAT2 p <= 0.01797 
Signal transducer and 
activator of transcription 
that mediates signalling by 
type I IFNs 
up 
WARS p <= 0.006259 
Catalyzes the 
aminoacylation of 
up 
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* Genes that were validated by RT-PCR in this study: IFI6, (Interferon alpha-inducible 
protein 6); IFN- β, (Interferon beta); IFN-γ (interferon gamma); IL-1β (Interleukin-1 beta); IL-6, 
(interleukin 6); IL1RN, (interleukin 1 receptor antagonist); ISG, (interferon stimulated gene); MIP, 
(Major intrinsic protein of lens fiber); OAS (2'-5'-oligoadenylate synthetase); PKR, (protein kinase R); 
STAT, (Signal Transducer and Activator of Transcription); WARS, (Tryptophanyl-tRNA synthetase).        
 
3.4.5 Quantitative real time PCR corroboration of 14 DE genes 
Following microarray analysis, quantitative real-time PCR (qRT-PCR) was performed using 
the same RNA samples, in order to validate expression patterns of the selected genes. We 
analysed 14 DE genes (CCL8, CXCL10, IFIH1, IFNB, IFNG, IL6, IL1Beta, IRF7, IRF9, 
OAS1 to 3, PKR and TLR-7), shown in Figure 3.8, which were related to interferon function 
and immune response. All 14 DE genes showed consistent trends between qRT-PCR and 
microarray (Figure 3.8).  
With the help of GraphPad Prism
®
 a more in-depth correlation analysis was performed for 
individual genes, in order to validate the significance of their expression in q-RTPCR, 
followed by validation of correlation between microarray and q-RTPCR expression trends. 
Using the GraphPad software, we obtained statistical values q-RTPCR result and its 
correlation with the microarray data (shown in Figure 3.9). For each of the genes, standard 
coefficient correlation and paired t test were performed to show how the genes expressed 
between different groups, as well as their significance. We identified 13 of 14 genes showing 
evidence for statistically significant relationship in expression trends, between microarray and 
q-RTPCR, with OAS3 being the only exception (Figure 3.9). Although 13 of 14 genes 
showed confident R
2
 values, the genes PKR, CXCL10, CCL8, IL-6, OAS2, IFNbeta and IFN 
delta showing R
2
 value >0.5 with excellent p values (Figure 3.8). On the contrary, in q-
RTPCR only 11 of 14 achieved statistical significance, with PKR, TLR7 and OAS2 being the 
exceptions (Figure 3.9). However, these 3 genes showed perfect correlation in expression 
trends between microarray and q-RTPCR.   
tRNA(trp) with 
tryptophan and is induced 
by interferon;    associated 
with angiogenesis 
Chapter 3 
 
98 
The University of Sydney 
CCL8
CXCL1
0
IFIH1 IFNB IFNG IL6 ILI1ᵦ IRF7 IRF9 OAS1 OAS2 OAS3 PKR TLR-7
Microarray FC 1.28 1.33 1.12 1.17 1.14 1.31 1.13 1.11 1.01 1 1.15 1.01 1.07 1.09
PCR FC 1.86 2.36 3.01 4.54 3.02 1.53 1.39 2.36 2.62 2.62 1.47 2.62 2.69 3.14
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
F
o
ld
 C
h
a
n
g
e 
  .Figure 3.8. qRT-PCR validation of 14 significant DE genes. 
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Figure 3.9. Association of gene expression by real-time PCR of the DE found significant in our 
analysis (a, c, e, g, i, k, m, o, q, s, u, x and w). Representative scatterplots with linear regression 
analysis confirm the association between expression levels between microarray and q-RTPCR (figures 
b, d, f, h, j, l, n, p, r, t, v, y and z). p-values for the expression between the different groups were 
measured using the GraphPad Prism
® 
software and also correlation values. The significant ones were 
in the range of p< 0.001 and with the R
2
 value closer to 1. 
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3.5 Discussion 
Even though there have been many reports of gene expression changes at different stages of 
HIV infection (Giri, Nebozhyn et al. 2006), the information on how genomic modulation 
occurs in HIV-infected individuals before and after HAART therapy, and the genomic basis 
of the effects of anti-HIV drugs leading to recovery of genes involved in immune 
reconstitution is still very limited. 
All 14 patients enrolled in the study were responders, which was consistent with concomitant 
rise in their CD4+ T cell counts, coupled with reduction in plasma viremia, following 
HAART. The immune reconstitution falls under the value of 200 CD4+ T cells/μl, which is 
considered as a critical threshold, and this occurs in 5–27% of patients receiving HAART 
(Grabar, Le Moing et al. 2000; Kaufmann, Perrin et al. 2003). In fact, CD4+T-cell counts 
persistently <250 cells/μl or a percentage of CD4 T cells <17, have been considered a sign of 
poor immune reconstitution (Benveniste, Flahault et al. 2005). In our study, all our patients 
showed CD4+ T cell counts of 300 and above. Therefore, we believe that successful HAART 
treatment in responders will better reflect the genomic basis of immunologic reconstitution. 
In this study, we investigated 14 HIV+ patients and analysed the PBMCs for the genome-
wide expression analysis at two time-points, pre- and post-HAART. The aim was to ascertain 
whether HIV leads to perturbations in immunity-related genes, and, if so, how these immune 
function-related genes recover from insults incurred by HIV following HAART, when virus 
becomes below detectable (<20 copies of HIV RNA/mL). We analysed the total T cell 
lymphocyte population in the peripheral blood, to obtain a global picture of the differences in 
gene expressions emanating as a consequence of host-virus interaction. In fact, we detected 
234 differentially expressed genes between pre- and post-therapy time points. Through the 
analysis of these DE genes, we detected distinct transcriptional signatures that segregated the 
pre-therapy viremic, and post-therapy (aviremic) time points in HIV+ patients.  
For the first time, we have shown, through these comparisons, that untreated stage (TP1) was 
characterized by up-regulation of genes that were related to immune system function, 
inflammation and activation. 8 of top 10 pathway maps were functionally related to immune 
response genes encompassing antiviral interferons and their signalling, DC maturation and 
migration, IL-1 signalling, etc. Other 2 pathway maps were related to development and 
transcriptional regulation. In contrast, treated stage (TP2), where plasma virus was below 
detectable (<20 copies/ml plasma), a mirror regulation of these genes was observed, showing 
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systematic down-regulation of these functional categories seen during untreated stage of HIV 
infection. This suggests that most of the alterations in gene expression observed in untreated 
stage resumed almost normal functioning upon HAART treatment. It should be noted that 
post-therapy down-regulation of immune function related genes, specifically to interferon 
antiviral/signalling genes, inflammatory and cellular activation, may be indicative of 
reduction in cellular activation, which gradually occurs with potent antiretroviral therapy and 
more rapidly in responders, as evidenced in this study.  
This argument becomes even more conceivable when the degree of T-cell activation is 
compared between two groups. It has been shown that the degree of T cell activation is lower 
in controllers than in non-controllers, but higher than observed in HIV uninfected individuals 
and higher than observed in antiretroviral-treated patients (Emu, Sinclair et al. 2005). This 
corroborates with our observations, showing considerably reduced cellular activation levels 
upon successful HAART, signalled by systematic down-regulation of genes involved in this 
functional pathways. Therefore, it is plausible to hypothesize that gene expression and its 
modulation pre-therapy is possibly guided, in part, by cellular activation. Also, the down-
regulation of these functional pathways may have aided immune reconstitution upon 
successful HAART. This is the first analysis to show this aspect of host gene expression pre- 
and post-HAART. These findings also corroborate with the studies on the role of HAART 
treatment in HIV-1+ individuals in slowing the rate of disease progression and AIDS, with 
improved patient outcomes (Cossarini, Boeri et al. 2011).  
The interferon (IFN) system is a well-studied branch of the innate immune system active 
against viruses. The infection of cells by many viruses provokes synthesis and secretion of 
IFNs which mediate induction of a cellular antiviral state, obstructing further viral spread. 
For HIV, previous studies have implicated IFNs in blocking both early and late stages of the 
HIV-1 life cycle (Kamga, Kahi et al. 2005; Shmelkov, Tang et al. 2011). Our data not only 
confirmed these previous studies, but are also unique in showing molecular signatures, up-
regulation and over-representation immune response genes enriched in IFN and IFN-related 
pathways, with over 25 statistically significant genes during untreated HIV infection, as 
opposed to the treated stage. A closer examination of top 5 immune response pathways 
showed that, even though a considerable number of genes were overlapping between them, 
they were all functionally related to IFN family within the immune response folder. The top 
ranking pathway was antiviral action of Interferon, and enrichment of over 12 DE genes 
(IFN-beta, IFN-gamma, STAT1, STAT2, IRF9, WARS, PKR, OAS1, OAS2, OAS3, MxA, 
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ADAR1) during untreated stage.  All these genes have in common is the activation of the IFN 
family. It is known that HIV-1 interacts through multiple signalling pathways to reprogram 
the transcriptome and the proteome of host cells (Brown, Kohler et al. 2008). 
The second most significant pathway involved during the untreated stage is related to the 
signalling of IFN-beta and gamma, both produced by the immune cells. These type II 
interferons are also related to antiviral responses, and are implicated in blocking both early 
and late stages of the HIV-1 lifecycle (Barr, Smiley et al. 2008). Most of the genes 
overlapped with the top ranked pathway and all of these genes were related to IFN signalling. 
They were also all up-regulated during the untreated stages of HIV infection. 
The third most significant pathway that we show here is related to HMGB1 and TLR 
signalling, down-regulated in TP2 (Figure 3.7). High mobility group box 1 (HMGB1) is a 
DNA-binding nuclear protein that can act as an alarmin, a danger signal to alert the innate 
immune system about the initiation of host defence (Gougeon, Melki et al. 2012). They 
recognize distinct pathogen-associated molecular patterns and play a critical role in innate 
immune responses (Bowie and Haga 2005; Blasius and Beutler 2010; Li, Jiang et al. 2010). 
The most significant genes in this particular pathway were Ik-B, MIP-α, IL-6, IL1RN, IL-ᵦ, 
IRF7, IFN-ß. Previous studies have shown that Toll-like receptor (TLR) pathway contributes 
to the persistent immune activation, observed in chronic HIV-1–infected individuals. Even 
though the link between immune activation and HIV-1 disease progression is well 
established, the underlying genomic basis through which HIV-1 induces immune activation 
remains unclear. In our study, the TLR7 was enriched in the top ranked immune response 
pathway (p<0.001926). It has been demonstrated that HIV-1 encodes for multiple TLR7/8 
ligands that can mediate direct activation of the immune system in vitro (Meier, Alter et al. 
2007). Moreover, Baezinger et al., have provided further evidence for a role of chronic TLR 
stimulation in HIV-1 pathogenesis. Through a murine model, they show that chronic 
activation of TLR7 can directly lead to immune activation, as well as an array of immune 
dysfunction similar to those observed in human HIV-1 chronic infection (Baenziger, 
Heikenwalder et al. 2009). Interestingly, recent data from the nonhuman primate model of 
HIV-1 infection provided additional support for a role of the TLR7 pathway in HIV-1 
pathogenesis (Mandl, Barry et al. 2008). Apart from this, other genes involved in immune 
activation (such as CD38, CD83 and TNFSR family) were also significantly expressed and 
up-regulated during the untreated phase, suggesting immune activation as one of the key 
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aspects of the viremic stage and acute infection. This is also consistent with the increased 
gene expression changes associated with increased viral loads in viremic patients. 
The most notable aspect of these studies is an unambiguous demonstration of up-regulation in 
most pathways related to immune response during the untreated stage of HIV infection, 
followed by a mirror down-regulation of the same pathways in the HAART treated stage of 
HIV infection.  By up-regulating most of the pathways related to the IFN system, the host 
cells could be more in control of virus replication, which will determine the course of the 
infection. This is even more conceivable when we see that the increase of IFN production is 
negatively linked to viral loads. Therefore, it is obvious that the immune activation in patients 
without HAART treatment, experiencing plasma viremia, is trying to protect the disease 
spread. If we compare this scenario in chronically-infected individuals, who control the virus 
in the absence of therapy to below detectable HIV, there is an emerging consensus that much 
of the inflammatory response related to cellular activation over time does more harm than 
good. What we have shown here is that the virus causes more profound changes in the host 
cell gene machinery by regulating the most important part of the immune system, thereby 
leading to inflammation and immune system activation. In this context, not only the IFN 
system pathway and the immune response pathways were the most significant, but the high 
mobility group box 1 (HMB1) was up-regulated in patients before treatment, which signals 
heightened innate immune responses to virus infection. This pathway has more profound 
importance and is related to the response to exogenous pathogens molecules, acting as a 
danger signal and triggering inflammation (Gougeon, Melki et al. 2012), as discussed before. 
That means that the HIV-1 virus regulates all the levels of the innate immune response, 
including signalling inflammation by up-regulating the genes related to this role, such as 
STAT-1, MIP-1α, IL-6, IL1RN and IL1β.  
Overall, our study is unique in demonstrating how virus subverts the host gene machinery by 
up-regulating key immune response genes involved in inflammation, in the absence of 
therapy, and how these genomic insults are neutralized upon the initiation of HAART therapy 
at the gene level. These are the first studies to show the genomic basis of HIV infection pre-
and post-therapy. Thus, in simple terms, the successful outcome of HAART therapy can be 
now be directly associated with the down-regulation of particular immune and inflammation 
genes, as this study has shown. It is known that therapy leads to the reconstitution of the 
immune system. We show that the down-regulation of the most important genes related to 
immune system response and inflammation may provide respite from cellular 
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activation/inflammation in HIV patients. Untreated HIV-1 infection progresses through acute 
and asymptomatic stages to AIDS. HAART treatment can improve clinical, virologic, and 
immunologic characteristics, the reflection of which is apparent in the host transcriptome in 
our analyses. Very little is known of the host molecular mechanisms underlying untreated 
versus HAART treated stage of the same patient. Our work shows that, although there are 
common sets of key genes associated with HIV altered expression at both stages, each stage 
(pre- and post-therapy) was also characterized by its own unique molecular signatures. 
Genome-wide analysis is important to enrich the list of factors in the HIV–host interaction, in 
order to identify new candidates for HIV therapeutics. Overall, the results presented in this 
study offer new comparative insights related to disease status that can distinguish 
differentiated patterns of gene expression between HIV patients before and after HAART. 
This reveals how genomic insults incurred by HIV recover following HAART. Taken 
together, the innovative approach we have used can be applied to disease conditions other 
than HIV, where correlating complex cellular and molecular signatures of immunity may 
provide new insights in the mechanisms of pathogenesis and success of therapy.  
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3.6 Conclusions 
This is the first study to carry out genome-wide analysis in primary PBMCs derived from the 
same patient, at 2 time points (pre- and post-therapy). As a result, through the genome-wide 
analysis we demonstrate for the first time the key genomic differences that highlight how 
virus subverts the host gene machinery and how antiretroviral drugs overcome this effect at 
the level of host genome by inhibiting viral proteins, thereby decreasing the immune 
activation. Thus, these studies provide the first global snapshot of genomic events related to 
pre- and post-therapy stages in HIV-infected individuals, which could form the genomic basis 
of drug-mediated control of plasma viremia.   
Genome-wide analyses are important to enrich the list of factors in the HIV–host interaction, 
in order to identify new candidates for HIV therapeutics. Overall, the results presented in this 
study not only offer new comparative genomic insights related to disease status in HIV-
infected individuals, but they also provide valuable data on functional annotation of genes 
and pathways that are crucial in host cellular activation and inflammation. It also shows the 
role that antiretroviral drugs play in neutralizing these insults incurred by HIV, leading to 
partial immune reconstitution. Many of the genes and pathways identified in this study will 
further facilitate the development of new generation of therapeutic interventions for HIV 
patients. 
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4.1 Summary 
Objective 
To investigate the genomic basis of natural immunological control of plasma viremia in the 
absence of HAART therapy in long-term non-progressors (LTNPs) and identify new generation of 
genomic biomarkers that are involved in disease staging. 
Design 
The genomic basis of this natural effective immunological control of viremia in HIV
+
 elite 
controllers (EC), i.e., those who control HIV viremia naturally with no apparent signs of 
disease progression, is unknown. We carried out a genome-wide comparative 
transcriptomic expression analysis, using whole primary peripheral blood mononuclear 
cells (PBMC) derived from 14 HIV
+
 patients pre-HAART (TP1 viremia) and post-HAART 
(TP2: below detectable level (BDL) of plasma HIV <40 copies of HIV RNA/mL plasma). 
We compared these against 9 therapy-naive ECs to unravel genomic basis of natural 
control of viremia in ECs, as opposed to drug-mediated control in HIV
+
 patients. 
Methods 
Genomic RNA extracted from the PBMCs was used in genome-wide microarray analysis 
using HT-12V2 Illumina chips. Quantile normalization was performed for the 
normalization of data and inter-patient variability. BeadStudio was used to obtain 
differentially expressed (DE) genes. Only the significant genes with p value <0.01 and 
FDR of <1% were considered appropriate for analysis. Pathway analysis was performed in 
MetaCore
TM
 to derive functional annotations. Functionally significant genes were validated 
by quantitative real time PCR and Flow cytometry. 
Results 
Our results show the first evidence that natural control of HIV in EC is guided by the genes 
enriched in the immune response, cytoskeleton remodelling, apoptosis and T-cell signaling 
pathways. Another striking observation was that, even though the LTNP and TP2 groups 
maintained BDL of plasma viremia (<40 copies), the LTNP group was genomically 
distinct from the TP2 who controlled viremia with HAART, highlighting a critical role of 
enriched pathways in natural control of viremia in the LTNPs. Seventeen genes 
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encompassing all these pathways were validated by q-PCR, which showed consistent 
trends between microarray and q-RT PCR. One gene in particular, the Thrombospondin 
(THBS1) (R
2
= 0.942) was identified as a biomarker in our study, discriminating between 
viremic patients and LTNP at the genomic (R
2
= 0.942, p<2.654e.08) and proteomic levels 
(p<0.003761). The levels of expression of THBS1 showed excellent correlation with plasma 
viremia (R
2 
=0.81557; p<.0.0003761). 
Conclusions  
Therapy-mediated control of HIV viremia is genomically different from the natural control 
seen in LTNPs. The natural control of HIV is guided through a well-orchestrated and 
coordinated response of genes related to immune response, cytoskeleton remodelling and 
apoptosis genes. The systematic down-regulation of apoptosis pathway was the key feature 
characterizing LTNPs. Thrombospondin is a new biomarker for predicting plasma viremia 
in HIV patients. 
 
4.2 Aims  
Analyse genome-wide profiles from the whole primary PBMCs to elucidate underlying 
genomic basis of drug-mediated control of HIV, as opposed to natural control of HIV in 
the absence of therapy in LTNPs. Also, to define the biological relevance of the highly 
relevant biomarkers involved in HIV disease staging.  
 
4.3 Background 
HIV is able to manipulate and subvert the human gene machinery through a series of 
complex interactions with the host immune system. The virus is strictly dependent on the 
host cell for replication, but it is constantly exposed to the immune response of the infected 
host. This host response to manipulation by HIV forms the host-virus interaction, during 
which panoply of host genes and proteins are altered (Wu, Sasse et al. 2013).  
In general, clinical progression of HIV-1 disease is relatively slow, taking several years 
from the initial infection to the development of severe immunodeficiency. A subset of 
individuals who are persistently infected with HIV-1, show no signs of disease progression 
Chapter 4 
 
113 
The University of Sydney 
for over 15-20 years or more, remain asymptomatic with high CD4
+
 and CD8
+
 T cell 
counts and below detectable plasma viremia (20 copies/ml plasma) in the absence of 
antiretroviral therapy. These individuals are termed as Long Term Non Progressors 
(LTNPs). In LTNPs, the cell-mediated and humoral immune responses and the production 
of neutralizing antibodies are usually robust in the absence of any antiretroviral therapy, 
possibly a guide to non-progressive HIV disease (Pastori, Weiser et al. 2006; Mahajan, 
Agosto-Mojica et al. 2010). In relation to clinical progression, it varies between individuals 
and factors such as host susceptibility, genetics and immune function as well as viral 
genetics may affect the rate of progression to AIDS (Canducci, Marinozzi et al. 2009; 
Mahajan, Agosto-Mojica et al. 2010). Moreover, despite considerable work, the underlying 
genomic reasons for the lack of progression, and absence of plasma viremia accompanied 
by durable natural control of HIV in LTNPs in the absence of HAART, remains unclear. 
The recognition of what factors are the main determinants for protection against HIV-1 
disease progression is of great importance, since it may allow new treatment strategies to 
be designed, leading to possible cure (Rodes, Toro et al. 2004).  
HIV
+
 individuals in HAART are required to control plasma viremia, while maintaining 
levels of plasma viremia to below detectable levels (<20 copies of HIVRNA /mL plasma) 
by conventional diagnostics. These levels of viremia are comparable to levels seen in 
LTNP, in the absence of HAART. But despite effective HAART and control of plasma 
viremia, the immune system in individuals receiving HAART never recovers to normal 
levels. Thus, there is a clear biological distinction between HIV
+
 individuals who control 
plasma viremia through drug mediation, as opposed to HIV
+
 individuals who control 
plasma viremia naturally through the strength of the immune system, such as LTNPs.  
The underlying genomic reasons for this distinction between two groups, has never been 
explored before. Our study is the first to dissect the genomic basis of drug-mediated 
control of HIV, as opposed to natural control in LTNPs. This was achieved by comparing 
genome-wide transcriptomes, encompassing all 25,000 human gene (=48,000 transcripts or 
probes), to define critical molecular differences between these two groups at various 
immune functional levels. Current microarray platforms allow a high-throughput analysis 
of genome-wide transcriptome, making possible the understanding of fundamental cellular, 
molecular and genetic mechanisms underlying non-progressive HIV disease (Sturn, 
Quackenbush et al. 2002). 
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Previous gene microarray studies in relation to HIV disease have used specific cell-types, 
such as CD8
+
T cells, macrophages, cell lines, dendritic cells etc., in order to understand 
gene regulation during HIV infection (McLaren, Mayne et al. 2004; Wu, Dwyer et al. 
2011) . In this study, we have used the whole primary peripheral blood mononuclear cells 
(PBMCs) in order to represent holistic genome-wide expression. Secondly, since we have 
used two time points and archival samples from chronically-infected LTNPs and other HIV 
groups, all our work was only possible on whole frozen PBMCs, from which separation of 
individual cell types was experimentally not feasible due to their low quantities of cells and 
loss of RNA. 
Here we show the genome-wide primary PBMC transcriptome analysis from 9 long term 
non progressors (LTNPs), who displayed below detectable levels of plasma viremia and 
durable CD4
+
 T cell counts for >15 to 17 years post-infection, in the absence of 
antiretroviral therapy. We compared, in parallel, the genome-wide dataset from 9 LTNPs 
against the genome-wide dataset derived from 14 HIV patients at two time points (TP1-
pre-therapy) and TP2 (post-therapy). The main purpose of this inter-group comparison of 
genome-wide dataset was to find out what was the underlying genomic basis of natural 
versus drug-mediated control in HIV patients, and whether the LTNPs are truly a unique 
group, in comparison to HIV
+
 patients, who fully control HIV while on HAART. 
Focusing on the global dysregulation of genetic networks, our analysis at the gene set and 
pathway level has shown the first clear transcriptomic distinction between therapy-
mediated control and natural control of HIV. Between these groups, the down-regulation of 
the interrelated pathways in cell signalling, apoptosis and immune response genes was 
unique to LTNPs. This suggests, firstly, that the genomic basis of natural control of 
viremia is distinct from drug-mediated control of plasma viremia; secondly, that there is a 
considerable genomic relationship between HIV patients pre- and post- therapy; and, 
ultimately, that LTNPs are a genomically distinct group from other HIV
+
 groups, due to 
the uniqueness of their immune system, which was reflected in  the transcriptomic 
analysis. 
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4.4 Results 
4.4.1 Clinical profiling of patients enrolled in the study 
In chapter 3, we have fully explained the clinical profiles of the patients enrolled in the 
study where we analyzed PBMCs from 14 HIV
+
 patients before (TP1) and after (TP2) the 
initiation of HAART (Table 3.1). In this chapter, in addition to the 14 HIV patients, we 
have included nine therapy naïve chronically-infected HIV
+
 patients, classified as long-
term non-progressors (LTNPs). The duration of infection was >15 years in each case, 
coupled with high CD4
+
T cell counts (range-690-910/µL blood) (Table 4.1).  
 
Table 4.1. HIV
+
 LTNP individuals enrolled in this study. Their average length of infection and 
CD4 counts are shown in the table. 
 
 
 
 
 
 
 
 
 
 
 
 
*NB: All 9 LTNPs were naïve for HAART throughout the duration of 
infection. 
LTNP PATIENTS 
(viral load <40 
copies/ml) 
Length of infection 
S6 (CD4-760) 17 years (since 1995) 
S12 (CD4-890) 17 years (since 1995) 
S16(CD4-720) 16 years (since 1996) 
S23(CD4-910) 16 years (since 1996) 
S24(CD4-690) 15 years (since 1997) 
C13(CD4-780) 17 years (since 1995) 
C53(CD4-910) 15 years (since 1997) 
C64(CD4-860) 16 years (since 1996) 
C122(CD4-800) 17 years (since 1995) 
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4.2.2 Microarray and clustering analysis with identification of the differently expressed 
genes  
All the frozen samples were thawed and the cells immediately lyzed for RNA extraction, 
following protocol explained in chapter 2. Following that, we performed microarray chip 
analysis using the Illumina HumanHT-12 v3 Expression BeadChip, to obtain differentially 
expressed (DE) genes. Using the BeadStudio software provided with the Illumina package 
(see chapter 2), these genes were normalized by quantile normalization process, in order to 
minimize biological errors. The results were a median of 24, 000 genes from each 
comparison. For further analysis, the software BRB Array Tools was used to get a smaller 
list of DE genes. This software integrated package is used for the visualization and 
statistical analysis of DNA microarray gene expression data. Each differential gene had a 
detection p value of less than 0.01 (indicating that the transcript was detected) in at least 
one group, with a differential score of <-20 or >20 corresponding to significance level of 
p<0.01 (down-regulation or up-regulation, respectively).  
To ascertain the validity of each group, hierarchical clustering analysis was performed on 
the whole normalized dataset, using BRB Array Tools software. This showed a clear 
separation between LTNPs and TP1 (Figure 4.1a) and LTNPs and TP2 (Figure 4.1b), 
with each group forming an independent cluster. In LTNP versus TP1 comparison, only 
one patient did not show a clear separation and clustered with the LTNPs (Figure 4.1a), 
but this did not affect our differential expression analysis.  
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a)                                                                                                            b) 
 
 
 
 
 
 
 
 
 
Figure 4.1 a and b) Hierarchical clustering analysis of global gene expression profiles between LTNP vs TP1 (a) and LTNP vs TP2 (b). The differences between the 
groups are very distinct and clear. Similarities in the gene expression patterns among individuals were evaluated and visualized with BRB Array Tools Analysis. The 
algorithm used is named Correlation, which computes the Pearson correlation using a 1-r distance measure. The distance on the X axis represents the similarity 
relationships among samples.  
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The analysis of differentially expressed genes between LTNP and TP1 resulted in 965 DE genes 
(Appendix 4) for this comparison. Of 965 DE genes, 706 genes were up-regulated and 259 genes 
were down-regulated (according to their fold-change calculated by the MeV software, as explained 
in Chapter 2).On the other hand, in the next contrast, when LTNP were compared against the TP2 
group, 1181 DE genes (Appendix 5) were differentially expressed, with 727 genes up-regulated 
and 454 genes down-regulated. Only partial heatmaps, based on top 100 DE genes list is shown in 
Figure 4.2a (LTNP vs TP1) and b (LTNP vs TP2), due to the fact that the DE lists were long. 
Nonetheless, the sole aim of this depiction was to show the regulation of these genes in respect to 
each other, and their differential relationship at the group level based on the DE genes. Secondly, it 
was also performed to visualize our findings on hierarchical clustering shown in Figure 4.1a and b. 
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a)                                                      b)                                                                 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Heatmap representations of only the top 100 most significant genes from the DE list. Due to the large 
number of genes, only the top classifiers were chosen for the heatmaps. (a) LTNP vs TP1 comparison; (b) LTNP vs TP2 
comparison, as calculated by the MEV software. Green: down-regulated and Red: up-regulated; the panel of genes are 
shown on the right hand side of each map. 
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We next performed Significance Analysis of Microarrays (SAM), which is a statistical technique, to 
determine whether changes in gene expression are statistically significant, and obtained a smaller 
list that represents the top 100 most significant genes. We used paired SAM in both comparisons 
and observed that all the genes were significantly related to the immune response. Transcriptomic 
analysis of this kind has not been performed previously by other studies, and these analyses are 
unique in this respect.  
 
4.4.3 MetaCore
TM
 from GeneGo, Inc Pathway Analysis 
To further test the functional attributes of the DE genes between each contrast, we performed a 
more profound gene analysis in MetaCore
TM
 in order to analyse the significance of DE genes at the 
pathways level for each contrast. We used Metacore
TM
 website to cross-examine the biological 
context of the DE lists generated from the microarray analysis. MetaCore
TM
 analyses high-
throughput data in the context of pathways, networks, and maps, in order to identify and rank 
important pathways, networks, and disease terms for the lists of genes, proteins, transcripts, or 
compounds. 
The DE genes lists were integrated in the MetaCore
TM
 from GeneGo, Inc for a detailed pathways 
analysis for each contrast. We analysed therapy naïve LTNPs against the two time-points pre- and 
post-therapy (TP1 and TP2) from HIV
+
 individuals shown in Chapter 3. 
  
4.4.3.1 Comparison between LTNP vs TP1: Natural control in LTNP versus viremic patients 
prior to HAART initiation 
4.4.3.1.1 Analysis of up-regulated genes 
Genetic pathways were evaluated using the MetaCore Analytical Suite (GeneGo Inc). The data 
shown using Map Folder tool (a label, which MetaCore provides to sets of genes with an 
overarching function of pathway participation), which demonstrates that immune response is the 
most significant one on the comparison between LTNP and TP1. In these experiments we 
determined the differences in gene expression caused by the virus infection against the patients that 
naturally control HIV disease. 
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Our data shows (Figure 4.3) that the most significant folder for this comparison are was the 
immune response (13% with 11 of 54 DE genes enriched in this pathway) (p<1.03e-07), followed 
by, in the order of significance: the vascular development and tissue re-modeling; wound repair and 
mitogenic signalling (12%); inflammatory response (11%); cell differentiation (9%); apoptosis 
(9%); DNA damage response and calcium signalling (7%). Figure 4.4 represents the hyper-
geometric distribution of the map folders according to their-log (p-value) (FDR<0.01 and p-
value<00.1). Most of the pathways involved in these folders are all related to immune response and 
were up-regulated in the LTNPs.  
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Figure 4.3. Statistically significant map folders, showing the 10 most significant map folders up-regulated in the group LTNP in comparison to the TP1. Percentage 
was calculated by -LOG(base 10) in Excel from the p-value calculated by MetaCore
TM
. 
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Figure 4.4.  Statistically significant map folders up regulated in the LTNP vs TP1 comparison. Bars 
represent significance as −log(p-value) for hypergeometric distribution. Ontology enrichments were all 
filtered to allow no more than 1% false discovery rate. 
 
All these map folders showed significant p values (Table 4.2). As it can be seen, each map folder 
comprises of a series of pathways maps related to it. On Table 4.2 we show only the top 10 most 
significant pathways with their respective p-value and ratio (the number of genes appearing in the 
pathway that belong to the uploaded DE list versus total number of genes on the pathway).  
These results clearly confirm that the immune system response was the most significant function 
up-regulated in LTNP (p<1.12e-06), when compared to the HIV
+
 patients with detectable viremia. 
We have discussed only the top two pathways here, but in Appendix 6, we have shown the rest of 
the pathway maps, in order of significance, for all the ones shown in Table 4.2. 
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Table 4.2 Summary of the top 10 map folders and respective pathway map up-regulated in LTNP when 
compared with TP1 according with their p-value and ratio. These are all ANOVA-based analyses. 
╟p-value calculated by MetaCoreTM from GeneGo, Inc. Pathway analysis; † ratio meaning the number of 
differentially regulated pathway genes versus total number of genes comprising the pathway; (B-cell antigen 
Map Folder ╟p-value †Ratio Pathway Maps ╟p-value †Ratio 
Immune system 
response 
1.12e-06 51/1000 Immune response_BCR pathway 1.03e-07 11\54 
Vascular 
development 
(Angiogenesis) 
1.36e-06 34/543 
Transport_Macropinocytosis 
regulation by growth factors 
5.41e-07 11\63 
Tissue remodeling 
and wound repair 
2.43e-06 34/557 
Development_Slit-Robo 
signalling 
6.62e-07 8\30 
Mitogenic 
signalling 
2.97e-06 34/562 
Immune response_CD16 
signalling in NK cells 
1.40e-06 11\69 
Inflammatory 
response 
7.26e-06 41/775 
Immune response _CCR3 
signalling in eosinophils 
4.27e-06 11\77 
Cell 
differentiation 
3.15e-05 45/940 
Chemotaxis_CCL2-induced 
chemotaxis 
1.04e-05 9\55 
Blood clotting 4.03e-05 20/279 
Blood coagulation_GPVI-
dependent platelet activation 
1.04e-05 9\55 
Apoptosis 2.00e-04 43/953 
Chemotaxis_C5a-induced 
chemotaxis 
1.22e-05 8\43 
DNA-damage 
response 
3.79e-04 21/354 
Blood coagulation_GPCRs in 
platelet aggregation 
1.34e-05 10\71 
Calcium 
signalling 
5.28e-04 25/469 
Development_S1P4 receptor 
signalling pathway 
1.53e-05 6\22 
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receptor (BCR); Cluster of Differentiation 16 (CD16); Natural Killer cells (NK), C-C chemokine receptor 
type 3 (CCR3). 
 
4.4.3.1.1.1 Gene set enrichment analysis of consistently present probe sets up-regulated in the 
LTNP as compared to TP1 group 
In order to evaluate the potential of expression profiles generated from the comparison of LTNP to 
the TP1 group, all probe sets detected as present, across two sample groups (LTNP and TP1), were 
imported into MetaCore for the gene set enrichment analysis. Several significant GeneGO pathways 
were identified and the genes were enriched in functional ontologies, largely related to immune 
response in GeneGo maps. Further under process network, confirmation of the involvement of 
immune response and B-cell receptor pathway was evident with it being the top ranked network 
process (p<4.390e-8) with 26 of 137 genes being enriched in this network. In addition, the role of 
the B cell in LTNPs was also evident from its high enrichment also in GeneGo disease (p<2.414e-
9), with 51 of 393 genes enriched in B cell and lymphoma. Thus, taken together, the GeneGo maps, 
GeneGo process network and GenGo Disease underpin the importance of immune response and B-
cell/B-cell-receptor pathway, being significantly enriched and correlating positively with the LTNP 
group and negatively with the TP1 group (Figure 4.5).   
 
a) Pathway Maps 
 
 
 
 
 
 
 
 
Chapter 4 
 
126 
The University of Sydney 
b) Process Networks 
 
 
 
 
 
 
 
 
c) Disease by Biomarkers 
 
 
 
 
 
 
 
d) Metabolic Networks 
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e) GO process 
 
 
 
 
  
 
 
Figure 4.5. Enrichment in functional ontologies for the comparison between LTNP versus TP1 up-regulated 
in LTNP. Enrichment analysis across five ontologies in MetaCore: (a) GeneGo pathway maps; (b) GeneGo 
processes; (c) GeneGo disease by biomarkers and (d) GO processes. The associated false discovery rate is 
less than 0.01 for a P value threshold less than or equal to 0.01. Bars represent significance as −log(p-value) 
for hyper-geometric distribution. Ontology enrichments were all filtered to allow no more than 1% false 
discovery rate. 
 
Furthermore, we found enrichment of genes positively correlating with the LTNPs in metabolic 
networks, with 1,2-didocosahexaenoyl-sn-glycerol 3-phosphate pathway (Figure 4.5d) being the 
top ranked, and in GeneGO processes cellular metabolic being the most prominent (p<3.035e-20), 
with 553 of 9400 genes enriched (Figure 4.5e) having functions in various signalling pathways, 
positive regulation of biological processes, signal transduction, phosphorylation, etc. Table 4.3 
shows some of the enriched genes in the cellular metabolic process with their respective shared 
network and function. The association between the networks were highly significant (Table 4.3).   
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Table 4.3. This table contains the genes of the uploaded file, which was used as the input list for generation 
of biological networks by MetaCore 
TM
 for the cellular metabolic process GO process section of the 
enrichment analysis. This is a variant of the shortest paths algorithm with main parameters of relative 
enrichment with the uploaded data, and relative saturation of networks with canonical pathways. These 
networks are built on the fly and unique for the uploaded data. In this workflow the networks are prioritized 
based on the number of canonical fragments .   
 
Key network objects GO Processes ╟p-value 
Ephrin-B receptors, 
H-Ras, CDC42, 
Ephrin-A, RhoA 
Enzyme linked receptor protein 
signalling pathway (80.8%), 
transmembrane receptor protein 
tyrosine kinase signalling pathway 
(75.0%), neuron projection 
development (69.2%), neuron 
development (71.2%), generation of 
neurons (78.8%) 
9.53e-10 
NLK, KLF15, WNK1, 
FATP, EDF1 
Intracellular signal transduction 
(50.0%), positive regulation of 
biological process (68.0%), positive 
regulation of molecular function 
(44.0%), protein phosphorylation 
(36.0%), regulation of cellular 
process (94.0%) 
1.10e-24 
UBE3A (E6-AP), 
ZNF364, 
MKL2(MRTF-B), 
RAD23A, Catalase 
Positive regulation of biological 
process (73.5%), signal transduction 
by p53 class mediator (22.4%), viral 
reproduction (38.8%), 
multi-organism process (53.1%), 
cellular metabolic process (93.9%) 
4.04e-21 
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PUS3, PPCS, ALG2, 
FKBP3, HSPC142 
Gene expression (72.0%), 
exonucleolytic nuclear-transcribed 
mRNA catabolic process involved 
in deadenylation-dependent decay 
(16.0%), nuclear-transcribed mRNA 
catabolic process, exonucleolytic 
(16.0%), nuclear-transcribed mRNA 
catabolic process, 
deadenylation-dependent decay 
(18.0%), cellular metabolic process 
(90.0%) 
1.88e-21 
RhoA, NFIX, SULT1A1, 
TCP1-alpha, PLC-beta2 
Locomotion (50.0%), multicellular 
organismal process (92.0%), 
single-multicellular organism 
process (92.0%), signal transduction 
(80.0%), cell migration (40.0%) 
2.77e-21 
 
The enrichment analysis of the pathways provided by the MetaCore
TM
 system also performs a 
comparative analysis of the overrepresented genes among the pathways. This analysis assesses the 
overall functional character of the sample set, providing a ranked representation of ontologies that 
are most saturated or "enriched" with the input data. Each GeneGo Process Network represents a 
comprehensive biological process with a specific functional theme. The Figure 4.6 shows the top 
ten most enriched GeneGo processes for the sample set (LTNP vs TP1) with their respective p 
values. 4 of 10 enrichments, which fully represent only the genes from our DE list between LTNP 
and TP1, were in the immune response supported by strong p values. Interesting to note was that, 
apart from the top ranked enrichment in the BCR pathway, which positively correlates with LTNPs, 
enrichments in GO processes in the immune response related to protein folding, cell adhesion and 
cytoskeleton, phagocytosis, inflammation and signalling were also highly significant (Figure 4.6).  
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Figure 4.6. Process network derived from the comparison between LTNP x TP1. Each enriched category has its own p value shown at the bottom of the bar for the 
respective GO process. The genes shown within the bar are the DE genes derived from our microarray analysis. 
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, M9, 
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1, 
DNAJC
3, 
RPL23, 
eIF1A, 
RPLP2, 
RPS27, 
RPL35, 
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RPL11, 
RPL17, 
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response_BC
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folding_Prot
ein folding 
nucleus 
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4.390e-08  
2.416e-05 
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4.4.3.1.1.2. Pathway analysis of up regulated DE genes between LTNP and TP1 
In order to shed light on the role of differential modulation of genes, we carried out pathway 
analysis by using the DE gene list obtained from the comparison of LTNP and TP1 contrast. . 
As can be seen in Table 4.2, the most significant pathway up-regulated in the LTNP is the B-cell 
receptor (BCR) signalling pathway (p<1.03e-07), which was also confirmed from enrichment 
analysis (Figure 4.6) and by pathway analysis (Figure 4.7). This signalling pathway is involved in 
many distinct outcomes, including survival, tolerance or apoptosis, cytoskeletal changes, DNA 
damage and repair, proliferation, and differentiation into antibody-producing cells or memory B 
cells. A total of 11 of 54 DE genes were overrepresented in this pathway, with all of them recording 
high p-values (Table 4.4). The genes from our DE list for this contrast involved in this pathway are 
related to the immune response activation of the antigen presenting cells, such as MAPK1/3, CD79, 
BtK, Syk, SHIP and HRAS, respectively (see Table 4.4 for p values). Interesting to note was the 
strongest statistical association of CD22 (p-8.25e-05) in this pathway, which was up-regulated in 
the LTNP group. This has high functional significance, because CD22 is found on the surface of 
mature B cells, and, to a lesser extent, on some immature B cells. Generally speaking, CD22 is a 
regulatory molecule that prevents the over-activation of the immune system (see significance of 
individual genes in this pathway in Table 4.4). To emphasize the functional relevance of the BCR 
pathway in non-progressive HIV disease, strong association was also seen with the CD79 complex 
(p<0.0001467) (Table 4.4; Figure 4.7). CD79 is a trans-membrane protein that forms a complex 
with the B-cell receptor (BCR) and generates a signal following recognition of antigen by the BCR. 
Thus, it is clear that, the genes in the BCR network and their up-regulation during non-progressive 
HIV disease, when compared with HIV patients with detectable viremia (TP1), may be functionally 
important, which has not been shown before. 
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Figure 4.7. Immune response_BCR (B cell receptor) pathway. Upward thermometers with red 
colour indicate up-regulated genes. The circles around the genes mark the ones that are in the DE 
list provided from the microarray data. Refer to their p values in Table 4.4. 
 
 
 
 
 
Chapter 4 
 
133 
The University of Sydney 
Table 4.4.  Genes are up-regulated in LTNPs when compared with TP1. These genes showed the highest p-
values in the BCR pathway (Figure 4.7). The DE list was uploaded into MeV.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Full annotation of genes represented in  table 4.4: * CD22, (cluster of differentiation-22); CD79a (cluster 
of differentiation- 79); FCGR2A, (low affinity immunoglobulin gamma Fc region receptor II-a); SYK (Spleen 
tyrosine kinase); BTK, (Bruton's tyrosine kinase); INPP5D (inositol polyphosphate-5-phosphatase); CDC42, 
(cell division control protein 42); HRAS, (transforming protein p21); CALM2, (calmodulin 2); PPP3CA, 
(protein phosphatase 3, catalytic subunit, alpha isozyme); MAPK3, (Mitogen-activated protein kinase 3). 
p-value calculated by Wilcoxon signed-rank test.  
¶ Shared genes between BCR and Transport macropinocytosis pathways. 
 
Gene symbol ╟p value 
¶HRAS 0.000138 
FCGR2A 0.000372 
INPP5D 0.000751 
SYK 0.000943 
¶CDC42 0.000943 
MAPK3 0.001178 
CD79A 0.001467 
PPP3CA 0.001467 
BTK 0.00277 
CALM2 0.00277 
CD22 8.25E-05 
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The second most significant pathway related in the comparison was the 
Transport_Macropinocytosis regulation by growth factors (p-5.41e-07), with 11 of 63 DE genes 
overrepresented in this pathway (Figure 4.8). All these genes were up-regulated in the LTNPs. The 
macro-pinocytosis is an actin-dependent process, cell-type-specific receptor-independent endocytic 
pathway, associated with actin-dependent plasma membrane ruffling, mostly used by dendritic cells 
to engulf whole pathogens. Furthermore, between macro-pinocytosis pathway (Figure 4.8) and the 
BCR pathway (Figure 4.7), some of the most significant genes, such as HRAS, CDC42 overlapped 
between both pathways, suggesting functional interaction between these two pathways. 
Significant to note was the clustering of the highly significant DE genes in the Actin cytoskeletal 
area of the macropinocytosis pathway, which regulate signalling pathways that control diverse 
cellular functions, including: cell morphology; migration; endocytosis and cell cycle progression 
(CDC42); genes that regulate actin polymerization in response to extracellular signals (Profilin);  
genes involved in cellular proliferation (CtBP1); actin polymerization (Destrin or DSTN) and actin 
cytoskeleton (WASP, Profilin) (Figure 4.8). All these genes show strong p values and were up-
regulated in LTNPs (Table 4.5). This is a significant observation, as the genes related to actin 
cytoskeleton play an important functional role in HIV disease.  
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Figure 4.8 Transport_Macropinocytosis regulation by growth factors pathway.Upward thermometers (within 
the circles) with red colour indicate up-regulated genes. Their statistical values are shown in Table 4.5. 
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Table 4.5. Up-regulated genes in the LTNP group with the highest p-values, when compared to TP1 in the 
Transport macropinocytosis pathway (Figure 4.8) The DE list was uploaded into MeV.  
 
 
 
 
 
 
 
 
 
 
 
 
 
*Full annotation of genes represented in table 4.5: * CDC42, (cell division control protein 42); HRAS, 
(transforming protein p21); PDGFRA (Platelet-derived growth factor receptor, alpha polypeptide); CSF1R 
(colony stimulating factor 1 receptor); WAS, (Wiskott-Aldrich syndrome); PFN1(Profilin-1); ACTR3, (Actin-
related protein 3); CTBP1, (C-terminal binding protein 1); DSTN, (destrin (actin depolymerizing factor); 
ACTB, (Actin, beta). 
╟p-values calculated by Wilcoxon signed-rank test. 
† Common genes shared with the immune response pathway. 
 
 
Gene symbol ╟pvalue 
†HRAS 0.000138 
ACTR3 0.000138 
CTBP1 0.000138 
DSTN 0.000229 
PDGFRA 0.000292 
ACTB 0.000597 
WASP 0.000751 
†CDC42 0.000943 
CSF1R 0.000943 
PFN1 0.00182 
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4.4.3.1.2Analysis of down-regulated genes (LTNP versus TP1) 
Next, we determined the relevance of the down regulated genes between LTNP and TP1 contrast, to 
find out how gene modulation relates to pathway modulation. As shown in the maps folder analysis 
(Figure 4.9), we found that the most significantly down-regulated pathways in the LTNP group 
were either directly or indirectly involved in the apoptosis (19%), followed by inflammatory 
response, cell cycle and its regulation, DNA-damage response (12%), vascular development 
(Angiogenesis) (11%), immune system response (10%), mitogenic signalling (10%), cystic fibrosis 
disease (7%), calcium signalling and cell differentiation (5%). Figure 4.10 represents the hyper-
geometric distribution of the map folders according to their -log (p-value) (FDR<0.01 and p-
value<00.1). The majority of pathways involved in these folders are directly and indirectly related 
to apoptosis, and there was a coordinated down-regulation of this pathway uniquely in the LTNP 
group, when compared against the TP1 group. 
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Figure 4.9. Statistically significant map folders, showing the 10 most significant map folders down-regulated in the group LTNP, in comparison to the TP1. 
Percentage calculated by –LOG (base 10) in Excel from the p-value calculated by MetaCoreTM.. 
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Figure 4.10.  Statistically significant map folders down regulated in the LTNP in LTNP vs TP1 
comparison. Bars represent significance as −log(p-value) for hyper-geometric distribution. 
Ontology enrichments were all filtered to allow no more than 1% false discovery rate. 
 
To visualize a more profound view of the map folders, in Table 4.6, we show the top 10 map 
folders, taken from figure 4.10, in their order of significance. It is noteworthy that again, 5 of 10 
pathways were related to apoptosis and immune response with significant p values (Table 4.6). This  
is consistent with the LTNP versus TP1 contrast for the up-regulated genes discussed earlier in this 
chapter. The p values in each case were derived with FDR less than 0.01 and the cut-off p-value 
<00.1. Thus, even though there was overlap between up-regulated and down-regulated genes 
between LTNP and TP1 contrast at the level of immune response, a stark difference was the 
coordinated down regulation of apoptosis-related pathways involving genes related to apoptosis, 
DNA damage, cell cycle regulation and cell differentiation, etc. (Table 4.6).   
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Table 4.6. Top 10 map folder and respective pathway maps down-regulated in the LTNP group when 
compared with TP1 shown according to their p-values. 
╟p-values calculated by MetaCoreTM from GeneGo, Inc. Pathway analysis; † ratio meaning the number of 
differentially regulated pathway genes versus total number of genes comprising the pathway; Pigment 
Epithelium-Derived Factor (PEDF); Tumour-Necrosis Factor Receptor-1 (TNFR1); Inhibitors of Apoptosis 
(IAP); cathelicidin Antimicrobial Peptide (cAMP); Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4). 
 
Map Folder p-value Ratio Pathway Maps p-value Ratio 
Apoptosis 7.04e-09 36/953 Development_PEDF signalling 2.30e-06 7\ 49 
Inflammatory 
response 
5.33e-06 27/775 
Apoptosis and survival_TNFR1 signalling 
pathway 
1.45e-05 6\43 
Cell cycle and its 
regulation 
7.49e-06 21/516 
Apoptosis and survival_Role of IAP-
proteins in apoptosis 
3.78e-05 5\31 
DNA-damage 
response 
7.58e-06 17/354 
Development_Beta-adrenergic receptors 
signaling via cAMP 
4.42e-05 6\52 
Vascular 
development 
(Angiogenesis) 
1.65e-05 21/543 
Immune response_Regulation of T cell 
function by CTLA-4 
7.98e-05 5\36 
Immune system 
response 
2.77e-05 30/1000 
Development_Glucocorticoid receptor 
signalling 
2.08e-04 4\24 
Mitogenic 
signalling 
7.72e-04 18/562 
Immune response_MIF - the 
neuroendocrine-macrophage connector 
2.63e-04 5\46 
Cystic fibrosis 
disease 
1.26e-03 19/636 
Regulation of degradation of deltaF508 
CFTR in CF 
3.34e-04 4\27 
Calcium signalling 5.93e-03 14/469 
Apoptosis and survival_Granzyme B 
signalling 
6.53e-04 4\32 
Cell differentiation 1.06e-02 22/940 Regulation of CFTR activity (norm and CF) 7.79e-04 5\58 
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4.4.3.1.2.1  Pathway analysis down regulated DE genes between LTNP and TP1 
The apoptosis is the most significant function (p<7.04e-09) and it is systematically down-regulated 
in the LTNP group. In Appendix 7, we show the complete list of pathway maps, in the order of 
significance. In the apoptosis map folder, the most significant down-regulated pathway was the 
pigment epithelium-derived factor (PEDF) (p<2.30e-06), followed by Apoptosis survival TNRF1 
signalling pathway (p<1.45e-05) in the inflammatory response map folder (p<5.33e-06) (Table 4.6 
and Figures 4.11 and 4.12). 
PEDF is also known as Serpin F1 (SERPINF1), a multifunctional secreted protein that has anti-
angiogenic, anti-tumorigenic, and neurotrophic functions. This pathway shows genes related to 
cellular responses to virus infection, such as NF-kB and anti-apoptotic genes (SOD2, c-IAP-1 and 
2), being very significant in this pathway. A more profound view of the PEDF pathway showed an 
intense clustering of genes related to the family of anti-apoptosis, or apoptosis inhibitor family of 
genes (cIAP-1 and cIAP-2, SOD2), in the anti-apoptosis pathway, along with functionally-
associating genes in this network (NFkB p50 and p65 and GDNF) (Figure 4.11).  
The other significant represented pathway, which was also down-regulated in the LTNPs, was the 
Tumour-Necrosis Factor Receptor-1 (TNFR1) signalling pathway, shown in Figure 4.12. This is 
the second most significant pathway down-regulated in the LTNP group. Noteworthy was that, all 
of anti-apoptosis genes (SOD2, c-IAP-1 and c-IAP-2, Diablo-Smac) were down-regulated in the 
LTNP group and were also shared in this pathway (Figures 4.11 and 4.12), suggesting a 
considerable functional interaction between these two pathways. 
Overall, there was a coordinated down-regulation unique to LTNPs, providing a possible 
mechanistic insight into possible long-term survival of LTNPs with HIV and progression of disease 
in the absence of HAART. This is a unique observation found in this study, which demarcates 
natural controllers from HIV patients with viremia in the absence of HAART. Moreover, the 
independent visualization of both up- and down-regulated genes has provided a clear view of how 
gene modulation occurs in guiding a disease stage in HIV infection, in this case between LTNPs 
and viremic patients in the absence of HAART (TP1). 
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Figure 4.11. Development-PEDF signalling pathway.Upward thermometers with blue colour (shown within 
circles) indicate down-regulated genes from the DE list provided from the microarray data. 
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Figure 4.12. Tumour-Necrosis Factor Receptor-1 (TNFR1) signalling pathway.Upward thermometers 
with blue colour (shown within circles) indicate down-regulated genes from the DE list provided from the 
microarray data. 
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4.4.3.2 Natural control of viremia versus drug mediated control of HIV: Comparison between 
LTNP vs TP2 
4.4.3.2.1 Analysis of up-regulated genes in the LTNP as compared to TP2 group 
We performed the same analysis for the LTNP versus TP2, and the results were consistent with the 
aforementioned contrast - LTNP versus TP1.Both comparisons share highly related functional 
transcriptomic profiles, suggesting, for the first time, that there is little to demarcate 
transcriptomically between TP1 and TP2 when LTNPs are compared together. Secondly, these data 
also imply that LTNPs are a unique group from HIV patients with detectable viremia in the absence 
of HAART (TP1), and HIV patients with suppressed viremia while on HAART (TP2). 
Alternatively, these data also imply that, even though both LTNPs and TP2 have below detectable 
levels of HIV (<20 or <40 copies of HIV RNA/mL), the LTNPs are still distinct in their 
immunological make-up, suggesting that despite suppressed viremia with HAART, the 
immunological deficits prevail in the TP2 group. 
The analysis of the Map Folders demonstrates that immune response is the most significant, being 
up-regulated in the comparison between LTNP and TP2 (p-3.79e-14). Our data (Figure 4.14) shows 
that the most significant folders for this comparison are: immune response (15%); inflammatory 
response (14%); DNA damage response (13%); mitogenic signalling (10%); apoptosis; cell cycle 
and its regulation; cystic fibrosis disease and vascular development (8%); and calcium signalling 
(7%). Figure 4.13 represents the hyper-geometric distribution of those map folders according to 
their log (p-value) (FDR<0.01 and p-value<00.1).  Most of the pathways involved in these folders 
were all related to immune response, and up-regulated in the LTNPs when compared against the 
TP2. A more profound view of the map folders, in order of significance, of the top 10 pathways is 
shown in in Table 4.7. We observed that 3 of 10 pathway were related to immune response 
pathway in BCR signalling (top ranked) (p-1.15e-09), CD16-signaling (p-1.44e-08), CCR3 
signalling (p1.80-08) and VEGF signalling (p-8.79e-08), with strong p values. In addition, 2 of 10 
pathways were in cytoskeletal remodelling and regulation, again with strong p values (Table 4.7). 
In each of these pathways, there was considerable over representation of genes from our DE list 
with strong statistical support, suggesting the validity of the differential expression of the up-
regulated between LTNP and TP2. 
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Figure 4.13. Statistically significant map folders showing the 10 most significant map folders up-regulated in the group LTNP group, when compared with the TP2 
group. Percentage calculated by -LOG(base 10) in Excel from the p-value calculated by MetaCore
TM
. 
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Figure 4.14.  Statistically significant map folders up-regulated in the LTNP and TP2 comparison. Bars 
represent significance as −log(p-value) for hyper-geometric distribution. Ontology enrichments were all 
filtered to allow no more than 1% false discovery rate. The top ten map folders and the respective pathways 
maps according to their p-value calculated by the software are listed in Table 4.7. The level of significance 
is very high, as it is stated by high p-values observed throughout this comparison. 
 
Table 4.7. Top 10 map folder and their respective pathway maps up-regulated in LTNP when compared with 
TP2 according to their p-values and ratios. 
Map Folder p-value Ratio Pathway Maps p-value Ratio 
Immune system response 3.79e-14 121/1000 Immune response_BCR pathway 1.15e-09 18/54 
Inflammatory response 2.49e-13 100/775 
LRRK2 in neurons in Parkinson's 
disease 
2.15e-09 14/33 
DNA-damage response 4.42e-13 60/354 
Signal transduction_Calcium 
signalling 
3.33e-09 16/45 
Mitogenic signalling 1.64e-09 72/562 
Immune response_CD16 signalling in 
NK cells 
1.44e-08 19/69 
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*p-values calculated in MetaCore
TM
 from GeneGo, Inc. Pathway analysis; B cell antigen receptor (BCR), 
Leucine-Rich Repeat Kinase2 (LRRK2), Cluster of Differentiation 16 (CD16), Chemokine C-C motif 
receptor 3 (CCR3), Vascular Endothelial Growth Factor (VEGF), Vascular Endothelial Growth Factor 
Receptor 2 (VEGF2), Transforming Growth Factor (TGF), Hydrolyze Guanosine Triphosphate (GTP), 
Chemokine CXC motif receptor 4 (CXCR4).   
 
4.4.3.2.1.1  Pathway analysis up regulated DE genes between LTNP and TP2 
For the up-regulated genes between LTNP and TP2, the most significant up-regulated pathway was 
the BCR pathway (Figure 4.15), which is analogous to the comparison LTNP vs TP1. Most of the 
pathways involved in this comparison are immune response related, and are fully shown in 
Appendix 8. It is clear, from this comparison between LTNP and TP2, that there are far more 
significant genes within the pathway with greater statistical significance. A total of 18 significant 
DE genes were overrepresented in the BCR pathway with high p-values (Table 4.8). A large 
majority of genes identified in this pathway play important roles in B cell signalling and activation 
of key host cell types involved in immune response against HIV. Overall, a large number of genes 
seen in LTNP vs TP1 (Figure 4.7) and LTNP vs TP2 (Figure 4.15) contrast overlapped, but when 
the top 10 genes were examined in the order of significance, 6 of 10 genes overlapped between 
these contrasts (Table 4.8). This suggests that there was little to separate between TP1 and TP2 
groups when compared against the LTNP group.  
Tissue remodelling and 
wound repair 
2.72e-09 71/557 
Immune response _CCR3 signalling in 
eosinophils 
1.80e-08 20/77 
Apoptosis 4.54e-08 100/953 
Development_VEGF signalling via 
VEGFR2 - generic cascades 
8.79e-08 20/84 
Cell cycle and its 
regulation 
5.51e-08 64/516 
Cytoskeleton remodelling_TGF, WNT 
and cytoskeletal remodelling 
1.50e-07 23/111 
Cystic fibrosis disease 6.56e-08 74/636 
Cytoskeleton remodelling_Regulation 
of actin cytoskeleton by Rho GTPases 
3.44e-07 10\23 
Vascular development 
(Angiogenesis) 
7.30e-08 66/543 
Chemotaxis_CXCR4 signalling 
pathway 
3.49e-07 12\34 
Calcium signalling 1.19e-07 59/469 Development_Slit-Robo signalling 6.97e-07 11\30 
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Figure 4.15.  Immune response_BCR (B cell receptor) pathway.Upward encircled thermometers with red 
colour indicate up-regulated genes derived from the DE list (LTNP vs TP2) for the microarray data. 
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Table 4.8. Of the 18 overrepresented pathway genes in the BCR pathway, only the top 10 are shown in the 
order of their significance, along with the overlaps they share with the comparison of LTNP vs TP1. Genes 
with the highest p-values from the DE list were uploaded into MeV. All these genes were up-regulated in the 
LTNPs when compared to TP2. 
 
 
 
 
 
 
 
 
 
 
 
€
Full annotation of genes represented in table 4.8:
 CD79, (Cluster of Differentiation 79); BTK (Bruton 
agammaglobulinemia tyrosine kinase); CALM2 (calmodulin 2); HRas, (transforming protein p21); 
MAPK1, ( mitogen-activated protein kinase 3); MAPK3, ( mitogen-activated protein kinase 3); Akt, 
(Protein Kinase B); PKCB, (Protein Kinase C, Beta1); CD22, (Cluster of Differentiation 22). 
╟╟p-value calculated by Wilcoxon signed-rank test 
* Genes that overlap with the BCR pathway seen for LTNP vs TP1 comparison for the up-regulated genes. 
 
4.4.3.2.2 Analysis of the DE down-regulated genes between LTNP and TP2 groups 
Here, in this section, we have compared the transcriptomic profiles between two groups, LTNP and 
TP2, where there is below detectable levels of plasma viremia. The key difference was the natural 
control of viremia, as opposed to drug-mediated control in HIV patients. 
€
Gene symbol 
╟
pvalue 
*CD79 p<0.0004721 
*Btk p<0.005059 
*CALM2 p<0.002249 
*HRAS p< 0.0002286 
MAPK1 p<0.01816 
*MAPK3 p<0.005059 
AKT 0.0007513 
PKCB p<0.002112 
*CD22 p<0.0005967 
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As seen in LTNP vs TP1 contrast for the down-regulated genes, apoptosis was again the single most 
discriminatory feature between LTNPs and HIV patients on and off therapy. To further continue the 
investigation, we analysed the Map folders shown in Figure 4.16. Only the top 10 map folders are 
shown in the order of significance, for the LTNP vs TP2 comparison for the down-regulated gene. 
The hypergeometric distribution showed that apoptosis was the most significant (18%), followed 
by: DNA damage response (14%); cell cycle and its regulation (13%); mitogenic signalling (11%); 
cell differentiation (10%); protein degradation (9%); vascular development (7%); inflammatory 
response; tissue remodelling and wound repair; and protein synthesis (6%). Figure 4.17 represents 
these map folders as a hyper-geometric distribution for these maps folders.  
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Figure 4.16. Statistically significant map folders showing the top 10 most significant map folders down-regulated in the group LTNP in comparison to the TP2. 
Percentage calculated by -LOG(base 10) in Excel from the p-values calculated by MetaCore
TM
.
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Figure 4.17.  Statistically significant map folders down-regulated in the LTNP vs TP2 comparison. Bars 
represent significance as −log(p-value) for hyper-geometric distribution. Ontology enrichments were all 
filtered to allow no more than 1% false discovery rate. 
 
All these map folders showed significant p values. As it can be seen, each map folder comprises of 
a series of pathways maps related to it. Table 4.9 shows only the summary of the top 10 most 
significant pathways with their respective p-values and ratios (meaning the number of genes 
appearing in the pathway that belong to the uploaded DE list versus total number of genes on the 
pathway).  
These results clearly confirm that apoptosis is the most significant function down-regulated in 
LTNP (p<5.97e-18), when compared to the HIV
+
 patients after HAART treatment. We have 
discussed only the top two pathways here, but in appendix 9 we show the rest of the pathway maps, 
in order of significance, for all the ones shown in Table 4.9. Comparing the top 10 pathways 
between LTNP vs TP1 and LTNP vs TP2 for the down-regulate genes, it is apparent that, at the top 
ranked pathway levels, there was considerable overlap between them (Tables 4.6 and 4.9). There 
was  a dominance of apoptosis related pathways in both contrasts, suggesting apoptosis as being the 
fundamental cellular process that plays a key role in HIV disease. Moreover, its down-regulation is 
the key mechanism for non-progression of HIV disease. 
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Table 4.9. Top 10 map folders and their respective pathway maps down-regulated in the LTNPs when 
compared with TP2 according to their p-values and ratios. 
Map Folder p-value Ratio Pathway Maps p-value Ratio 
Apoptosis 5.97e-18 93/953 Apoptosis and 
survival_Role of 
IAP-proteins in 
apoptosis 
5.86e-09 11\31 
DNA-damage 
response 
1.09e-13 47/354 Apoptosis and 
survival_TNFR1 
signalling pathway 
2.60e-08 12\43 
Cell cycle and its 
regulation 
1.57e-13 58/516 Development_WNT 
signalling pathway. 
Part 1. Degradation 
of beta-catenin in 
the absence WNT 
signalling 
1.57e-07 8\19 
Mitogenic 
signalling 
2.02e-11 57/562 Apoptosis and 
survival_Apoptotic 
TNF-family 
pathways 
2.06e-07 11\42 
Cell 
differentiation 
9.12e-10 75/940 Apoptosis and 
survival_FAS 
signalling cascades 
3.46e-07 11\44 
Protein 
degradation 
1.54e-09 34/269 Apoptosis and 
survival_Granzyme 
B signalling 
1.41e-06 9\32 
Vascular 
development 
(Angiogenesis) 
9.56e-08 48/543 Signal 
transduction_AKT 
signalling 
2.46e-06 10\43 
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*p-value calculated by MetaCoreTM from GeneGo, Inc. Pathway analysis; B cell antigen receptor (BCR), 
Leucine-Rich Repeat Kinase2 (LRRK2), Cluster of Diferentiation 16 (CD16), Chemokine C-C motif receptor 
3 (CCR3), Vascular Endothelial Growth Factor (VEGF), Vascular Endothelial Growth Factor), Hydrolyze 
Guanosine Triphosphate (GTP), Chemokine CXC motif receptor 4 (CXCR4).   
 
4.4.3.2.2.1 Gene set enrichment analysis of consistently present probe sets down-regulated in the 
LTNP as compared to the TP2 group 
In order to clarify the significance of the down-regulated genes between LTNP and TP2, we again 
used the enrichment analysis tools for a detailed look into the most significant Map Folder. The 
summary of this type of MetaCore
TM
 analysis can be observed by the enrichment analysis process, 
as demonstrated in Figure 4.18. Several significant GeneGO pathways were identified and the 
genes were enriched in functional ontologies largely related to apoptosis in GeneGo maps. Further 
under process network, confirmation of the involvement of apoptosis and protein degradation 
pathway was evident, with this being the top ranked network process (p<7.606e-10), with 35 of 166 
genes enriched in this network. Thus, taken together, the GeneGo maps, GeneGo process network 
and GenGo Disease again underpin the importance of apoptosis pathway being significantly 
enriched and positively correlating with the LTNP group and negatively with the TP1 group 
(Figure 4.18).    
Inflammatory 
response 
1.19e-06 58/775 Immune 
response_Regulation 
of T cell function by 
CTLA-4 
4.15e-06 9\36 
Tissue 
remodelling and 
wound repair 
3.24e-06 45/557 Translation 
_Regulation of EIF2 
activity 
8.47e-06 9\39 
Protein 
synthesis 
4.13e-06 30/306 Translation_Non-
genomic (rapid) 
action of Androgen 
Receptor 
1.06e-05 9\40 
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a) Pathway Maps 
 
 
 
 
 
 
b) Process Network 
 
 
 
 
 
 
 
c) Disease by Biomarkers 
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d) Metabolic Networks 
 
 
 
 
 
 
e) GO Processes 
 
 
 
 
 
Figure 4.18. Comparison of LTNP versus TP2 for the gene enrichment in functional ontologies for the 
down-regulated genes in LTNP vs TP2 contrast. Enrichment analysis across five ontologies in MetaCore: (a) 
GeneGo pathway maps; (b) GeneGo processes; (c) GeneGo disease by biomarkers and (d) GO processes. 
The associated false discovery rate is less than 0.01, for a P value threshold less than or equal to 0.01. Bars 
represent significance as −log(p-value) for hyper-geometric distribution. Ontology enrichments were all 
filtered to allow no more than 1% false discovery rate. 
Furthermore, as before, we again observed a significant enrichment of metabolic networks in 
LTNPs, with 1-linoleylglycerol, 3 phosphate pathway (p-1.533e-5) (Figure 4.18d) being the top 
ranked, and in GeneGO processes cellular macro-metabolic being the most prominent (p<6.257e-
55), with 690 of 7016 genes enriched (Figure 4.18e). Table 4.10 shows some of the enriched genes 
in the cellular macro-metabolic process with the respective network and function they share. The 
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functional association between the networks were highly significant (Table 4.10).  Again, the 
enrichment analysis of LTNP vs TP1 and LTNP vs TP2 contrasts for the down-regulated genes 
clearly show a functional involvement of metabolic networks involved in a variety of cellular 
functions, such as: axon guidance; cellular organization, morphogenesis; cellular metabolic 
processes; electron transport; and cellular metabolic and catabolic processes. These analyses imply 
that the down-regulation was a significant feature of the LTNPs. 
The enrichment analysis of the pathways provided by the MetaCore
TM
 system also performs a 
comparison analysis of the over-represented genes among the pathways, as explained before in 
section 4.4.3.1.1.1. To visualize the individual genes represented in the process networks, Figure 
4.19 shows the top ten most enriched GeneGo processes for the sample set, according to their p 
values shown for each enriched process within the network. Consistent with our observations of the 
down-regulated genes in the LTNP vs TP1 contrast, the LTNP vs TP2 also showed the dominance 
of apoptosis related genes enriched in the process networks (Figure 4.19). 
Table 4.10. This table content shows the genes of the uploaded file, which was used as the input list for 
generation of biological networks by MetaCore
TM
 for the cellular macromolecule metabolic process section 
of the enrichment analysis in GO processes section. This is a variant of the shortest paths algorithm with 
main parameters of relative enrichment with the uploaded data and relative saturation of networks with 
canonical pathways. These networks are built on the fly and unique for the uploaded data. In this workflow 
the networks are prioritized based on the number of canonical fragments .   
Key network objects GO Processes P value 
Ephrin-A, 
TAK1(MAP3K7), ERM 
proteins, c-Src, 
Ephrin-B receptors 
Axon guidance (66.0%), neuron projection 
development (74.0%), axonogenesis (70.0%), cell 
projection organization (78.0%), cell 
morphogenesis involved in neuron differentiation 
(70.0%) 
2.27e-03 
Beta-catenin, STAT3, 
SMAD4, gp130, Cyclin E 
Cellular metabolic process (95.9%), mitochondrial 
electron transport, NADH to ubiquinone (18.4%), 
energy derivation by oxidation of organic 
compounds (30.6%), ATP synthesis coupled 
electron transport (18.4%), mitochondrial ATP 
synthesis coupled electron transport (18.4%) 
6.92e-12 
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PRAME, SERTAD3, 
BRF2, Cyclin E, MIER1 
Cellular metabolic process (94.0%), cellular 
macromolecule metabolic process (82.0%), 
metabolic process (94.0%), primary metabolic 
process (90.0%), positive regulation of cell cycle 
(20.0%) 
2.34e-30 
HIC1/2, MLL/MEN 
fusion protein, 
ZNF658B, DUSP11, 
FBXO11 
Cellular macromolecule metabolic process 
(88.0%), macromolecule metabolic process 
(90.0%), nucleic acid metabolic process (68.0%), 
RNA metabolic process (62.0%), primary 
metabolic process (92.0%) 
1.88e-26 
NIX, SLBP, DNAJC3, 
PSMA7, RPL4 
Cellular macromolecule catabolic process 
(52.0%), macromolecule catabolic process 
(52.0%), cellular protein metabolic process 
(76.0%), protein metabolic process (78.0%), 
cellular macromolecule metabolic process (92.0%) 
3.08e-21 
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Figure 4.19. Process-network for the comparison between LTNP x TP1. Enriched genes in each process within the network are shown within the bars, 
along with the p values for each process network shown at the bottom of each bar. 
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4.4.3.2.2.2.  Pathway analysis down regulated DE genes between LTNP and TP2 
Pathway analysis (Figure 4.20) showed that the most significant pathway is the role of IAP proteins 
in apoptosis, with significant down-regulation of all the important pro-apoptotic genes on this 
pathway, as shown in table 4.11. The TNFR1 pathway is the second most significant pathway 
down-regulated in LTNP, when compared with the TP2 patients (Figure 4.21). This pathway is 
mostly involved in inflammation and apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. Apoptosis and survival role of IAP proteins in apoptosis pathway. Blue downward 
thermometers imply down-regulation of the DE genes.  
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Table 4.11. Genes with the highest p-values (shown in Figure 4.20) from the DE list uploaded into MeV. 
All these genes are down-regulated in LTNPs when compared to TP2. 
 
 
 
 
 
 
 
 
 
 
 
*Full annotation of genes shown in the pathways: Smac-Diablo and c-IAP1 and c-IAP2 correspond to 
BIRC2 (Baculoviral IAP repeat-containing protein 2); Bid, (BH3 interacting domain death agonist); FADD, 
(Fas-Associated protein with Death Domain); HSP70, (70 kilodalton heat shock proteins).
╟
 p-value 
calculated by Wilcoxon signed-rank test 
Further, between IAP apoptosis and TBFR1 pathway (Figure 4.21), some of the most significant 
genes (Table 4.12), such as the Caspases 3, 8 and 9, Bid, BIRC2, and FADD overlapped between 
both pathways, suggesting functional interaction between these two pathways. 
Thus, the down-regulation of apoptosis genes, coupled with the down-regulation of anti-apoptotic 
genes uniquely in LTNPs is the single most significant feature of non-progressive HIV disease.  
 
 
 
€
Gene symbol 
╟
pvalue 
Bid p<0.00277 
BIRC2 p<0.0009425 
Ubiquitin p<0.0002922 
Caspase-3 p< 0.007423 
Caspase-8 p<0.007423 
FADD p<0.00182 
Caspase-9 p<0.004154 
Presenilin1 p<0.008942 
HSP70 p<0.0007513 
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Figure 4.21. Overrepresentation of genes in the Apoptosis and survival_TNFR1 signalling pathway. Blue 
downward thermometers imply down-regulation.  
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Table 4.12. Genes overrepresented in the pathway shown in Figure 4.21. Genes with the highest p-values 
from the DE list uploaded into MeV are shown here in this table. All these genes were down-regulated in 
LTNPs when compared to the TP2 group. 
 
 
 
  
 
 
 
 
 
 
 
*Full annotation of genes represented in the pathways: 
£
Smac-Diablo and c-IAP1 and c-IAP2 correspond to 
BIRC2 genes; Bid, (BH3 interacting domain death agonist); FADD, (Fas-Associated protein with Death 
Domain); GCK,(MAP4K2), (Glucokinase (hexokinase 4).) 
╟
 p-value calculated by Wilcoxon signed-rank test 
† common genes between pathways shown in Figures 4.20 and 4.21. 
 
 
 
 
 
€
Gene symbol 
╟
pvalue 
†FADD p<0.00182 
†Caspase-9 p<0.004154 
†Caspase-3 p< 0.007423 
†BIRC2 p<0.0009425 
Caspase-10 p<0.0001384 
†Bid p<0.00277 
†Caspase-8 p<0.007423 
NF-kB p<0.006139 
GCK 
(MAP4K2) 
p<0.006139 
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4.4.4 Quantitative RT-PCR validation of functionally significant genes 
To confirm the differential expression of genes from Illumina microarray, mRNA expression levels 
of 16 functionally significant genes in HIV infection were validated by quantitative PCR. For 
validation of these genes, the mRNA from the PBMC of the same patient for both time points (TP1 
and TP2), along with the therapy naïve LTNPs, were used in qPCR analysis.  
For the contrast LTNP and TP1, we validated 8 genes (OAS2, IFIT1, STAT1, CD74, FKBP3, 
THBS1, IFIT3 and MAPK3, respectively) shown in Table 4.13 with their qPCR fold-change and 
function. As it can be seen, these genes are involved directly or indirectly in host immune response 
to HIV.  
Table 4.13. q-RTPCR validation of selected genes for the LTNP vs TP1 contrast. 
GENE SYMBOL FOLD-CHANGE HOMOLOGY 
FKBP3 1.56 
 
Play a role in immuno-regulation 
and basic cellular processes 
involving protein folding and 
trafficking 
IFIT3 -1.59 
 
Interferon-induced protein with 
tetratricopeptide repeats 3 
THBS1 -7.22 Play roles in platelet aggregation, 
angiogenesis, and tumorigenesis 
CD74 1.79 
 
Involved in the formation and 
transport of MHC class II protein 
STAT1 -2.28 Involved in up-regulating genes 
due to a signal by either type I, type 
II or type III interferons 
OAS2 -2.37 
 
Involved in the innate immune 
response to viral infection 
IFIT1 -48.11 
 
Interferon-induced protein with 
tetratricopeptide repeats 1 
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* 
FKBP3 (FK506-binding protein 3); IFIT3 (Interferon-induced protein with tetratricopeptide repeats 3); 
THBS1 (Thrombospondin 1); CD74 (LA-DR antigens-associated invariant chain or Cluster of 
Differentiation 74); STAT1 (Signal transducer and activator of transcription 1); OAS2 (2'-5'-oligoadenylate 
synthetase 2); IFIT1 (Interferon-induced protein with tetratricopeptide repeats 1); MAPK3 (Mitogen-
activated protein kinase 3). 
We found that all 8 genes showed consistent patterns of expression trends between microarray and 
q-RT PCR (Figure 4.22), which was further analysed separately using R square correlation (Figure 
4.23 a-p). In statistics, the coefficient of determination, denoted R
2
, is used in the context of 
statistical models, whose main purpose is the prediction of future outcomes on the basis of other 
related information. R
2
 is most often seen as a number between 0 and 1, used to describe how well a 
regression line fits a set of data. An R
2
 near 1 indicates that a regression line fits the data well, while 
an R
2
 closer to 0 indicates a regression line that does not fit the data very well.  
The IFN-related genes constituted half of the total of 8 validated genes (OAS2, IFIT1, STAT1 and 
IFIT3), which were down-regulated between both microarray and q-RTPCR (Figure 4.23). Of the 
remaining 4 non-IFN-induced genes, three genes (CD74, FKBP3, and MAPK3) showed up-
regulation, with the exception of gene THBS1, which showed consistent down-regulation. 
Although 5 of 8 genes validated by q-RT PCR showed good statistical significance, 3 did not 
(Figures 4.23 a,c,e,g,I,k,m,o). However, when the same genes were analysed for correlation 
between q-RTPCR and microarray, there were also 5 of 8 genes significant (Figures 4.23 
b,d,f,h,j,l,n,p), but these genes were different between q-RTPCR and correlation analysis. For 
instance, IFIT1 was highly significant in q-RTPCR, but not in correlation analysis (Figures 4.23 c 
and d). Similar was the case with STAT1 and FKBP3 genes, which were significant in q-RTPCR, 
but not in correlation analysis (Figure 4.23 e,f, i and j). The most significant of all 8 genes was the 
THBS1, which showed p<0.003759 in q-RTPCR and p<0.001 in correlation analysis with R
2
 value 
of 0.9361 (Figure 4.23 k and l). Therefore, in the subsequent sections of this work, we have 
analysed the full functional and biological significance of Thrombospondin (THBS1) in the context 
of HIV infection. 
MAPK3 12.53 
 
Act in a signalling cascade that 
regulates various cellular processes 
such as proliferation, 
differentiation, and cell cycle 
progression in response to a variety 
of extracellular signals. 
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Figure 4.22. Correlation between RT-PCR and Microarray fold-changes of the 8 DE genes significant for the LTNP and TP1 comparison, involving a combination 
of both up- and -down-regulated genes. Fold-change is calculated simply as the ratio of final value to the initial value.  
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Figure 4.23. Association of gene expression by real-time PCR of the DE found significant in our analysis (a, 
c, e, g, i, k, m). Representative scatterplots with linear regression analysis confirm the association between 
expression levels between microarray and q-RTPCR (figures b, d, f, h, j, l, n) p-values for the expression 
between the different group were measured using the GraphPad Prism®software and also correlation values. 
Next, for the contrast TP2 versus LTNP, we also validated 10 genes by q-RTPCR (FKBP3, IFIT3, 
THBS1, CD47, CD46, BIRC2, FADD, CASP3, OAS2 and MAPK3) (Table 4.14). Table 4.14 also 
shows the functional significance of each of the genes included in the q-RTPCR analysis. It is to be 
noted that FKBP3, MAPK3 and THBS1 were significant to both LTNP vs TP1 and LTNP vs TP2 
contrasts. Therefore, these genes have been included in both contrasts for q-RTPCR validation. Of 
10 genes selected for q-RTPCR validation, 5 genes were up-regulated and 5 down-regulated in the 
microarray expression analysis between LTNP vs TP2 (Table 4.14). 
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Table 4.14. q-RTPCR validation of selected genes for the LTNP vs TP2 group 
GENE SYMBOL 
FOLD 
CHANGE 
HOMOLOGY 
FKBP3 
2.17 
 
 
Play a role in 
immunoregulation and basic 
cellular processes involving 
protein folding and 
trafficking 
IFIT3 
-2.66 
 
 
Interferon-induced protein 
with tetratricopeptide repeats 
3 
THBS1 -10.74 
Play roles in platelet 
aggregation, angiogenesis, 
and tumorigenesis 
CD47 
1.89 
 
functions as a "don't eat me" 
signal for phagocytic cells 
CD46 
2.58 
 
An inhibitory complement 
receptor 
BIRC2 
-1.20 
 
 
A member of the Inhibitor of 
Apoptosis family that inhibit 
apoptosis by interfering with 
the activation of caspases 
FADD 
-1.79 
 
An adaptor molecule that 
bridges the Fas-receptor, to 
caspase-8 through its death 
domain to form the death-
inducing signalling complex 
(DISC) during apoptosis. 
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*Full gene annotations: *FKBP3 (FK506-binding protein 3); IFIT3 (Interferon-induced protein with 
tetratricopeptide repeats 3); THBS1 (Thrombospondin 1); MAPK3 (Mitogen-activated protein kinase 3); 
CD47 (Cluster of Differentiation 47); CD46 (Cluster of Differentiation 46); BIRC2 (Baculoviral IAP repeat 
containing 2); FADD (Fas(TNFRSF6)-associated via death domain); CASP3 (Caspase 3, apoptosis-related 
cysteine peptidase); OAS2 (2'-5'-oligoadenylate synthetase 2); IFIT1 (Interferon-induced protein with 
tetratricopeptide repeats 1); MAPK3 (Mitogen-activated protein kinase 3)
 
As explained in the previous section, of 10 genes 5 were up-regulated and 5 were down-regulated in 
the microarray gene expression experiments. In q-RTPCR validation, the same occurred, with 5 of 
10 genes down-regulated (BIRC2, FADD, CASP3, IFIT3 and THBS1) and 5 up-regulated (FKBP3, 
CD46, CD47, OAS2 and MAPK3) (Figure 4.25). Thus, all 10 genes showed consistent trends of 
expression between microarray and q-RTPCR (Figure 4.25).  
We further visualized this dataset with statistical rigor, by first analysing the significance of 
expression of individual genes in q-RTPCR assay, followed by calculation of R square correlation 
CASP3 -3.02 
Caspase protein that interacts 
with caspase 8 and caspase 9. 
OAS2 1.68 
Involved in the innate 
immune response to viral 
infection 
MAPK3 10.65 
Act in a signalling cascade 
that regulates various cellular 
processes such as 
proliferation, differentiation, 
and cell cycle progression in 
response to a variety of 
extracellular signals. 
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and also correlation values (as explained above), in order to delineate correlation between microarray 
and q-RTPCR data (Figure 4.26 a-t). 
Of the ten genes included in functional validation, the CD46, CD47, FKBP3, THBS1 and CASP3 
genes were statistically significant in both q-RTPCR (Figure 4.26 c,e,I, k and o), with THBS1 
being the most significant in both q-RTPCR (p<0.0011) and correlation analysis (R
2
=0.942 and 
p<2.65e-08) (Figure 4.26 k and l), along with Integrin-associated protein (IAP or CD47), which is 
a receptor for thrombospondin family members (p<0.0321 and R
2
.=0.375) (Figure 4.26 e-f). This 
was also consistent with our observations on its validity, in the LTNP vs TP1 contrast. BIRC2 and 
MAPK3 (Figure 4.26 a, b, m and n) did not achieve statistical significance, especially MAPK3, 
which showed R
2
=0.5476. The FADD gene was only significant in q-RTPCR (p<0.0081), but not in 
correlation analysis (4.26 g and h). Genes which showed perfect concordance between q-RTPCR 
and microarray were CD46, CD47, FKBP3, THBS1, CASP3, IFIT3 and OAS2 (Figure 4.26 c, d, e, 
f, i, j, k, l, o, p, q, r, s and t). Thus 7 of 10 genes showed perfect statistical concordance between q-
RTPCR and microarray, suggesting their strong functional significance in the LTNP vs TP2 
contrast.   
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Figure 4.25. Correlation between RT-PCR and Microarray fold-changes. Fold-change is calculated simply as the ratio of the final value to the initial value.  
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Figure 4.26. Association of gene expression by real-time PCR of the DE genes found significant in our 
analysis (a, c, e, g, i, k, m, o,). Representative scatter plots with linear regression analysis confirm the 
association of expression levels between microarray and q-RTPCR (figures b, d, f, h, j, l, n, p,). p-values for 
the expression between the different group were measured using the GraphPad Prism®software  
 
4.4.5 Microscopic analysis for the cellular localization of THBS1or TSP1 protein in PBMC and 
monocytes   
For the biological analyses using Confocal/Delta Vision microscopy and flow cytometry, we 
recruited 5 therapy naïve patients resembling in clinical profiles to the TP1 group, with detectable 
plasma viral load in all cases (meaning > 400 copies per mL), to represent the TP1 group. Similarly, 
we recruited 5 patients on HAART with below detectable levels (BDL) of plasma viremia in all 
cases (<40 copies of HIV RNA/mL plasma), to represent the TP2 group. For the LTNPs, we used 
the frozen LTNP cells and included HIV negative individuals as negative controls. 
Using confocal and Delta Vision microscopy, our main objective was to analyse cellular 
localization of THBS1 in whole PBMC and in bead separated monocytes derived from healthy 
donors, HIV viremic patients and HIV
+
 LTNPs. Initially, we performed staining of the whole 
PBMCs for different patient groups, using Deltavision microscopy. The protocol for DV 
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experiments is explained in Chapter 2. As it is shown in Figure 4.26, we show the localization of 
the THBS1 protein in the membrane and also the perinuclear space of the cells in patients with high 
viral load (a), patients with no HIV infection (b), and LTNPs (c). 
Because of the frequent technical breakdown of the Deltavision microscope, we were forced to 
move to confocal microscopy for further analysis. The protocol was the same as used for the 
Deltavision microscopy, but this time we used only monocytes, because of the excellent staining of 
Thrombospondin. Thrombospondin is a platelet-associated protein, but its expression in diverse 
blood leukocytes is not known clearly. As shown in Figure 4.26, we analysed patients with 
detectable viral loads; HIV negative individuals and HIV
+
 LTNPs. These data show the staining of 
monocytes in these three groups (Figure 4.26 panels a, d, g), followed by DAPI staining, which 
shows the evidence for membrane and peri-nuclear localization of THBS1 in monocytes (Figure 
4.26 panels b, e, h). Similarly, the staining of the whole PBMC for the same groups was also 
performed, and it showed results similar to monocytes (Figure 4.27 panels a-i). Because of the 
specific staining in monocytes in all three groups, we chose to quantitatively analyse THBS1 in 
monocytes in all three patient groups using flow cytometry.   
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Figure 4.26. Confocal micrographs showing localization of the THBS1 protein (arrows) in CD14 positive 
monocytes derived from health donor (a-c), HIV positive viremic (d-f) and LTNP (g-i) patients. THBS1 was 
found distributed in a punctate pattern throughout the perinuclear cytoplasm and plasma membrane in all 
three patient cells. Panels a, d, g show anti-THBS1 stained with A488 (green). Panels b, e, h show overlay of 
THBS1 (green) and DAPI (blue) (nucleus) over corresponding DIC image. Panels c, f, i show corresponding 
DIC images. Bars, 5 μm.  
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Figure 4.27 Visualization of THBS1 protein (arrows) by wide-field deconvolution microscopy in PBMC 
derived from health donor (a-c), HIV positive viremic (d-f) and LTNP (g-i) patients. THBS1 was found 
distributed in a punctate pattern throughout the perinuclear cytoplasm and plasma membrane in all three 
patient cells. Panels a, d, g show anti-THBS1 stained with A488 (green). Panels b, e, h show overlay of 
THBS1 (green) and DAPI (blue) (nucleus) over corresponding DIC image. Panels c, f, i show corresponding 
DIC images. Bars, 5 μm.  
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4.4.6 Flow cytometry (FACS) analysis of the THBS1 expression between the different patient 
groups 
Flow cytometry was used for a quantitative analysis of Thrombospondin in monocytes derived from 
HIV patients with detectable viral loads, HIV negative individuals and HIV
+
 LTNPs. We used 
whole PBMCs from the patient groups (HIV
+
 patients with below detectable virus in plasma, HIV
+
 
individuals with detectable virus and LTNPs) and the gated on CD14 and CD16 monocytes.  
The main objective of these experiments was to delineate the functional relevance of THBS1 at the 
protein level in monocytes, and also identify its correlation with plasma viremia. For these 
experiments, whole frozen PBMC were used for each group. Initially, we wanted to determine 
which cell population would have more expression of the protein. So, using flow cytometer (BD 
FACSCanto II), we gate different cell population for each group and found, in all of them, that 
THBS1 was mostly stained in monocytes (Figure 4.8). Each colour line represents one group, and it 
is clear that THBS1 is highly expressed in monocytes. Therefore, for a better analysis, we chose to 
concentrate our data set only in the monocyte population. 
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a)                                                               b)                                                                                c) 
 
 
 
 
 
 
 
 
Figure 4.28.  The fluorescence histogram presented above of FACS analysis was design by FlowJo, each groups are represented by a line color: blue (BDL), orange 
(LTNP), green (Viremic). The percentage of the expression of THBS1 is determined by the comparison with the negative control marked by the red color line 
histogram presented below. PBMCs were stained with THBS1 in the PE channel (y-axis). The x axis- percentage of cells positively stained.
Negative control 
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For the rest of the experiment we focused only on the CD14
+
 cells. The cells were frozen and 
thawed according to the protocol stated in Chapter 2. Initially, the PBMC were stained 
LIVE/DEAD® Fixable Dead Cell Stain Kit from Invitrogen® to check for cell viability since our 
samples were frozen. So first we stained the samples with DAPI from the kit to check the viability, 
then we stained with CD14, CD16 and THBS1 antibodies. Using flow cytometer (BD FACSCanto 
II), the DAPI
+
 cell population from all groups were gated first (P3 = Figure 4.29 b) from the 
monocytes population (P1 = Figure 4.29 a), and then CD14
+
 (P4), and CD16
+
 and THBS1
+
 cell 
populations were analysed subsequently. We used five patients with BD viral load, five with 
detectable VL before HAART treatment, five LTNPs and five health donors HIV
-
 (Table 4.15). 
Table 4.16 shows the percentages of the each quadrate of the gates, for the expression of THBS1 
and CD16. 
Table 4.15. Viral load of the selected patients for flow cytometry 
Patient groups 
(n=-5) 
Viral load 
LTNP 
 
<20 
BDL <40 
Viremic 2539.6 
Health Donors 0 
*Average viral load (HIV RNA copies)/mL plasma for each patient for the flow cytometer. 
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Figure 4.29. Gating process for analysis of THBS1 expression in monocytes showing THBS1 expression in 
monocytes. In (a), a representative (out of 5 independent experiments) flow cytometry plots showing gating 
of monocytes in the LTNPs. In (b), CD14
+
 gate in monocytes, and (c) THBS1 gate with CD16
+
 gate in 
monocytes.  
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Table 4.16 Quadrates representing the percentage of the antibodies 
 
 
 
 
 
 
 
a) Below Detectable Level (BDL) 
 
 
Quadrate CD16 THBS1 
Q1 Low High 
Q2 High High 
Q3 Low Low  
Q4 High Low 
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b) Viremic 
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c)  Long-term Non-progressors (LTNPs) 
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d) Healthy Donors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30. Analysis of different groups by flow cytometer to determine the expression value for THBS1 in 
monocytes. a) Viremic patients with viral load >50 copies/mL; b) Below detectable levels patients (BDL) with viral 
load <50 copies /mL; c) Patients that naturally controls the infection (Long term non progressors); d) Health Donors 
that are not infected. 
To measure the expression value from the FACS results (Table 4.17), we used the Mean 
Fluorescence Intensity (MFI) to normalize the stained samples of the negative control, in order 
to report them more accurately. We also used the percentage (%) of cells expressing THBS1, 
these values were used to determine the expression, and as can be seen from our results, THBS1 
is highly expressed in the patients with high viral loads, when compared with any of the groups, 
especially LTNP. As shown in Table 4.18, it can be noted that the p-value for the comparisons 
based on the expression values of the groups were highly significant, affirming the critical 
difference in THBS1 expression in monocytes discriminating viremic and LTNPs HIV groups 
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(p<0.003761). Similarly, this difference in THBS1 expression was also evident in healthy 
donors and viremic patients monocytes (p<0.00376), suggesting that the LTNPs are closer to the 
HIV negative healthy donors that LTNPs are any other group including the BDL which control 
viremia with HAART therapy. 
                       Table 4.17 Mean fluorescence intensity of the different groups for THBS1 and percentage of 
cells expressing THBS1 
Groups MFI (THBS1) Percentage of cells 
expressing THBS1 
LTNP 161 3.75 
BDL 250.4 18.5 
Viremic 1175 48.3 
Health 
Donors 
199 2.35 
*MFI (Mean Fluorescence Intensity); LTNP (long term non progressors);BDL 
(below detectable levels); HD (health donors). 
 
Table 4.18. Statistical value of p-value calculated from a t-test from the comparison of the 
different groups MFI for THBS1 
 
 
 
 
 
 
*MLTNP (long term non progressors); BDL (below detectable levels). 
p-value THBS1 
LTNP vs Viremic 0.003761 
LTNP vs BDL 0.073377 
Health Donors vs 
Viremic 
0.00376 
Health Donors vs BDL 0.29756 
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4.5 Discussion  
Employing the vast scientific knowledge of the immune system in humans, and understanding the 
natural immune control of HIV infection will enable the translation of this knowledge into the 
development of effective immunotherapies, leading to new preventative strategies and possible 
cure. This is the current focus of several studies globally. Not only there is interest in HIV 
persistence in the face of HAART, there is also a renewed focus on the co-existence of host and 
virus in the absence of therapeutic drugs, as observed in long-term non-progressing individuals, or 
elite controllers, who represent <1% of the HIV-1-infected individuals (Blankson 2010; Migueles 
and Connors 2010). 
The LTNPs maintain their CD4
+
T-cell counts within the normal range (Mandalia, Westrop et al. 
2012), with below detectable levels of HIV RNA (<20 copies/mL plasma) in the absence of therapy 
for >15 years or more. Such individuals hold clues to HIV cure, and novel immunological factors 
that can be used in immunotherapies for HIV-infected individuals.  
With the advent of high throughput technologies, we are now able to look at the genomic and 
proteomic modalities encompassing all 25,000 human genes, which, in turn, allow us to look into 
the genomic basis of drug-free survival in some HIV patients exhibiting durable control of HIV. 
Microarray gene expression profiling has been applied to sub-categorize complex diseases, predict 
treatment outcomes, and disease progression using “gene signatures” which represent differentially 
expressed genes that correlate with the disease phenotype (Nikolsky, Ekins et al. 2005). Together, 
these technologies, combined with web-based computational platforms for data analysis, not only 
assist in visualization of the dataset, but have also aided in providing a clear understanding of the 
HIV-host interactions and identify host targets for developing anti-HIV therapeutics (Ekins, 
Andreyev et al. 2006).  
Therefore, in this study, using the Illumina Human-12 v3 Expression BeadChip encompassing all 
25,000 human genes (>48,000 genes transcripts or probes), we performed a genome-wide analysis 
of 9 HIV
+
, therapy naïve long-term non-progressors, to define genomic basis of natural control of 
HIV in these individuals. Based on whole genome transcriptome, we compared HIV
+
 LTNPs to 
HIV patients off drugs while experiencing detectable plasma viremia (TP1), and patients on 
HAART with below detectable viremia (<40 copies of HIV RNA/mL plasma) (TP2). These 
analyses provide deeper comparative insights into the genes and pathways that are differentially 
expressed in each group, thereby explaining what underlies each disease stage during HIV 
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infection. These are the first comparative analyses, based on the whole human genome, which 
demonstrate the genomic basis of natural control of HIV as opposed to drug-mediated control. 
We detected more than a thousand significant differentially expressed genes between the patients 
groups LTNP and TP1 and also between LTNP and TP2. Through these comparisons, we 
demonstrate that the immune system response pathway was down-regulated in patients with 
detectable viremia in the absence of HAART (TP1) and BDL patients on HAART (TP2), when 
compared with the therapy näive LTNPs. This is in sharp contrast to the findings presented in 
Chapter 3, where in TP1 and TP2 comparisons, the immune response system was up-regulated in 
TP1. When LTNPs were compared against TP1, the most significant pathway up-regulated in the 
LTNP is the B-cell receptor (BCR) signalling pathway (p<1.03e-07) which was also confirmed 
from enrichment analysis and by pathway analysis. This signalling pathway is involved in many 
distinct outcomes, including survival, tolerance or apoptosis, cytoskeletal changes, DNA damage 
and repair, proliferation, and differentiation into antibody-producing cells or memory B cells. A 
total of 11 of 54 DE genes were overrepresented in this pathway, with all of them recording high p-
values. The genes in this pathway are related to the immune response activation of the antigen 
presenting cells, such as CD22, MAPK1/3, CD79, BtK, Syk, SHIP and HRAS, respectively.  
It is known that the HIV infection overwhelms the immune system's capacity to regenerate or fight 
other infections. Due to its specific interaction with the CD4 receptor on helper T-cells, HIV 
specifically infects the very cells, which are vital in activating both B-cell and cytotoxic T-cell 
immune response (Oguntibeju, van den Heever et al. 2009). That explains why the virus causes 
deregulation of the genes related to the immune response (H-Ras, SHP-1, CDC42, STAT1, CD79 
complex, etc.), as seen in our study. Without the helper T-cells, neither it is possible to make 
antibodies effectively by the host, nor does it eliminate the infected cell concealing HIV, thereby 
resulting in the collapse of the immune system, leading to the progression of HIV disease. 
As demonstrated in our study, the BCR pathway has a huge impact on both groups TP1 and TP2. 
We further analysed this pathway and found its great importance on the progression of the HIV 
infection. Studies by Moir et al. (2004), showed that most of the B cell defects are directly 
associated with high levels of HIV plasma viremia. They also showed that several other studies 
determined that a reduction of the HIV plasma viremia by HAART therapy leads to normalization 
of B cell activities. This is evidenced by reductions in polyclonal and HIV-specific Ig levels, 
restoration of APC function, responsiveness to CD4
+
T cell help and normalization of expression of 
B cell markers of activation (Abbate, Dianzani et al. 2000; Moir, Malaspina et al. 2004; Moir, 
Malaspina et al. 2004; Moir and Fauci 2009). 
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Our results corroborated with these studies, showing that the expression of this receptor is 
dysregulated in HIV-infected patients. It has been shown before that there is a wide-range of B cell 
dysfunctions in the setting of HIV infection, several of which are associated with cellular 
hyperactivation, induced by ongoing viral replication. The aberrant immune activation induced by 
HIV represents a systemic effect, that is best illustrated by the profound effects of HIV on B cells 
and CD8
+
T cells, two populations of lymphocytes that are not direct targets for productive HIV 
replication (Moir, Malaspina et al. 2004; Malaspina, Moir et al. 2006; Xu, He et al. 2008). It has 
also been shown that the activation of this pathway, along with others, leads to immune responses 
including antigen processing and presentation, immunoglobulin production, and interferon-
mediated antiviral effects, and the expression of this receptor is deregulated in HIV-infected 
patients (Silva, Moir et al. 2011; Chen, Wang et al. 2012). This is in agreement with our results. 
HIV-induced immune activation of B cells is thought to be a contributing factor to the increased 
frequency of B-cell malignancies observed in HIV-infected individuals, which were especially 
observed before the widespread use of effective ART (Moir and Fauci 2008), meaning that virus 
has a direct effect on B-cell functioning. More importantly, the up-regulation of the BCR pathway 
in LTNPs may result in vigorous immune response against HIV, which may play a pivotal role in 
prolonging the asymptomatic phase of the infection (Paroli, Propato et al. 2001) – a glimpse of that 
can be seen in our study.  
In the context of the BCR pathway, it was interesting to note the strongest statistical association of 
CD22 (p-8.25e-05) in this pathway, which was up-regulated in the LTNP group. This has a direct 
high functional relevance, as CD22 is found on the surface of mature B cells and, to a lesser extent, 
on some immature B cells. Generally speaking, CD22 is a regulatory molecule that prevents the 
over-activation of the immune system (McLaren, Mayne et al. 2004). To emphasize the functional 
relevance of the BCR pathway in non-progressive HIV disease, strong association was also seen 
with the CD79 complex (p<0.0001467). CD79 is a transmembrane protein that forms a complex 
with the B-cell receptor (BCR) and generates a signal, following recognition of antigen by the BCR. 
Thus, it is clear that genes in the BCR network and their up-regulation during non-progressive HIV 
disease, when compared with HIV patients with detectable viremia (TP1), may be functionally 
important in the long-term natural control of HIV, which has not been shown before.  
But when the down-regulated genes were compared between LTNP and TP1, apoptosis was the 
standout feature, with evidence for coordinated down-regulation in the LTNPs (p<7.04e-09), with 6 
of top 10 pathways in apoptosis and immune response. The most significant down-regulated 
pathway was the pigment epithelium-derived factor (PEDF) (p<2.30e-06), followed by apoptosis 
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survival TNRF1 signalling pathway (p<1.45e-05) in the inflammatory response map folder 
(p<5.33e-06). PEDF is also known as Serpin F1 (SERPINF1), a multifunctional secreted protein 
that has anti-angiogenic, anti-tumorigenic, and neurotrophic functions. This pathway shows genes 
related with cellular responses to virus infection, such as NF-kB and anti-apoptotic genes (SOD2, c-
IAP-1 and 2), being very significant in this pathway. A more profound view of the PEDF and the 
TNFR1 signalling pathways showed an intense clustering of genes related to the family of anti-
apoptosis, or apoptosis inhibitor family of genes (cIAP-1 and cIAP-2, SOD2, Diablo-smac), in and 
around the anti-apoptosis part of the pathway, along with their functionally-associating genes in the 
anti-apoptosis network (NFkB p50 and p65 and GDNF) (Figure 4.11). The similarities between 
these pathways suggest a considerable functional interaction between them.  
It has been previously reported that LTNP patients present a low level of apoptosis and a 
consequent reduced rate of CD4
+
 loss (Kirchhoff, Greenough et al. 1995). On the contrary, 
progressors (TP1) presented up-regulated genes like CD38, described to have a strong relationship 
with activation and cell death. These results are in full accordance with previous studies, showing 
CD38 expression on CD8
+
 T cells as a marker associated with HIV disease progression (Liu, 
Cumberland et al. 1997). Activated genes for positive regulation of apoptosis in progressors are in 
agreement with other activated functions in this group, such as cell cycle and DNA replication, 
which were implicated in several pathways linked with cellular death. T-cell apoptosis is thought to 
be one strategy by which HIV-1 evades host immune supervision, and that is intact because of the 
tight regulation by the down-regulation of anti-apoptotic genes, as seen in our study.  
Activation-induced apoptosis is a mechanism for the loss of T cells during the continuous 
stimulation of the immune system, and has been proposed as an important factor in the pathogenesis 
of HIV-1 infection (Jiao, Fu et al. 2009). Apoptosis is linked to several events which are typical of 
HIV- infection, including cell-activation, cytopathic effect of HIV, etc. (Franceschi, Franceschini et 
al. 1997). We found that serpin F1 (SERPINF1) was down-regulated in the LTNP group. This gene 
has anti-angiogenic actions and protects cerebellar granule cells from apoptosis, as well as inducing 
apoptosis in endothelial cells (Anguissola, McCormack et al. 2011). It has been shown on gene 
profile expression studies in cell lines, infected in vitro with HIV, an increased expression of pro-
apoptotic genes (Badley, Parato et al. 1999) and serpin 1, which is in agreement with our findings, 
with their up-regulation during viremia. 
It has also been show that AIDS pathogenesis could be explained by an immune dysregulation 
involving proinflammatory cytokines, especially tumor necrosis factor (TNF) α (TNF). These 
studies confirm our results that, in patients that are on the initial phase of the infection (TP1), 
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apoptosis is up-regulated and contributes to HIV immune-pathogenesis. In contrast, the LTNPs are 
able to prevent the course of this rapidly evolving infection, and some believe it is directly related to 
the low levels of apoptosis on peripheral lymphocytes, when compared to normal patients that 
progress to AIDS (Moretti, Marcellini et al. 2000). However, it appears from our data that it could 
be tied to the intense clustering and down-modulation of anti-apoptotic genes (cIAP-1, 2, 
Diablo/smac, SOD2, etc.), and their associating partners in the apoptosis pathway. 
HIV-infected individuals undergoing treatment with a combination of antiretroviral drugs, show 
decreased FAS and FAS ligand (FAS-L), the inhibition of apoptosis induced by FAS or by TNFR-1 
and TNFR-2, and inhibited expression of TNF-related apoptosis-inducing ligand (TRAIL), as well 
as an increased BCL-2 expression, in response to treatment (Balestrieri, Grelli et al. 2007). TNF is 
secreted by activated macrophages and lymphocytes, and induces diverse responses, including 
inflammation and apoptosis. It can be directly or indirectly involved in the modulation of T cell 
apoptosis via members of the TNFR superfamily, such as TNFR1, TNFR2, and Fas, or it can be 
responsible for stimulating HIV-1 replication in infected cells (Garg and Blumenthal 2006; Herbein 
and Khan 2008; Cummins and Badley 2010). HIV-1 proteins target the TNFR signalling pathway, 
modulating gene expression, especially HIV long terminal repeat (LTR) stimulation and T cell 
apoptosis, leading, in turn, both to immune suppression and to the formation of viral reservoirs in 
HIV infection (Herbein and Khan 2008; Herbein, Gras et al. 2010). LTNPs have lower frequencies 
of apoptotic T cells and lymphocytes expressing FAS and FASL, when compared to AIDS patients 
(Moretti, Marcellini et al. 2000). These findings are in perfect agreement with our studies. Our 
results show that apoptosis is up-regulated in patients on therapy, in comparison to patients that 
naturally control the disease. It has also been shown before the up-regulation of the physiologic 
mechanisms controlling peripheral CD4 T-cell deletion, which depends on the expression of a 
family of ligands (CD95 ligand[CD95-L], tumor necrosis factor [TNF], tumor necrosis factor 
related apoptosis-inducing ligand [TRAIL]), and death receptors (CD95, TNFR1, and TNFR2), that 
mediate apoptosis in susceptible cells (de Oliveira Pinto, Garcia et al. 2002). These studies concur 
with our findings. 
Overall, it appears that there is a block to apoptosis in LTNPs and the down-regulation of apoptosis 
pathways is possibly a significant mechanism that confers durable protection in conjunction with 
strong immune responses in natural controllers. 
Furthermore, the transcriptomic differences that segregated LTNPs from the TP2 group also yielded 
vital information on natural control of viremia, as opposed to drug-mediated control of HIV. Based 
on the below detectable levels of viremia in both groups, we hypothesized the possibility of 
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considerable genomic overlaps between these two groups.However, the genomic comparisons 
between these groups revealed that natural control of viremia in LTNPs is guided by a distinct set of 
immunological and genetic factors than that which is seen during drug-mediated control in HIV 
patients. Even more surprising was that, even though TP1 and TP2 are transcriptomically separated 
based on the DE genes (as shown in Chapter 3), the simultaneous comparison of TP1 and TP2 
against the LTNPs showed that there was very little to separate TP1 and TP2 from each other 
transcriptomically. This panoramic view of host gene modulation was only visible by the inclusion 
of the LTNPs as a comparator, suggesting that: 1. LTNPs are a distinct group immunologically and 
genomically; 2. The immunological deficits that exist in HIV viremic patients off therapy continue 
to prevail even in the presence of HAART, possibly because of poor immune reconstitution; and 3. 
There is a genomic basis to viral control in natural controllers, which is completely different from 
suppressed viremia while on HAART. Overall, these data reinforce the fact that, even though virus 
can be controlled to BDL levels with HAART, the immune restoration remains a huge challenge in 
HAART-treated patients, which make LTNPs a distinct group immunologically. These are the first 
studies to show this aspect of HIV pathogenesis through a panorama of host genome expression. 
These inter-group transcriptomic comparisons have given us a more profound transcriptomic view 
on the host genes/pathways that guide the natural control of HIV in vivo and underlying 
immunological deficits in HIV patients during suppressive HAART.  
Retroviruses exploit the cytoskeletal network to facilitate viral infection and dissemination. It is 
activated by growth factors or phorbol esters in certain cell types, such as macrophages and 
epithelial cells, and operates constitutively in dendritic cells. Our results are in agreement with these 
studies, showing that actin-dependent filopodial bridges and intercellular membrane nanotubes 
mediate cell-to-cell transmission of retroviruses. Thus, their down-regulation in viremic patients 
and up-regulation in LTNPs bears direct relationship with HIV disease staging and possibly plasma 
viremia (Marechal, Prevost et al. 2001; Wang, Wells et al. 2008). 
It has been determined before that the decrease of the HIV-1 virus evolution correlates with weaker 
viral fitness, and also with the inability to evade the host immune system. Some studies have shown 
that virus strains from LTNPs are less evolved and thus less capable of evading the host 
immunological response, when compared with progressors strains. But the components of the host 
immune system that keep the virus in check in LTNPs, and the genomic basis of it, is not known.  
Our results are confirmed by studies which showed that, in PBMC from HIV-1-infected subjects, in 
all stages of the disease, there is a decrease of the STAT gene family, probably as a consequence of 
chronic activation of certain signal transduction patterns by dysregulated cytokine production, that 
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can be, in turn, exhausted or down-modulated. HIV can impair T-cell and monocyte function by 
disrupting cytokine-dependent and antigen dependent signal transduction (Abbate, Dianzani et al. 
2000; Alhetheel, Yakubtsov et al. 2008; Zhou, Xu et al. 2008). 
One of the most notable findings in our work was the identification of a novel biomarker for HIV 
viremia - the thrombospondin-1 (THBS1), which was very significant in LTNP vs TP1 and LTNP 
vs TP2 comparisons, with its down-regulation in the natural controllers. Thrombospondin 1 (TSP-1) 
is encoded by THBS1. It was first isolated from platelets that had been stimulated with thrombin, 
and as such was designated 'thrombin-sensitive protein' (Baenziger, Brodie et al. 1971). Since its 
first recognition, functions for TSP-1 have been found in multiple biological processes, including 
angiogenesis, apoptosis, activation of TGF-beta and immune regulation. As such, TSP-1 is 
designated a multifunctional protein. Also, other studies have shown that THBS1 affects 
vasculature systems such as platelet activation, angiogenesis, and wound healing. Therefore, an 
increase in THBS1 expression have been linked to disease states, including tumor progression, 
atherosclerosis, and arthritis (McLaughlin, Mazzoni et al. 2005). 
In the context of its relevance in HIV infection, several studies have shown that this membrane 
protein has anti-HIV 1 activity, due to the fact that it can be considered a physical barrier on 
mucosal transmission, as it was highly expressed in saliva (Crombie, Silverstein et al. 1998; 
Crombie 2000). Same studies also showed that TSP1 inhibits HIV-1 infection of peripheral blood 
mononuclear cells and proved that THBS1 has functional binding domains in conserved regions, 
flanking the v3 loop of gp120, and so provided a molecular mechanism to inhibit HIV-1 activity. 
Despite several studies on THBS1 and its relevance in HIV infection explained, there is 
considerable lack of understanding of how this protein and possibly its family members (TSP 2-5) 
may influence plasma viremia. According to our data, the THBS1 is down-regulated uniquely in the 
LTNP group. When we compared the CD14 and CD16 monocytes from patients belonging to the 
TP1 and TP2 group for correlation between its expression and plasma viremia, we found no 
correlation. But comparing the HIV patients with detectable viremia against the LTNPs gave a 
highly credible and confident result on expression levels of thrombospondin and also its receptor 
CD47 and its association with viremia, suggesting that TSP1 may be implicated in the progression 
of AIDS and in AIDS-associated pathologies by possibly by modulating the bioavailability and 
biological activity of extracellular Tat as shown by Rusnati et al. 2000. This concurs with our 
findings on microarray expression of THBS1 and validation by q-RTPCR, which showed the up-
regulation of THBS1 in viremic group as opposed to LTNPs, where this gene was down regulated. 
Since our study was based on different set of HIV patients, which differed between microarray and 
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protein validation by FACS, we believe that the statistical significance was beyond the patients 
recruited for microarray experiments and that the significance of TSP1 expression in viremic and 
LTNP groups is universal and may have immense biological, clinical and diagnostic significance. 
This has given more confidence to our analysis and has provided a more profound view of its 
association with viremia in HIV patients, based on which it is plausible to say that thrombospondin 
is a new biomarker for predicting viremia in HIV patients. 
Overall, these data are the first in providing a panoramic snapshot of genomic events that guide 
natural control of viremia in HIV
+
 LTNPs, along with showing how similar genomic events are 
guided upon the initiation of HAART in HIV patients. Modalities designed to control apoptosis or 
using apoptosis pathways as therapeutic targets may aid future treatments for HIV disease. 
 
 
 CHAPTER 5 
 
 
 
 General Discussion and Future directions  
Chapter 5 
 
198 
The University of Sydney 
5.1 Summary and conclusions  
The focus of this study was to understand the difference in molecular mechanisms by 
which the HIV-1 virus regulates gene expression between HIV+ viremic patients, before 
and after the initiation of highly active antiretroviral treatment (HAART) and in the 
complete absence of HAART, in therapy naïve HIV+ long term non progressors - a group 
that naturally controls plasma viremia with the strength of their immune system. For this 
purpose, we chose peripheral blood mononuclear cells (PBMCs) as our target cell type for 
a full transcriptome analysis, as these cells comprise all blood cell types present in blood 
and give a more holistic view of the transcriptome modulation at different stages of HIV 
disease.  
The advent of genome-wide analyses created an important tool to fully understand the 
genetic basis of the virus infection. The HIV–host interaction studies become essential to 
the search of new candidates for HIV therapeutics. Overall, the results in this study shed 
light on the intrinsic interactions between disease progression and the host genetic 
machinery (Salgado, Lopez-Romero et al. 2011). We observed distinct and differentiated 
patterns of gene expression between patients, before and after treatment and in HIV 
patients that naturally control HIV viremia. The most noteworthy finding was the level of 
activation of the immune response system in patients at the initial infection, when 
compared with the patients after therapy.  Another important aspect found was how 
immune and apoptosis functions are profoundly dysregulated pre-therapy, as opposed to 
what is seen post-therapy and in LTNPs.  
In Chapter 3, we analysed the genome-wide differences within the same patients before 
and after the treatment, to identify the key genes for the activation of innate and adaptive 
immune responses. Studies have shown that HIV-induced immunodeficiency is rather 
more dominated by chronic immune activation and high cell turnover, than by inactivity of 
the immune system. It is widely accepted that persistent immune activation plays a central 
part in driving immune-pathogenesis and progression to AIDS (Hazenberg, Stuart et al. 
2000; Grossman, Meier-Schellersheim et al. 2006; Mogensen, Melchjorsen et al. 2010). 
We found that the interferon (IFN) family was the most significant one being up-regulated 
in the patients at the pre-therapy or initial stages of HIV infection. The IFNs are known to 
mediate induction of a cellular antiviral state that obstructs further viral spread (Barr, 
Smiley et al. 2008). This cellular activation and the genes related to inflammation which 
were up-regulated pre-therapy were down-regulated following the initiation of HAART, 
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suggesting that drugs have a crucial role in modulating gene expression by reducing 
viremia. Even though these observations are intuitive, never before such comparisons have 
been made at two time points of HIV patients, at the level of whole genome. They provide 
a more profound, in-depth and panoramic snapshot of key genes and pathways involved 
during viremia, and also when viremia was completely suppressed with HAART, showing 
the path to new generation of strategies for the control of HIV. 
In chapter IV, we analysed the dataset by involving Long-term non-progressors and 
comparing them transcriptomically with TP1 and TP2. About 10 per cent of the individuals 
who contract HIV, do not progress to AIDS disease, and remain asymptomatic for more 
than 10 years, even in the absence of treatment, maintaining low viremia and normal CD4 
counts (Sharma, Kaur et al. 2011). However, the actual truly non-progressing HIV+ 
individuals with > 25 years of survival, undetectable viremia and high/stable CD4+ T cell 
counts remains at <1% globally (Saksena et al., 2007). Little is known about the full 
transcriptome genomics of this group and more research is needed to understand which 
factors contribute to this variability in terms of genetic control of the virus.  
 
When we compared LTNPs with the patients before and after treatment, it was surprising 
to see how distant the LTNPs were from the HAART treated patients with suppressed 
plasma viremia. This was unexpected due to the fact they both have below detectable 
levels of plasma virus, making them a biologically closer. However the LTNPs are a 
transcriptomically distinct group, suggesting that despite complete suppression of plasma 
viremia in HIV-treated individuals, there are still immunological deficits prevailing, which 
hampers the path to full immune-reconstitution. This is a significant finding, as it falls in 
line with previous clinical and biological observations on immune-reconstitution disease 
being a problem in HAART-treated patients. These studies are unique in transcriptomically 
affirming the validity of these previous observations. Thus, overall, our studies are novel in 
showing that the LTNPs are a unique entity among the HIV+ individuals characterized by 
down-modulation of apoptosis by virtue of the down-modulation, largely clustered in the 
anti-apoptotic gene family and associating gene partners. This is a unique observation that 
may have greater clinical significance in using apoptosis as a target for therapeutic 
intervention in HIV infected individuals.     
On the genes that were assessed for validation, we discovered that thrombonspondin was 
down-regulated in the LTNP, and it attained significance of a biomarker, which our study 
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could underpin. This has enormous value in HIV diagnostics and prognostics and has never 
been shown before. 
Genome-wide analysis is an important tool to enrich the list of factors in the HIV–host 
interaction in order to identify new candidates for HIV therapeutics. The data presented in 
this study show genomic insights into the relationship between disease status in HIV-
infected individuals at the pathway level, particularly in providing functional annotation of 
genes and pathways that are crucial in host cellular activation, genomic modulation during 
antiretroviral drug treatment, genes possibly involved in immune reconstitution, and 
natural control of HIV in LTNPs. Many of these genes and pathways identified in this 
study will further facilitate the development of new generation of therapeutic interventions 
for HIV patients. 
Overall, this study is the first to underpin an important aspect of HIV pathogenesis by 
showing, at the level of whole human genome, how antiretroviral drugs neutralize virus 
effect and down-modulate the very genes that cause viremia, as well as what genomic 
modalities lead to natural control of viremia in LTNPs. These observations may serve as a 
great platform to launch a search of new generation of HIV therapeutics, which will be 
guided by some of the significant genes/pathways we have shown to be involved at various 
stages of HIV infection. 
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5.2 Future directions 
The work detailed within this thesis will be further complemented with studies examining: 
1. Further analysis of thrombonspondin protein in a clinical setting in a pre-clinical 
trial format.  
2. Biological assessment of anti-apoptotic family of genes in non-progression and 
evaluation of targeting these genes as a therapeutic target in HIV infected 
individuals. 
3. Proteomic validation of several of the key genes and pathways, which this study 
could not achieve. 
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Appendix 2 
32 map folders corresponding to the comparison between TP1 and TP2  
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Appendix 3 
Pathway maps of the comparisons between TP1 versus TP2 
Maps pValue Ratio 
Immune response_Antiviral actions of Interferons 4.325E-17 14/52 
Immune response_IFN alpha/beta signaling pathway 7.557E-13 9/24 
Immune response_Role of PKR in stress-induced antiviral 
cell response 
1.727E-10 1057 
Immune response_HMGB1/TLR signaling pathway 5.168E-08 736 
Development_PEDF signaling 4.789E-07 7/49 
Immune response_Innate immune response to RNA viral 
infection 
7.313E-06 5/28 
Immune response_HMGB1/RAGE signaling pathway 1.325E-05 6/53 
Apoptosis and survival_Role of PKR in stress-induced 
apoptosis 
1.325E-05 6/53 
Transcription_Role of AP-1 in regulation of cellular 
metabolism 
3.453E-05 5/38 
Immune response_MIF-mediated glucocorticoid regulation 5.958E-05 4/22 
LRRK2 and immune function in Parkinson's disease 5.958E-05 4/22 
Immune response_Bacterial infections in normal airways 1.327E-04 5/50 
Immune response_Role of HMGB1 in dendritic cell 
maturation and migration 
1.376E-04 4/27 
Immune response _IFN gamma signaling pathway 1.919E-04 5/54 
Immune response_TLR signaling pathways 1.919E-04 5/54 
Bacterial infections in CF airways 2.695E-04 5/58 
Development_Angiotensin signaling via STATs 2.714E-04 4/32 
Immune response_TREM1 signaling pathway 2.921E-04 5/59 
Immune response_MIF in innate immunity response 6.490E-04 4/40 
Apoptosis and survival_Inhibition of ROS-induced 
apoptosis by 17beta-estradiol 
9.352E-04 4/44 
Immune response_IL-1 signaling pathway 9.352E-04 4/44 
Immune response_Inhibitory action of Lipoxins on pro-
inflammatory TNF-alpha signaling 
1.107E-03 44/46 
Cell cycle_Chromosome condensation in prometaphase 1.130E-03 3/21 
Immune response_IL-15 signaling via JAK-STAT cascade 1.483E-03 3/23 
Immune response_Histamine signaling in dendritic cells 1.516E-03 4/50 
Immune response_HSP60 and HSP70/ TLR signaling 
pathway 
2.020E-03 4/54 
Immune response_Antigen presentation by MHC class I 2.646E-03 3/28 
Immune response_CD137 signaling in immune cell 2.930E-03 3/29 
Immune response_IL-15 signaling 3.762E-03 4/64 
Development_PDGF signaling via STATs and NF-kB 3.892E-03 3/32 
Apoptosis and survival_Caspase cascade 4.251E-03 3/33 
Development_NOTCH1-mediated pathway for NF-KB 
activity modulation 
4.629E-03 3/34 
Development_Angiopoietin - Tie2 signaling 5.026E-03 3/35 
Inhibitory action of Lipoxin A4 on PDGF, EGF and LTD4 
signaling 
5.026E-03 3/35 
Immune response_Lipoxins and Resolvin E1 inhibitory 5.026E-03 3/35 
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action on neutrophil functions 
Influence of low doses of Arsenite on Glucose stimulated 
Insulin secretion in pancreatic cells 
5.444E-03 3/36 
Development_Lipoxin inhibitory action on PDGF, EGF and 
LTD4 signaling 
5.444E-03 3/36 
Inhibitory action of Lipoxins and Resolvin E1 on neutrophil 
functions 
7.320E-03 3/40 
Immune response_Th1 and Th2 cell differentiation 7.320E-03 3/40 
Immune response_HMGB1 release from the cell 7.842E-03 3/41 
Apoptosis and survival_TNFR1 signaling pathway 8.950E-03 3/43 
Apoptosis and survival_FAS signaling cascades 9.536E-03 3/44 
IL-1 beta-dependent CFTR expression 1.085E-02 2/16 
Immune response_Histamine H1 receptor signaling in 
immune response 
1.210E-02 3/48 
LRRK2 in neuronal apoptosis in Parkinson's disease 1.221E-02 2/17 
Development_G-CSF signaling 1.280E-02 3/49 
Mucin expression in CF via TLRs, EGFR signaling 
pathways 
1.352E-02 3/50 
Apoptosis and survival_Endoplasmic reticulum stress 
response pathway 
1.582E-02 3/53 
Immune response_CCL2 signaling 1.663E-02 3/54 
Cell cycle_Sister chromatid cohesion 2.008E-02 2/22 
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Appendix 4 
List of DE genes of the comparison between LTNP x TP1 
 
Gene symbol 
RNF214 CCDC88B LOC642502 OGDH TIPARP 
GLT8D1 ARRB1 CAP1 RTN4 MORF4L2 
PHF14 ARFGEF1 SNX10 TIAF1 DHX40 
PDCD6 LOC643035 RASSF2 ANXA2P1 TIPRL 
SMAP1 C16orf56 LOC644039 GNAI2 STRN 
RPL11 KIAA1604 N-PAC PSMC5 HIST2H2AA3 
LOC653314 CHES1 S100A11 VCAN AP1G1 
CALM2 NUDCD2 FAM102B FYB TMUB2 
ITPK1 NAGK RNF130 DGKA MX1 
ANP32A CD160 RXRA LAT2 C22orf28 
RNF166 SULF2 HDAC2 HVCN1 DIABLO 
ZNF700 UGP2 PLXNB2 GTF3C2 CCL8 
NACA CD302 JAZF1 GIMAP2 WDR22 
CNPY3 DHTKD1 FAM129C BRWD2 CKAP2 
LYPLA3 OSBPL2 CENTB1 MINA ADCY3 
SRRM2 GBL NACA HSPA4 CNOT2 
ABHD5 GPR177 PFN1 MYO18A ZNF207 
CTR9 MRPL18 UBQLN2 CTSC POLE3 
BTK TMEM154 PARVG YIPF3 NAMPT 
HIGD1A SMARCC2 CCT7 C7orf11 LOC642082 
CHP EP400 LOC220433 BPTF OASL 
SLC25A11 TMEM154 PFDN5 DDX17 LDLR 
NIPSNAP1 ME2 FKBP1A RNH1 TOMM34 
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CYP2S1 C11orf35 COMMD8 FAM113A SEC61A1 
CD1E COPG2 RANBP1 FLJ11151 PIGP 
SMC3 LOC648000 LOC653773 FAM96A CASZ1 
ABI3 EXOSC10 WAS C18orf32 FAM91A1 
TCP1 LOC729985 LRP10 LOC732165 UIMC1 
PTP4A3 CCDC95 CCNY DPYD ZDHHC5 
AAMP TBC1D9B PCTP PYGL GALC 
RNF214 NT5E C21orf57 ACAD10 TIMM23 
RPS19 SULT1A1 COP1 MKL2 LNPEP 
VAMP3 LOC730740 AKTIP 
 
NEU4 
AHCYL1 RCBTB2 ATMIN ATP5J2 CYP26A1 
SIGLEC7 PTPRA PPA2 PAPSS1 ALG2 
U1SNRNPBP NAALADL1 PHKG2 ALDH1A1 UBN1 
FAM96A ATP5H DBP ATRN HIST1H2BK 
C7orf42 LOC646197 EFHA1 IQGAP1 LOC441019 
TOMM7 INPP5D PAK2 TACC3 SLC7A5 
UBE3C LOC389816 PRR13 ROBO3 SIN3A 
NIN C6orf160 SYTL1 C6orf115 BIRC2 
LOC644310 LARP1 DOCK8 MRPL48 RPL35A 
ACN9 CLSTN1 CORO1C RPS28 SS18 
PCK2 Sep-07 TMEM144 ARSD GRAMD3 
HOM-TES-103 MRPS21 U2AF2 CYFIP1 RDH14 
TOMM7 MTA1 RPL35 BAT1 PDE4D 
LOC283874 ERGIC2 LRRK2 C20orf108 OSBP 
SH3BP1 P704P KLHL2 FAHD2A SHFM1 
KRCC1 ADD1 S100A10 AUP1 UPB1 
LPGAT1 ZNF813 PURA FKBP3 YWHAQ 
C11orf51 SH3KBP1 SLC25A45 TXNL1 CDK2 
CD72 SLC38A6 AGPAT7 MID1IP1 IFIT3 
CENTG3 RPS27 LOC388344 SERINC3 RQCD1 
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UGDH RECK RAB6A TM9SF4 ACAT2 
NOL5A G6PD MYO9B LOC440341 PPFIA1 
LOC124512 FUCA1 SFXN5 RHOB SLC35A2 
FBXL16 AK2 RBBP4 MCTS1 UBQLN1 
EIF3M ALDH3B1 OFD1 CD4 OTUD4 
NHLRC3 
 
DNAJC10 DHRS7 SMS 
CD79B BBS1 YDJC GMFG UBQLN1 
RAI1 LOC648638 CSF1R LOC401019 CLDND1 
DPYSL2 LOC391656 AHNAK LOC642333 EZH2 
FAM45A ZDHHC7 PFDN5 AKAP1 PHACTR1 
SP3 KHDRBS1 PAK1IP1 INTS8 DNAJB11 
TMEM199 EDF1 EPHB6 BOLA2 
 
TMEM128 G6PD CNBP CYP4F22 INTS12 
 
C20orf59 
 
C3orf17 CAB39L 
AIG1 FAM49B TSNAX CIDEB ZSWIM4 
TMEM80 FYB GPSM3 ITGAM FEN1 
TATDN1 NOL8 CD79B PMS1 TAF2 
RPS3A VARS ATPIF1 MRPL38 ZNF364 
FLJ20920 ZNF681 MFSD1 IKBKB TXN 
AP1S2 RPLP2 UTP3 IMMT RPS7 
BTD PRKAR1A NNT CAT LOC440895 
LOC284988 C9orf5 DNASE1L1 TCL1A WBSCR16 
HMGN2 SLC44A2 EHMT2 LOC130355 SLC41A3 
DECR1 LOC648984 HS2ST1 CBL ATP2A2 
CTR9 OSCAR ARHGAP9 C19orf50 HES4 
STAT6 XYLT2 PPARGC1B GDI2 TCP11L1 
TEGT C14orf166 RPL14 PRCP CKAP2L 
P2RY13 MID1IP1 CC2D1A ILK KYNU 
SMYD4 PDGFRA RPL9 RABL2A LRRC42 
ST6GAL1 CLEC12A TRAPPC6B CMTM7 ACOT2 
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SLC38A10 NADSYN1 TNFSF12 CD22 IREB2 
SPTAN1 POLR2G SH2B1 GABARAPL2 STIL 
LOC388955 UBE1 NDUFAB1 SULF2 IFI44 
RASGRP2 KIAA0564 PDHA1 ATP1B3 FEZ1 
HSD17B4 VPS36 LOC402057 PPCS C2orf29 
PWWP2B PEBP1 
 
NOL5A XAF1 
LOC388621 
 
ANXA6 SKAP2 SNX6 
MBNL2 PAPSS1 PHB2 RPS6KA4 PARP6 
RPLP1 FDFT1 ZNF318 C11orf73 MSI2 
UBE1C PA2G4 TRIT1 LOC650321 NR3C1 
ESRRAP2 MAPK3 BUB3 PDIA3P ISG20 
PEPD TUBA4A TMEM16H 
 
AK3L1 
CAPZB ATP6V0E1 TRAF5 HSPB1 SPAG9 
YY1 CSTF3 CD74 CTBP1 TFG 
TIMP2 C6orf205 LOC642989 LSM6 LACTB 
CD74 LOC651202 RPS20 ANXA4 TP53INP1 
TAOK1 DOK2 SLC27A1 C4orf18 SNX5 
LOC613037 KIAA1033 MAN1C1 RHOC SFXN1 
LDLRAP1 RPL3 CDC42 ARD1A SLC30A5 
NRM TMC6 BLVRB METTL7A 
 
B3GALT6 RBBP7 MGST3 SORD TNFRSF9 
C14orf172 CD48 ACTR3 LOC645138 HSH2D 
CTBP1 FGR WNK1 CDKN1C 
 
NCOR2 VEGFB PPP2CB YY1AP1 SQLE 
 
OSTM1 RTN1 PTTG1 IRF7 
RAVER1 RPS27 PECI ZCCHC8 HNRNPC 
PCMTD1 RGS19 DENND1A FABP5 RNF38 
KRCC1 RPLP1 SNAP23 PTTG1 NIPA2 
UQCRH HMGN4 FOXO4 C20orf45 ZNF689 
CKLF NOXA1 FCGR2A LRWD1 SDHA 
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FNDC3A CCT3 
 
FUSIP1 LOC285074 
APBB1IP LOC728973 S100A12 SRF MGLL 
RAB33B SPI1 SPAST UBE2J1 SERPINB9 
UBE3B PNPLA6 NDUFA4 DTX2 TRIM37 
TRAPPC1 CD37 ATP11C HNRNPA3 ABCA1 
FAM62A LOC642489 ANXA2P1 RBM22 ZRANB2 
CAST C3orf28 INTS3 ARF4 PSMA1 
GRAMD4 TRIM41 CBX1 EHD1 CXCR7 
C1orf63 NPTN PIP5K1C SNX6 C3orf37 
BIN2 MBD3 ANKRD55 ARFGAP3 SQLE 
SAFB2 RASGRP2 MGC52000 RGS10 SLC35A3 
SEC31A NNT FXYD5 ATPBD1B MTHFD2 
CD79A ATP1A1 NPIP PTPN2 LILRA5 
SFI1 F11R BLOC1S1 NUSAP1 
 
CARS2 HS1BP3 PCYOX1L FKBP11 TDP1 
C7orf47 ODF2 SPIB PHGDH EDC4 
CAPN3 SYK CYBB SSR2 IFIT2 
LDHB NCOA1 LOC389787 EIF4H BAT2D1 
CDC42BPB GRHPR ZBTB2 KIAA1219 SERPINB8 
SAMD1 PLXDC2 LOC646900 LRRFIP2 FAM126B 
UQCRC2 SSBP1 GMPR2 CDCA7 EFNA4 
PTGDS ITFG2 RBM6 CDC42 NFKB1 
CSK FCRL3 SFRS8 JARID1A ST3GAL2 
MGC70857 KIAA0100 LOC134997 HMGCS1 PAXIP1 
ITGAL THUMPD1 USP5 KIAA0101 CCL2 
LOC648622 TMEM14B RNASEN SOD2 RAB43 
NAT6 NFIX KIFC2 TRAF3IP2 PPAP2B 
TMEM150 ZNF266 LOC116236 SMC3 RDBP 
PACS1 RAD23A PLCB2 FZD7 NOTCH1 
SMARCC2 SLC4A2 SERPINA1 LYRM1 AHNAK 
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RFX1 CYB5R3 C12orf62 BATF SERPINB8 
CARS CFDP1 LOC653658 DNAJA1 AQP9 
CYLN2 ATF1 FCER2 ATF2 KPNA4 
C19orf62 ATM AP1G2 ICOS SPAG9 
FCRLA AKR7A3 C19orf29 MGC4677 SOD2 
MSH2 SLC36A1 C16orf42 PRKY MAGEL2 
EIF1AX FAM49B AAAS BTBD11 LSAMP 
NUDCD2 LOC440525 NUCB2 CACYBP IFNAR2 
C1RL KIAA1598 PNPLA2 LTA 
 
ARHGAP1 LRRC26 ECHDC1 LAIR1 ELL2 
MBNL1 RHOA BTN3A3 MSL3L1 PPP2CA 
ITGB1BP1 C1orf43 GIMAP2 E2F3 HIST3H2A 
ZNF609 DC2 PRAM1 PPP2R5C FBXO11 
LOC23117 ARRDC2 NLK HERC5 TROVE2 
TBCB PRICKLE4 HNRPA2B1 ATAD2 MSI2 
ATN1 ATP2A3 LZTR1 FFAR2 C19orf48 
DICER1 TPK1 CTSS RFXAP CCRN4L 
LOC653702 PABPC1 ATP1B3 YIPF1 TRIM23 
ZNF558 FCGR3A SUMO2 C8orf76 LOC654189 
MMS19L ACTB GHDC IFIT1 PELO 
HMGN3 KLRF1 RTN3 VCP DNAJC3 
C7orf49 LOC440567 ADRM1 SEC22C NCOA7 
EPN1 SNX14 EEF1B2 GOLGA7 MIER1 
SSBP4 ADCK1 ANGEL1 LMNB1 
 
SIRT2 RLTPR LYST ISG15 
 
APBA2 DBI ATP5J2 C15orf48 
 
RIN3 LOC347376 HEXDC FAM46C 
 
BANF1 HK3 CTDSP1 RAB35 
 
SNRP70 ZNF266 TMEM30A UBE3A 
 
MAZ PTOV1 RPS15A LOC389286 
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KTN1 RNASEH2B C6orf211 LOC649897 
 
MGMT S100A9 OSBPL8 DYNLRB1 
 
MANBA G3BP1 EIF3K SH3GLB1 
 
GON4L ZNF226 PELP1 EIF2C2 
 
OCEL1 GMPR2 ERMAP RALGDS 
 
PUS3 NDUFS8 LOC284837 RNF19A 
 
GLB1 ASAHL NAGA OASL 
 
GLT25D1 GIMAP1 RPS3A KIF5B 
 
TMEM167 FUT8 RBED1 MED23 
 
COX7B RPL23 DHPS PIM2 
 
PYGB LOC402221 CLEC12A ARMC8 
 
GTF2H1 VKORC1 GLRX2 SMS 
 
NCL BLK PLOD3 BID 
 
CAMK1 SF3B14 HADHB RPS15 
 
BAT3 HPSE MYADM IFIT3 
 
GLOD4 CBARA1 PPP3CA LOC652481 
 
LTB C2CD2L C10orf11 THBS1 
 
C6orf32 LOC652071 LOC641848 ECOP 
 
STX7 GADD45GIP1 NDUFB10 RPS7 
 
PTMA C20orf117 DSTN CCDC44 
 
LOC649946 C14orf104 HRAS DCTN5 
 
IFT52 CTSZ OMA1 HSPA14 
 
CCDC91 LSP1 PTGES3 ADAR 
 
ZNF318 CAST TPPP3 AP1G1 
 
DPP4 AP2A1 CNPY4 CCDC117 
 
ADD3 IER3IP1 RSAD1 C15orf44 
 
ITFG3 EFTUD2 AHSA2 
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Appendix 5 
List of DE genes of the comparison between LTNP x TP2 
Gene symbol 
SKAP1 EIF1AX PSMB9 RPS6KA4 ZNF548 HNRNPC 
CRIP1 SMARCA2 GMPR2 MRPL15 PURG CAMLG 
RAB1B TIA1 RPL9 DGKA LTA RNMTL1 
LOC124512 SHISA5 ARRB1 CBL THBS1 ZNF682 
DDX11 EDF1 UBE3B RHOB ZRANB2 KIF5B 
ALDH6A1 CAPN3 TIAF1 CYP4F22 TRIM23 EDC4 
AGPAT1 KIAA0100 ODF2 NAGA ZSWIM1   
EXOSC10 PSMA4 GIYD1 DPP4 POLR2D ELF1 
DBNL HPSE ALCAM IER3IP1 C1orf124 ARRDC3 
C6orf190 APEH ZNF226 PCK2 RNASEH1 PHKA1 
FH FCGR3A ATP5J2 RBM6   POLE3 
G6PD UTP3 TM9SF3 LYST KPNA4 MED23 
CAPZB RPL23 RBCK1 TACC3 BRF2 CCNI 
  UGDH RPS27 UBE1 FEN1 ABL1 
RNASEL ERGIC2 TBC1D9 PCYOX1L FBXO21 SLBP 
UNC45A   NDUFB10 C6orf211 ZNF24 HP1BP3 
KRCC1 RAB6A ANKRD27 MGA FAM46C SMC3 
FAHD2A NACA RBX1 MYO18A ZNF207 LRRFIP2 
WDR59 SF3B14 AMMECR1 ARPC5 ZNF211 STAM 
SH2D1A CD46 ADCK1 MRPS28   FUSIP1 
HDAC4 TRIM41 FAM113A PCGF6 ZNF622 LOC643937 
PA2G4 ATP1A1 KIDINS220 CORO1C NOTCH1   
NDUFC1 NIN GALNT6 YWHAG RBM22 OTUB1 
ATN1 SUMO1 ARSD MKL2 XRN2 C11orf2 
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LOC642989 LBA1 SH2B1 ALDH1A1 LOC644422 UBQLN1 
RELL2 ETS1   SMARCC2 JARID1A NSFL1C 
CALML4 ITGB1BP1 MBNL1 COP1 UBE3A LOC644584 
PARC TMEM30A C10orf11 PYGL TFG LRG1 
CAST IGSF6 ZNF226   MTMR14   
C14orf104 PTGES3 RFX5 YIPF3 FEM1A LOC730820 
TMEM154 SULF2 RNASEN SPG11 PRNP RSBN1 
FAM156A LOC653147 SLC30A9 INTS8 LOC196752 LOC642082 
JOSD3 C6orf205 TUBD1 RNASEH2B LOC285074 CCDC147 
PRPF31 RECK CD160 CMTM7 ZNF800 LRP5L 
FAM45A ARHGEF1 FAM49B NLK SMCR7L VHL 
VCAN KIAA0240 SIPA1 ANXA2P1 MEF2D NGRN 
C7orf42 CTR9 FNDC3A LOC134997   RYK 
PNPLA2 ATRN SP110 C18orf32 RPUSD2 HABP4 
CCDC53 C20orf108 ATP5H CD164 DMD C6orf106 
GIMAP1 KIAA1033 HSPE1 BAT1 TIMM23   
SMUG1 LSM5   GIMAP2 LACTB   
FCER1G CD22 COMMD1 CCDC22 CDH2 DPH5 
CORO1A NUDT5 LARP1 PAPSS1 CENPN CCDC117 
OSTM1 C7orf26 LOC647037 WIPF1 GPR113 PHF3 
TMEM16F CCDC95 ROBO3 ARF3 C1orf108 E2F3 
PTMA CCDC91 ITGAM BUB3 BTBD11 SH2D5 
ARPC2 PPIB NDUFB3 HIGD1A YOD1 SQSTM1 
HDHD2 FKBP15 RABL2A PCMTD1 INTS12 FOXO3 
DAK TCL1A MRPL38 CDC42 ADCY3 LOC642017 
RNF135 CX3CR1 LMF2 OGDH CUL2 ZNF746 
C1orf43 CDC42BPB N-PAC ILK SCYL1BP1 VEGFA 
FKBP1A NDRG3 MAPK9 AP1G2 ABCF1 RP2 
  ZNF609 RNF13 C7orf11 STMN2 UHRF1BP1L 
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WRB RAVER1 PSMA5 BOLA2 EFNA4 LRWD1 
C16orf56 HK3 COX7B CTDSP1 ARMC8 AEBP2 
SMARCC2 CIDEB TM2D1 KHDRBS1 ZIK1 MSI2 
MGST3 ATP5J2 CD74 PSMA4 PDCD4 SHOX2 
PAK2 ARHGAP17 COMMD4 MINA ZNF350 C14orf138 
CHES1 CTBP1 LOC648638 TRAPPC6B ULK1 ATF2 
IQCG PPP2R5D VKORC1 C19orf50 TRAF3IP2 RNF19A 
SLC12A2 FCGR2A SUMO2 RSAD1 RYK   
IVD G6PD AKTIP GIMAP2 UBXD8 MRFAP1 
C14orf142 CD163 PSME2 RANBP1 C20orf107 KLF9 
LOC648000 NADSYN1 ABI3 FLI1   DNAJB6 
CD37 STIM1 LOC643997 DBI   NR1D2 
BRD7 LRRK2 ATP6V1C1 ATP1B3 C3orf19 MED6 
PTK2B AUP1 GAS2L1 MCTS1 CDK5RAP2 DKFZP564O0523 
CCBL2 PPARBP PITPNM1 PDCD10 BEXL1 TTF1 
HYOU1 FYN CLSTN1 LOC440525 ACOT2 FBXO3 
ERMAP RGS19 SMARCA5 LOC284837 C2orf29 FCAR 
LARP4 ALG8 SLC1A5 IKBKB SON MRRF 
C11orf35 DNAJC10 LOC732165 ATP11C TNPO1 B3GALT1 
DNM1L SMARCC1 S100A10 CBX1 UBE2W ARNTL 
LSM3 BTN3A3 HMGN4 FAM96A SLC2A3   
UQCRC2 RNF214 C1RL BPTF HMGCR PRAME 
MAP2K5 DHTKD1 POU2F2 FCRL3 FBXO11 LOC649897 
ANKRD10 IFT52 LOC642502 RABGAP1L ARIH1 ARFGAP3 
TSPAN14 NEDD9 LOC347376 CTSC SPRY1 GTPBP6 
PDIA4 SOLH PAK1IP1 PPCS FNTA HSBP1 
SFXN5 GAB3 PRKAR1A HDAC2 CCDC49 MTCH1 
CAP1 HUWE1 B3GALT6 NPIP ITCH SLC26A11 
FAM102B C14orf129 EFTUD2 PECI DHX40 UBXD4 
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HNRPH3 C7orf28A GHDC RAB6A PRDM4 LSM14A 
ATPIF1 TNFSF12 TSC22D4 ANXA2P1 LOC653994 STAG3L4 
TRAPPC1 RAB38 G3BP1 TM9SF4 EIF3B FAM126B 
LOC644931 CD48 P2RY13 PPP2CB FLJ38717 LSM8 
HSD17B4 HEMK1 ZNF266 LAT2 SLC25A26 DNAJB11 
CKLF HSPA8 MS4A7 LOC440341 C1orf128 ELK4 
TTC15 RYR1 VPS36 OSBPL8 NFX1 AMD1 
SIN3B ARD1A NOL8 LOC402644 FBXO11 ORAOV1 
LOC402057 MRPS21 RNH1 ACN9 C22orf32 CWC15 
HRSP12 CD47 MUS81 NDUFAB1 DYRK2 LEMD2 
RXRA KTN1 COMMD8 PPA2 PREI3 ABLIM1 
RPS20 GPSM3 SLC25A11 DDX17   REM2 
PARP10 LOC402221 CSTF3 SKAP2 ZFP91 FMO6P 
LOC441377 BTBD15 LOC391656 NUCB2 C3orf38 ZNF706 
ZC3H4 ROD1 GNAI2 ACTR3 LOC387820   
MAP3K11 FGR PPP3CA ATP2A3 NDST2 PPFIA1 
ITFG2 PHF14 SACM1L SNAP23 EEF1B2 CLK3 
CSF1R ATXN1 LOC116236 EFHA1 UBE2D3 C14orf131 
ANP32A NACAP1 USP5 NOL5A GGNBP2 LOC731999 
AP2A1 OFD1 RPS28 C11orf73 DIDO1 HNRNPA1 
WASPIP MRPL51 NCOA1 METTL7A   TFIP11 
OAS3 C16orf53 KIAA0564 LOC644310   SPO11 
FRG1 AGPAT7 PPARGC1B ATP1B3 GOLGA7 AZIN1 
TNFSF13B CYFIP1 GDI2 SIRT2 LEMD3 WBSCR16 
TAF1B GPBP1L1 CD74 MRPL18 UBE2G1 IFNGR1 
CD27 ACTN4 SNX14 NPTN RAB3GAP1   
ARL6IP1 LOC440348 ATM CDKN1C FZD7 PDE4D 
SNTB2 SPIB CD4 MS4A4A PTTG1 TIMM22 
CSK PIP5K1C AHCYL1 LSM6 FOLH1 EIF3EIP 
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FASTKD1 UCP2 AAMP SORD TIPARP CWF19L1 
NUDCD2 PRR13 UNC13D DOCK8 USP36 MAF 
FYB TTLL3 SSBP1 GLRX2 SPTY2D1 LOC648277 
INPP5D ARFGEF1 TRAF5 CTBP1 C9orf127 UBQLN1 
KIAA1604 TMEM14B HS1BP3 IMMT BAG3 ZDHHC9 
TMEM106B BRWD2 FAM26F C6orf115 C7orf20 NXT1 
LOC388955 KRCC1 PSMC5 CAT   PAPD1 
PTPRA UBQLN2 ATF1 SERINC3 DDX6 BNIP3L 
GMIP DLGAP4 AP2A1 LOC130355 LMNA TMEM115 
TMEM39B NIPSNAP1 MRCL3 ATMIN ZNF614 RNF38 
PABPC1 C2CD2L S100A12 MRPL48 LOC654259 ZBTB25 
ACOX3 GLRX GMPR2 FKBP3 TOMM34 AMFR 
ARHGAP1 C6orf173 DICER1 GABARAPL2 HRB AFG3L2 
FAM96A SERPINA1 ARHGEF1 LOC646900 LOC285074 GADD45A 
CENTG3 C16orf42 DECR1 ANXA4 TMUB2 RIOK3 
HMGB2 NAGK AKAP1 IQGAP1 C8orf76 KTN1 
EEF1B2 CCT7 RBBP7 LOC650321 C12orf41 NF2 
PDCD6 NAT6 TARS UIMC1 KIAA1429 KIAA2010 
S100A9 FAM49B CDK4 OSBP LOC646178   
KLRF1 TMEM80 AGL ZNF689 PELO C20orf11 
FKBP3 SLC38A10 PDIA3P ATPBD1B   TMEM30B 
COG5 CENTB1 CYBB LOC400027 GALC PRKY 
POFUT2 TRIT1 PARP10 CNOT2 ZBTB25 ZNF671 
PDHA1 TXNDC17 DSTN CCDC44 SELS LOC653105 
SIGIRR HLA-DRA TSNAX YY1AP1 FXR1 PHF5A 
SULT1A2 MTSS1 C3orf17 RPL32 DRG1 KLF11 
COQ9 CENTB2 LOC401019 MED10 TRIM60 SLC7A5 
CNPY4 C14orf130 IBTK C20orf45 GEMIN4 FBXO34 
LOC643035 TMEM16H RPS3A TFAM HADHA OGFRL1 
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CCDC88B ASCC3 GMFG LOC388275 LOC554208 PSMC1 
SLC25A45 ISOC2 SYTL1 RAB35 RSPO2 CHD7 
GLB1 LSP1 AMY1C PHF17 EIF4H EIF3J 
RNF135 S100A11 SLC36A1 ZNF586 EDARADD TP53INP1 
DNCL1 PRDX5 ADRM1 ZNF295 C1orf119   
STOM MYH9 RBBP4 SNX6 HSPA14 AHNAK 
LOC651202 OMA1 TSPAN13 FASTKD5 GAS2L3   
SMYD4 TCF7L2 TTC21A SLC30A5 EEF1B2 ZP3 
PARVG NAALADL1 OSCAR SSR2 PPTC7 NRAS 
TBC1D17 MFSD1 RBED1 VCP TNPO1 NIPA2 
TMEM154 MTMR4 Sep-11 DNAJB9 SEC22C FGF9 
HOM-TES-103 MLSTD1 LOC283874 RAE1 ODC1 CCNB1IP1 
ATP11B MTA1 RTN4 TDP1 FKBP11 C8orf34 
COPG2 SAC3D1 POLR2G COQ10B ZFAND2A FLJ35801 
LOC646197 Sep-06 ARHGAP27 SLC41A3 NOL1 C16orf44 
SLC24A1 KLRF1 SLC4A2 C19orf48 ADAM17 BMS1 
PREPL GORASP1 SNX10 RDH14 PPP3R1 IKZF5 
VPS4A AKNA MRPS18B ZNF101 CLK3 COIL 
HSPA4 DRAP1 Sep-07 ZNF134 LOC647210   
SP3 IQWD1 EP400 LUZP1 UPP1 LOC402066 
U2AF2 DIAPH1 C1orf63 CSNK1E ACVR1B TROVE2 
TRAPPC6B CTSC HNRPA2B1 FAM108B1 KIAA2010   
ITGB7 TMEM128 ADD3 SIAH1 TDG STIL 
RTN3 SRPK2 BIN2 RP9 POLR1C BEX2 
MTPN HSDL2 PLCB2 ZNF207 CRKL MAD2L1BP 
C10orf76 DNAJC7 PCNA ANKRA2 PGGT1B USP39 
TBCB GDI1 HLA-G   BRD2 FAM18B 
C16orf62 SLC39A3 AHNAK SRF CAMSAP1 ERN1 
ORC3L C8orf59 AP2S1 PSMA7 LOC389286 METT10D 
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RPGR PRCP BRDG1 LOC643446 COX19   
ADNP LOC220433 WNK1 GTF2B   LOC653270 
ZBTB2 PSMD14 Sep-15 NUFIP2 TRAK1   
AAAS ME2 PMS1 FOXJ2 PER2 WDR22 
CUL4A SFI1 YY1 ICOS SIN3A ERBB4 
HADHB TMEM4 NNT LOC730316 RIOK1 ILVBL 
ERAL1 DC2 C4orf18 EIF2C2 CKAP2   
FEZ2 AKT1 PELP1 ZNF586 ZRANB1 BANP 
AHSA2 GON4L LOC730740 UBN1 LOC727935 CASZ1 
C4orf41 RPS6KC1 DPYD C17orf48 MSH6 TMEM38B 
C4orf33 HRAS WAS SAFB ZNF256 BIRC2 
AP1S1 ANGEL1 JAZF1 KIAA0174 CDC42 CCDC28A 
SP4 NHLRC3 DHPS DHX37 TOPORS RANGAP1 
PKM2 LOC389787 FLJ11151 ZDHHC5 SERTAD2   
ABHD14A TXNL1 LOC642333 HNRNPA3 SEC61A1   
MRPL19 TMSB10   CGGBP1 UQCRFS1   
LOC644482 BLOC1S1 PTPLB FAM53C TPD52L2   
HS2ST1 HCK LRP10 C3orf37 PDRG1   
C3orf28 MOSPD2 UGP2 ZCCHC8 SNORD16   
RAD9A SH3BP1 ATP6V0E1 ACPT ULK1   
C12orf35 CCDC97 NNT LOC652481 LOC654126   
ANXA1 INTS3 PFN1 MIER1     
TMEM131 RHOC SYNE2   RFXAP   
PEBP1 FAM117A WSB2 HGS SNRPB   
CARS HSPB1   MORF4L2 RPL32   
LOC653773 LOC653658 GTF3C2 RNF38 ANKRD49   
ACP2 DYNLRB1 ACTB AHCTF1 AXUD1   
MSH2 NCL STX7   FBL   
VTI1B APBB1IP PEX14 A26C3 DTX2   
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LOC645138 CCDC91 ECHDC1 OTUD4 FXC1   
  ARHGAP9 ZNF318 FOXO1     
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Pathway maps up-regulated in LTNP of the comparisons between LTNP versus TP1  
Maps pValue Ratio 
Immune response_BCR pathway 1.034E-07 11/54 
Transport_Macropinocytosis 
regulation by growth factors 
5.413E-07 11/63 
Development_Slit-Robo signaling 6.616E-07 8/30 
Immune response_CD16 signaling 
in NK cells 
1.398E-06 11/69 
Immune response _CCR3 signaling 
in eosinophils 
4.265E-06 11/77 
Chemotaxis_CCL2-induced 
chemotaxis 
1.044E-05 9/55 
Blood coagulation_GPVI-dependent 
platelet activation 
1.044E-05 9/55 
Chemotaxis_C5a-induced 
chemotaxis 
1.224E-05 8/43 
Blood coagulation_GPCRs in 
platelet aggregation 
1.337E-05 10/71 
Development_S1P4 receptor 
signaling pathway 
1.527E-05 6/22 
Cytoskeleton remodeling_CDC42 in 
cellular processes 
1.527E-05 6/33 
LRRK2 in neurons in Parkinson's 
disease 
1.763E-05 723 
Cytoskeleton 
remodeling_Regulation of actin 
cytoskeleton by Rho GTPases 
2.021E-05 6/46 
Neurophysiological process_ACM 
regulation of nerve impulse 
2.060E-05 8/46 
Immune response_Fc gamma R-
mediated phagocytosis in 
macrophages 
2.060E-05 8/84 
Development_VEGF signaling via 
VEGFR2 - generic cascades 
5.953E-05 10/55 
Immune response_Fc epsilon RI 
pathway 
7.860E-05 8/56 
Regulation of lipid 
metabolism_Insulin regulation of 
glycogen metabolism 
8.967E-05 8/31 
Development_Osteopontin signaling 
in osteoclasts 
1.021E-04 6/31 
Immune response_ETV3 affect on 
CSF1-promoted macrophage 
differentiation 
1.238E-04 6/31 
Cytoskeleton remodeling_Reverse 
signaling by ephrin B 
1.238E-04 6/111 
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Cytoskeleton remodeling_TGF, 
WNT and cytoskeletal remodeling 
1.391E-04 11/46 
Signal transduction_Calcium 
signaling 
1.436E-04 7/46 
Immune response_MIF - the 
neuroendocrine-macrophage 
connector 
1.657E-04 7/34 
Development_S1P1 receptor 
signaling via beta-arrestin 
2.119E-04 6/49 
Chemotaxis_CXCR4 signaling 
pathway 
2.119E-04 6/35 
Signal transduction_IP3 signaling 2.489E-04 7/38 
G-protein signaling_RAC1 in 
cellular process 
2.503E-04 6/26 
Cytoskeleton remodeling_ACM3 
and ACM4 in keratinocyte 
migration 
3.988E-04 6/40 
Development_S1P2 and S1P3 
receptors in cell proliferation and 
differentiation 
4.798E-04 5/56 
Cytoskeleton remodeling_Role of 
PKA in cytoskeleton reorganisation 
5.310E-04 6/56 
Cell adhesion_Integrin inside-out 
signaling 
5.760E-04 7/42 
Immune response_Neurotensin-
induced activation of IL-8 in 
colonocytes 
6.949E-04 6/75 
Immune response_PIP3 signaling in 
B lymphocytes 
6.949E-04 6/76 
Chemotaxis_Leukocyte chemotaxis 6.974E-04 8/43 
Blood coagulation_GPIb-IX-V-
dependent platelet activation 
7.623E-04 8/43 
Development_ACM2 and ACM4 
activation of ERK 
7.903E-04 6/43 
Immune response_HTR2A-induced 
activation of cPLA2 
7.903E-04 659 
Development_S1P3 receptor 
signaling pathway 
7.903E-04 6/30 
Immune response_Immunological 
synapse formation 
7.933E-04 7/45 
Cytoskeleton remodeling_RalA 
regulation pathway 
9.550E-04 5/62 
Development_EPO-induced MAPK 
pathway 
1.011E-03 6/100 
Development_Alpha-2 adrenergic 
receptor activation of ERK 
1.071E-03 7/46 
Cell adhesion_Chemokines and 
adhesion 
1.135E-03 9/46 
Development_G-Proteins mediated 
regulation MAPK-ERK signaling 
1.138E-03 6/63 
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Chemotaxis_Lipoxin inhibitory 
action on fMLP-induced neutrophil 
chemotaxis 
1.138E-03 6/47 
Development_TGF-beta-dependent 
induction of EMT via RhoA,  PI3K 
and ILK. 
1.138E-03 6/102 
Transcription_PPAR Pathway 1.178E-03 7/45 
Transcription_CREB pathway 1.277E-03 6/23 
Cytoskeleton 
remodeling_Cytoskeleton 
remodeling 
1.306E-03 9/47 
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Appendix 7 
Pathway maps down-regulated in LTNP of the comparisons between LTNP versus TP1  
Maps pValue Ratio 
Development_PEDF signaling 2.299E-06 7/49 
Apoptosis and survival_TNFR1 signaling 
pathway 
1.450E-05 6/43 
Apoptosis and survival_Role of IAP-
proteins in apoptosis 
3.783E-05 5/31 
Development_Beta-adrenergic receptors 
signaling via cAMP 
4.418E-05 6/52 
Immune response_Regulation of T cell 
function by CTLA-4 
7.983E-05 5/36 
Development_Glucocorticoid receptor 
signaling 
2.084E-04 4/24 
Immune response_MIF - the 
neuroendocrine-macrophage connector 
2.627E-04 5/46 
Regulation of degradation of deltaF508 
CFTR in CF 
3.343E-04 4/27 
Apoptosis and survival_Granzyme B 
signaling 
6.527E-04 4/32 
Regulation of CFTR activity (norm and 
CF) 
7.791E-04 5/58 
Development_NOTCH1-mediated 
pathway for NF-KB activity modulation 
8.256E-04 4/34 
Immune response_CD40 signaling 1.310E-03 5/65 
Development_NOTCH-induced EMT 1.627E-03 3/19 
Apoptosis and survival_Lymphotoxin-
beta receptor signaling 
1.845E-03 4/42 
Development_A2A receptor signaling 2.014E-03 4/43 
Development_Notch Signaling Pathway 2.014E-03 4/44 
Apoptosis and survival_Inhibition of 
ROS-induced apoptosis by 17beta-
estradiol 
2.195E-03 4/44 
Apoptosis and survival_FAS signaling 
cascades 
2.195E-03 4/45 
Neurophysiological process_Glutamate 
regulation of Dopamine D1A receptor 
signaling 
2.386E-03 4/24 
Immune response_MIF-JAB1 signaling 3.246E-03 3/50 
Immune response_IFN alpha/beta 
signaling pathway 
3.246E-03 3/24 
Proteolysis_Role of Parkin in the 
Ubiquitin-Proteasomal Pathway 
3.246E-03 3/24 
Apoptosis and survival_HTR1A signaling 3.514E-03 4/24 
Signal transduction_PKA signaling 3.777E-03 4/50 
Neurophysiological process_Dopamine 
D2 receptor transactivation of PDGFR in 
CNS 
4.094E-03 3/51 
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Apoptosis and survival_Anti-apoptotic 
TNFs/NF-kB/IAP pathway 
4.564E-03 3/26 
Immune response_CD137 signaling in 
immune cell 
5.599E-03 3/27 
Immune response_IL-6 signaling 
pathway 
6.763E-03 3/29 
Development_Regulation of epithelial-to-
mesenchymal transition (EMT) 
8.479E-03 4/31 
Oxidative stress_Role of ASK1 under 
oxidative stress 
8.762E-03 3/64 
Inhibitory action of Lipoxin A4 on 
PDGF, EGF and LTD4 signaling 
9.497E-03 3/40 
Influence of low doses of Arsenite on 
Glucose stimulated Insulin secretion in 
pancreatic cells 
1.027E-02 3/42 
Development_Lipoxin inhibitory action 
on PDGF, EGF and LTD4 signaling 
1.027E-02 3/45 
Apoptosis and survival_Anti-apoptotic 
action of nuclear ESR1 and ESR2 
1.107E-02 3/45 
Cell cycle_Regulation of G1/S transition 
(part 1) 
1.191E-02 3/45 
Signal transduction_cAMP signaling 1.191E-02 3/17 
Reproduction_GnRH signaling 1.272E-02 4/46 
CFTR folding and maturation (norm and 
CF) 
1.296E-02 2/18 
Cell cycle_Nucleocytoplasmic transport 
of CDK/Cyclins 
1.296E-02 2/47 
Cytoskeleton remodeling_Role of PKA in 
cytoskeleton reorganisation 
1.370E-02 3/47 
Beta-2 adrenergic-dependent CFTR 
expression 
1.484E-02 2/47 
Apoptosis and survival_Apoptotic TNF-
family pathways 
1.563E-02 3/46 
Apoptosis and survival_BAD 
phosphorylation 
1.563E-02 3/17 
Regulation of lipid 
metabolism_Regulation of lipid 
metabolism by niacin and isoprenaline 
1.881E-02 3/1/ 
G-protein signaling_Regulation of cAMP 
levels by ACM 
1.881E-02 3/47 
LRRK2 in neuronal apoptosis in 
Parkinson's disease 
1.891E-02 2/47 
Immune response_ICOS pathway in T-
helper cell 
1.994E-02 3/47 
Regulation of degradation of wt-CFTR 2.110E-02 2/47 
Development_Beta-adrenergic receptors 
regulation of ERK 
2.111E-02 3/47 
Development_PDGF signaling via MAPK 
cascades 
2.111E-02 3/47 
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Appendix 8 
Pathway maps up-regulated in LTNP of the comparisons between LTNP versus TP2 
 
Maps pValue Ratio 
Immune response_BCR pathway 1.150E-09 18/54 
LRRK2 in neurons in Parkinson's disease 2.145E-09 14//33 
Signal transduction_Calcium signaling 3.325E-09 16/45 
Immune response_CD16 signaling in NK cells 1.443E-08 19/69 
Immune response _CCR3 signaling in 
eosinophils 
1.798E-08 20/77 
Development_VEGF signaling via VEGFR2 - 
generic cascades 
8.790E-08 20/84 
Cytoskeleton remodeling_TGF, WNT and 
cytoskeletal remodeling 
1.502E-07 23/111 
Cytoskeleton remodeling_Regulation of actin 
cytoskeleton by Rho GTPases 
3.441E-07 10/23 
Chemotaxis_CXCR4 signaling pathway 3.490E-07 12/34 
Development_Slit-Robo signaling 6.965E-07 11/30 
Development_Osteopontin signaling in 
osteoclasts 
6.965E-07 11/30 
G-protein signaling_G-Protein alpha-12 
signaling pathway 
9.969E-07 12/37 
Immune response_Immunological synapse 
formation 
1.495E-06 15/59 
Apoptosis and survival_APRIL and BAFF 
signaling 
1.882E-06 12/39 
Immune response_Fc gamma R-mediated 
phagocytosis in macrophages 
2.058E-06 13/46 
Immune response_Fc epsilon RI pathway 3.297E-06 14/55 
Immune response_IL-15 signaling 4.508E-06 1564 
Immune response_Function of MEF2 in T 
lymphocytes 
5.735E-06 13/43 
Development_S1P3 receptor signaling pathway 5.903E-06 12/102 
Cytoskeleton remodeling_Cytoskeleton 
remodeling 
9.545E-06 19/76 
Blood coagulation_GPIb-IX-V-dependent 
platelet activation 
9.610E-06 16/39 
G-protein signaling_Regulation of p38 and JNK 
signaling mediated by G-proteins 
1.296E-05 11/54 
Immune response_Role of DAP12 receptors in 
NK cells 
1.432E-05 13/50 
Blood coagulation_GPCRs in platelet 
aggregation 
1.742E-05 15/64 
Chemotaxis_CCL2-induced chemotaxis 1.773E-05 13/50 
Blood coagulation_GPVI-dependent platelet 
activation 
1.773E-05 13/43 
Transport_Macropinocytosis regulation by 1.806E-05 14/102 
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growth factors 
Signal transduction_Erk Interactions: Inhibition 
of Erk 
2.148E-05 10/76 
G-protein signaling_RhoA regulation pathway 2.148E-05 10/39 
Immune response_Antigen presentation by 
MHC class I 
2.524E-05 9/54 
Development_G-CSF signaling 2.541E-05 12/71 
Transcription_Role of heterochromatin protein 
1 (HP1) family in transcriptional silencing 
2.595E-05 8/55 
Cell adhesion_Chemokines and adhesion 2.659E-05 18/55 
Immune response_PIP3 signaling in B 
lymphocytes 
2.803E-05 11/63 
Apoptosis and survival_HTR1A signaling 3.163E-05 12/28 
Immune response_CCR5 signaling in 
macrophages and T lymphocytes 
3.259E-05 13/49 
G-protein signaling_Regulation of RAC1 
activity 
3.730E-05 10/22 
Immune response_NFAT in immune response 3.912E-05 12/100 
Apoptosis and survival_Granzyme A signaling 4.688E-05 9/42 
Development_EPO-induced MAPK pathway 5.629E-05 11/50 
Neurophysiological process_ACM regulation of 
nerve impulse 
7.000E-05 11/58 
Immune response_MIF - the neuroendocrine-
macrophage connector 
7.000E-05 11/58 
Immune response_CD28 signaling 7.153E-05 12/62 
Development_EGFR signaling pathway 8.177E-05 13/40 
Cytoskeleton remodeling_Role of PKA in 
cytoskeleton reorganisation 
9.984E-05 10/26 
Neurophysiological process_Dopamine D2 
receptor transactivation of PDGFR in CNS 
1.021E-04 8/26 
Development_S1P2 and S1P3 receptors in cell 
proliferation and differentiation 
1.021E-04 8/56 
Airway smooth muscle contraction in asthma 1.042E-04 12/54 
Cytoskeleton remodeling_Integrin outside-in 
signaling 
1.295E-04 11/63 
Chemotaxis_Leukocyte chemotaxis 1.382E-04 14/75 
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Appendix 9 
Pathway maps down-regulated in LTNP of the comparisons between LTNP versus TP2  
 
Maps pValue Ratio 
Apoptosis and survival_Role of IAP-proteins in 
apoptosis 
5.857E-09 11/31 
Apoptosis and survival_TNFR1 signaling pathway 2.603E-08 12/43 
Development_WNT signaling pathway. Part 1. 
Degradation of beta-catenin in the absence WNT 
signaling 
1.571E-07 8/19 
Apoptosis and survival_Apoptotic TNF-family 
pathways 
2.063E-07 11/42 
Apoptosis and survival_FAS signaling cascades 3.462E-07 11/44 
Apoptosis and survival_Granzyme B signaling 1.406E-06 9/32 
Signal transduction_AKT signaling 2.455E-06 10/43 
Immune response_Regulation of T cell function by 
CTLA-4 
4.146E-06 9/36 
Translation _Regulation of EIF2 activity 8.470E-06 9/40 
Translation_Non-genomic (rapid) action of Androgen 
Receptor 
1.058E-05 9/44 
Proteolysis_Role of Parkin in the Ubiquitin-
Proteasomal Pathway 
1.668E-05 7/24 
Apoptosis and survival_Role of PKR in stress-induced 
apoptosis 
1.803E-05 10/53 
Cell cycle_Influence of Ras and Rho proteins on G1/S 
Transition 
1.803E-05 10/53 
Apoptosis and survival_Caspase cascade 1.842E-05 833 
Development_Thrombopoietin-regulated cell processes 2.918E-05 9/46 
Signal transduction_PTEN pathway 3.513E-05 9/38 
Cell cycle_Regulation of G1/S transition (part 1) 5.530E-05 8/49 
Development_PEDF signaling 5.947E-05 9/39 
Proteolysis_Putative SUMO-1 pathway 6.425E-05 7/52 
Transcription_P53 signaling pathway 6.738E-05 8/51 
Apoptosis and survival_HTR1A signaling 7.022E-05 9/52 
Signal transduction_PKA signaling 8.257E-05 9/31 
Development_IGF-1 receptor signaling 9.669E-05 9/31 
Immune response_IL-6 signaling pathway 1.016E-04 765 
Development_Inhibition of angiogenesis by PEDF 1.016E-04 7/42 
Immune response_CD40 signaling 1.121E-04 10/42 
Translation_Insulin regulation of translation 1.175E-04 8/34 
Development_Growth hormone signaling via 
PI3K/AKT and MAPK cascades 
1.175E-04 8/34 
Apoptosis and survival_Role of CDK5 in neuronal 
death and survival 
1.892E-04 7/35 
Apoptosis and survival_Cytoplasmic/mitochondrial 
transport of proapoptotic proteins Bid, Bmf and Bim 
1.892E-04 7/58 
Neurophysiological process_Glutamate regulation of 1.950E-04 8/47 
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Dopamine D1A receptor signaling 
Development_Hedgehog signaling 2.286E-04 8/50 
Development_Angiopoietin - Tie2 signaling 2.292E-04 7/39 
Regulation of CFTR activity (norm and CF) 2.308E-04 9/39 
Development_PIP3 signaling in cardiac myocytes 2.669E-04 8/19 
Development_HGF signaling pathway 2.669E-04 8/29 
Cell adhesion_Chemokines and adhesion 2.743E-04 12/65 
Cytokine production by Th17 cells in CF (Mouse 
model) 
3.592E-04 8/53 
Development_TGF-beta receptor signaling 4.142E-04 854 
Cytokine production by Th17 cells in CF 4.623E-04 7/111 
Transcription_Receptor-mediated HIF regulation 4.623E-04 7/42 
Transcription_NF-kB signaling pathway 4.623E-04 7/39 
DNA damage_NHEJ mechanisms of DSBs repair 4.853E-04 5/59 
Apoptosis and survival_NGF activation of NF-kB 5.347E-04 6/58 
Apoptosis and survival_Ceramides signaling pathway 5.430E-04 7/96 
Development_Role of IL-8 in angiogenesis 5.534E-04 9/65 
Translation _Regulation of EIF4F activity 6.217E-04 8/33 
Immune response_HSP60 and HSP70/ TLR signaling 
pathway 
7.070E-04 8/63 
Cytoskeleton remodeling_TGF, WNT and cytoskeletal 
remodeling 
7.190E-04 12/111 
Apoptosis and survival_Lymphotoxin-beta receptor 
signaling 
7.380E-04 7/54 
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Appendix 10 
Primer sequences for the real-time PCR amplification of the significant regulated genes 
detected from Microarray study. 
 
GENE FORWARD (F) AND REVERSE (R) 
PRIMER SEQUENCE 5’-3’ 
TM (ºC) 
GAPDH F: CCAGGCGCCCAATACG 
R: CCACATCGCTCAGACACCAT 
66.5 
66.3 
FKBP3 
 
F: ACCCTCATCCAGGGTCTCTT 
R: GCAGGAACACGGTTCAGATT 
63.8 
64 
CD46 
 
F: TGGTCAAATGTCGATTTCCA 
R: TGGTCAAATGTCGATTTCCA 
63.9 
63.9 
CD47 F = GAGGACTCCTGCTTCTGTGG 
R = TTATTTGGGGTTCGCTCTTG 
64 
63.7 
BIRC2 F = CAACTTTTGGGGGAAGTCAA 
R = ATGCTGCAGGAAATGGAAAC 
63.9 
63.7 
MAPK3 
 
F = CTCATCCGTCGGGTCATAGT 
R = CAGTCTCTGCCCTCCAAGAC 
63.9 
64 
OAS2 F = GCACAAGAGAGCCTCCAAAC 
R = AAGCCCTCCCTACCTACCAA 
63.9 
63.5 
FADD 
 
F = CAACCATCACTGCCCCTACT 
R = TTTGTCCCATTTCCTTGGAG 
63.9 
63.7 
CASP3 
 
F = CAACGATCCCCTCTGAAAAA 
R = TGGAATTGATGCGTGATGTT 
63.8 
63.9 
STAT1 
 
F = GGGCATTCTGGGTAAGTTCA 
R = TGCAAAACCTTGCAGAACAG 
63.7 
63.9 
THBS1 
 
F = CGGTCTCCCACATCATCTCT 
R = AAAGGATAATTGCCCCAACC 
64.1 
63.5 
IFIT1 F = CACCTCAAATGTGGGCTTTT 
R= TCACCAGATAGGGCTTTGCT 
64 
63.7 
IFIT3 F = ATGGCCTGCTTCAAAACATC 
R= AGGAAGGGTGGACACAACTG 
63.9 
64 
CXCL10 F = GAATCGAAGGCCATCAAGAA 
R = CCTCTGTGTGGTCCATCCTT 
60 
60 
PKR F =TTTGGACAAAGCTTCCAACC 
R =GGTATGTATTAAGTTCCTCCATGA 
60 
60 
IFIH1 F =TTTTGCAGATTCTTCTGTAGTTTCA 
R = TGCTGTTATGTCCAAGACTTTCA 
60 
60 
TLR7 F = CCAGTGTCTAAAGAACCTGGAAA 
R = GGGACAGTGGTCAGTTGGTT 
60 
60 
IRF7 F = AGCTGTGCTGGCGAGAAG 
R = TGTGTGTGCCAGGAATGG 
60 
60 
IFNG F =  GGCATTTTGAAGAATTGGAAAG 
R = TTTGGATGCTCTGGTCATCTT 
59 
59 
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IFNB F = CGACACTGTTCGTGTTGTCA 
R = GAAGCACAACAGGAGAGCAA 
59 
59 
OAS3 F = CAAGCTCAAGAGCCTCATCC 
R = TGGGCTGTGTTGAAATGTGT 
60 
60 
OAS1 F = TGGATGGATGTTAGCCTGGT 
R = CTTGTGGCTTGGGTTTGAC 
60 
60 
 
